

# **Dennis G. Maki, M.D.**

June 2015

**Dr. Maki is the Ovid O. Meyer Professor of Medicine in the Divisions of Infectious Diseases and Pulmonary-Critical Care Medicine at the University of Wisconsin School of Medicine and Public Health in Madison, Wisconsin, attending physician in the UWMC Center for Trauma and Life Support and eICU, and former Head of the Division of Infectious Diseases 1979 through 2007.**

**Dr Maki, a 1967 graduate of the University of Wisconsin School of Medicine and Public Health, did his internal medicine residency training on the Harvard Medical Service of the Boston City Hospital, where he was the Chief Resident, and the Massachusetts General Hospital, where he also did his fellowship in infectious diseases, and during this period spent two years as an Epidemic Intelligence Service Officer with the Centers for Disease Control and Prevention. An infectious disease consultant, critical care physician and epidemiologist, he has devoted his research career to the prevention of nosocomial infections and management of life-threatening infections, and has published more than 350 original papers, editorials, chapters and reviews and 700 abstracts of research presented at national or international scientific meetings; his publications have been cited by other researchers more than 16,000 times and provide much of the scientific underpinning for the “bundle” of measures currently employed for prevention of line sepsis in hospitals worldwide. A past consultant to the CDC, NIH, FDA, HHS, GAO and the UK NHS, he is former President of the Society for Healthcare Epidemiology of America and Councillor of the Infectious Diseases Society of America. From 1987 to 1994, he was a member of the ASM-ICAAC Program Committee and from 1989 to 1995, served on the ABIM Board of Critical Care Medicine. Dr. Maki has been listed in every edition of *Best Doctors in America* since 1982 and received numerous awards for teaching at the University of Wisconsin and nationally. In 1994 he received the CIPI Award of the International Congress on Infection Control of the Societe de Pathologie Infectioense de Langue Francise, WHO and CDC for global contributions to the prevention of infection. In 2000 he was made a Master of the American College of Physicians and was cited by the Infectious Diseases Society of America for lifetime achievements in the field of infectious diseases. In 2001 he received the Hilldale and Belzer awards from the University of Wisconsin-Madison for contributions in teaching, research and service. In 2002 he was named to the HHS Secretary’s Council on Public Health Preparedness and in 2005, to the Editorial Board of CDC’s *Morbidity and Mortality Weekly Report*. In 2007, he was elected to the University Committee, the executive committee of the Faculty Senate and advisory to the Chancellor and Regents of the University of Wisconsin-Madison. In 2009, he received the Distinguished Alumni Award from the University of Wisconsin Medical Alumni Association.**



**1972-1974** Instructor in Medicine  
Harvard Medical School

**1974-1978** Assistant Professor of Medicine  
University of Wisconsin-Madison

**1974-1979** Chief, Section of Infectious Diseases  
University of Wisconsin Hospital and Clinics

**1974-2008** Hospital Epidemiologist  
University of Wisconsin Hospital and Clinics

**1975-** Ovid O. Meyer Chair in Medicine  
University of Wisconsin Medical School

**1976-** Attending Physician, Center for Trauma and Life Support  
University of Wisconsin Hospital and Clinics

**1978-1982** Associate Professor of Medicine  
University of Wisconsin-Madison

**1979-2007** Head, Division of Infectious Diseases and  
Director, Clinical and Research Fellowship in Infectious Disease  
Department of Medicine  
University of Wisconsin School of Medicine and Public Health  
Director, Infectious Disease Clinic  
University of Wisconsin Hospital and Clinics

**1980-1985** Director, Center for Trauma and Life Support  
University of Wisconsin Hospital and Clinics

**1982-** Ovid O. Meyer Professor of Medicine  
University of Wisconsin-Madison

**2008-** Attending Physician, eICU  
University of Wisconsin Hospital and Clinics.

**MEDICAL LICENSURE** Wisconsin (No. 18897)  
(Formerly, Massachusetts and Georgia)

### PROFESSIONAL CERTIFICATIONS

**1968** American Board of Medical Examiners

**1972** Internal Medicine - ABIM (**Recertified by MOC Examination, 2014**)

**1974** Infectious Diseases - ABIM (**Recertified by MOC Examination, 2014**)

**1987** Critical Care Medicine – ABIM (**Recertified by MOC Examination, 2012**)

**1991** Advanced Trauma Life Support - American College of Surgeons

**2008** Basic Cardiac Life Support

**2009** Advanced Cardiac Life Support

## PROFESSIONAL SOCIETIES

Alpha Omega Alpha (Faculty Counselor, University of Wisconsin, 1976-96;  
 National Board of Directors, 1983-88)  
 American Academy of Microbiology (Fellow)  
 American College of Chest Physicians (Fellow)  
 American College of Physicians (Master)  
 American Federation for Clinical Research  
 American Society for Microbiology  
 (ICAAC Scientific Program Committee, 1987-94)  
 Central Society for Clinical Research  
 (Specialty Counselor, 1983-87)  
 Infectious Diseases Society of America (Fellow)  
 (Member of the Council, 1992-95)  
 Society for Critical Care Medicine  
 Society of Hospital Epidemiologists of America  
 (Vice-president 1989; President, 1990; Past-president, 1991)  
 Surgical Infection Society (Fellow)  
 Interstate Postgraduate Medical Association  
 (President, 2003)  
 Biomedical Central Faculty of 1000

## NATIONAL/INTERNATIONAL SERVICE

1970-71 Editor, ***Primum Non Nocere***, Center for Disease Control  
 1971-72, 75-79 Subcommittee on Microbial and Pyrogenic Contamination, FDA/USP  
 National Coordinating Committee on Large-Volume Parenterals  
 1979-85 Consultant, ***AMA Drug Reviews***  
 1979-2003 Editorial Board, ***Infection Control and Hospital Epidemiology***  
 (Associate Editor, 1979-93)  
 1980-81 Panel for Developing National Guidelines for Infection Control in Infusion  
 Therapy, Centers for Disease Control.  
***Infect Control 3:68-72, (1981).***  
 1980-86 Editorial Board, ***Journal of Laboratory and Clinical Investigation***  
 1982-85 Editorial Board, ***Critical Care Monitor***  
 1982-85,86,89 Consultant and Contributor, ***USP-Drug Information Reviews;***  
***USP-DI Advice for the Patient***  
 1983 Site Visit team-member, NCI/NIH  
 1983-87 Specialty Councilor (Infectious Diseases),  
 Central Society for Clinical Research  
 1983-88 National Board of Directors, Alpha Omega Alpha  
 (Chairman, Student Scholarship Committee)  
 1985- Ad hoc grant reviewer, Veterans Administration  
 1985-95 Editorial Board, ***Journal of Critical Care***  
 1987-94 Scientific Program Committee, Interscience Conference on Antimicrobial Agents and  
 Chemotherapy-American Society for Microbiology  
 (Chairman, Subcommittee for ICAAC/ASM Young Investigator Award)  
 1988,89,90,91 Vice-president, President-Elect, President, Past-President,  
 Society of Hospital Epidemiologists of America  
 1988-90 Editorial Board, ***Journal of Infectious Diseases***  
 1988- Reviewer, Fellowship Programs, Infectious Disease and Critical Care  
 Medicine, American Committee on Graduate Medical Education (ACGME)  
 1989 New Antiviral Drugs Advisory Committee, FDA  
 1989-95 American Board of Internal Medicine,  
 Test Committee on Critical Care Medicine  
 (Chair, Credentials Subcommittee)  
 1989-2003 Editorial Board, ***Critical Care Medicine***  
 1990-91 Advisory Board, Second International Symposium on Nosocomial Infection  
 Control in Intensive Care, Freiburg, Germany

**NATIONAL/INTERNATIONAL SERVICE, Continued**

**Dennis G Maki, MD**

- 1991 Panelist, NIH State-of-the-Art Consensus Conference, Diagnosis and Treatment of Lyme Disease  
***Clinical Courier* 9:1-8 (1991)**
- 1991-92 Panelist, ACCP-SCCM Consensus Conference on the Sepsis Syndrome  
***Chest* 101:1644-55 (1992)**
- 1991-92 Scientific Program Committee, Second International Symposium on Prevention of Infection (CIPI-2), Nice, France
- 1992-93 Scientific Program Committee, Third International Symposium on Prevention of Infection (CIPI-3), Nice, France
- 1992-96 Scientific Program Committee, Annual Meeting of the Society of Hospital Epidemiologists of America
- 1993-94, 97-98 Consultant, University Hospitals Consortium for Institutional Guidelines for Use of Granulocyte Stimulating Factors, Management of Community-acquired Pneumonia
- 1993-94 Consultant, Medical Knowledge Self Assessment Program [MKSAP], American College of Physicians
- 1993-95 Member of the Council, Infectious Disease Society of America
- 1994-95 Consultant, CDC Hospital Infection Control Practices Advisory Committee (HICPAC): Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC).  
***MMWR* 44(RR-12)1-13, (1995).**
- 1996-98 Member, Task Force for Society of Critical Care Medicine to develop guidelines for evaluation of fever in the ICU.  
***Crit Care Med* 26:392-408 (1998).**
- 1996-98 Member, Expert Panel convened by the Hospital Society of Health-Systems Pharmacists to develop guidelines for surgical and nonsurgical prophylaxis.
- 1996-97 Advisory Board, Twentieth International Chemotherapy Congress, Sydney, Australia
- 1997 Consultant, Food and Drug Administration
- 1998 Invited Speaker, NIH Consensus Conference, Community-acquired Pneumonia in Adult and Elderly Populations.
- 1998 Consultant, FDA Committee on Anti-infectives
- 1999-2001 Vice-Chair, Antimicrobial Use and Clinical Trials Committee, Infectious Diseases Society of America
- 1999 Consultant, FDA Committee on OTC Topical Antimicrobials and Antiseptics
- 1999 Consultant, CDC-FDA-NIH, Development of a National Public Health Action Plan to Control Antimicrobial Resistance, Atlanta  
**[www.cdc.gov/drugresistance/healthcare](http://www.cdc.gov/drugresistance/healthcare)**
- 1999-2001 Member, Task Force of Society of Critical Care Medicine, Society of Healthcare Epidemiologists of American and the Infectious Diseases Society of America, CDC, to Develop Updated Guideline for Prevention of Intravascular Device-Related Infection  
***Fed Reg* 66:46801-12 (2001).**
- 2000-2002 Co-Chair, Clinical Evaluation Committee, International PROWESS Study Recombinant Activated Protein C for Treatment of Septic Shock  
***N Engl J Med* 344:699-709 (2001).**
- 2000-2003 Member, Steering Committee and Principle Investigator, NIH-NAIAD-DMID Bacteriology and Mycology Study Group (BAMSG)
- 2001 Member, Clinical Evaluation Committee, NIH REMATCH Multi-center Trial of LVAD
- 2001 Chair, Clinical Evaluation Committee, Multi-center Trial of New Medicated Arrow CVC
- 2001 Invited speaker and panelist, Symposium, Antimicrobial Device Testing, Center for Devices and Radiologic Health, Food and Drug Administration, Member, Clinical Evaluation Committee for Prevention of IV Catheter-related Bloodstream Infection
- 2001-2003 Consultant, Wisconsin Antibiotic Resistance Network
- 2001-2004 Member, Clinical Evaluation Committee, Multicenter Trial of novel Micrologix Peptide antibiotic for prevention of vascular catheter-related bloodstream infection
- 2001-4 Consultant, National Response to Bioterrorism, Centers for Disease Control
- 2002 Consultant, Control of Vancomycin-resistant *Staphylococcus aureus* Advisory Committee, Division of Healthcare Quality Promotion, National Center for Infectious Diseases, Centers for Disease Control and Prevention  
***MMWR* 51:565-7, 2002; 51:902 (2002).**

**NATIONAL/INTERNATIONAL SERVICE, Continued****Dennis G Maki, MD**

- 2002-6** Member, Council on Public Health Preparedness,  
U.S. Department of Health and Human Services
- 2003-8** Editorial Board,  
***Mayo Clinic Proceedings***
- 2004-12** Member, National Advisory Council,  
Marshfield Clinic (Chair, Independent Compensation Committee)
- 2004-** Editorial Board,  
***Morbidity and Mortality Weekly Report***,  
Centers for Disease Control and Prevention
- 2004-5** Member, Consensus Conference for International Guideline for Management of Sepsis/Septic Shock, U.S. Society of Critical Care Medicine and European Intensive Care Society, ***Crit Care Med 32:858-73 (2004)***.
- 2005** Member, Working Group to Develop Guidelines for Home Nutritional Support, American Society for Parenteral and Enteral Nutrition, ***JPEN (2006)***
- 2005** Member, Working Group on Guidelines for Prevention and Management of Ventilator-associated Pneumonia, American Association for Respiratory Care, ***Resp Care (2006)***
- 2005** Consultant, Task Force to Prevent Central Venous Catheter-associated Bloodstream Infections, Childrens Hospitals of America
- 2005-8** Member, Task Force for Society of Critical Care Medicine to develop updated guidelines for evaluation of fever in the ICU, ***Clin Infect Dis*** and ***Crit Care Med (in press)***.
- 2005-** Reviewer and Commentator,  
***McMaster Internet PLUS, PIER, BMJ Updates and the Evidence-Based Journals***.
- 2006-2008** Chair, Data Safety Monitoring Board,  
International multicenter trials of ceftobiprole for treatment of nosocomial pneumonia and community-acquired pneumonia.
- 2007-2009** Member, Annual Scientific Program Committee,  
American College of Physicians
- 2007-** Member, Board of Directors,  
International Nosocomial Infection Control Consortium (INIC)
- 2008** Consultant to GAO Report to Congress,  
***Health-Care-Associated Infections in Hospitals*** (GAO-08-1091R), Sept 26, 2008
- 2009** Consultant to UK NHS,  
***2009 NHS HCAI Innovative Technology Summit***
- 2009** Consultant to Health Ministry of Singapore,  
2009 Health Ministry Visiting Professor and Consultant
- 2010** Consultant to UK NHS,  
***The UK National Health Service HCAI Annual Conference. Reducing HCAs – A Transformation Process: Embedding the Culture of Patient Safety.***
- 2012-** Member, Board of Directors and Chair, Independent Compensation Committee,  
***Marshfield Clinic Healthcare System, Marshfield, WI***
- 2014-** Member, Healthcare-associated Infections Work Group, Healthy People 2020 Law and Health Policy Project, ***DHSS-ODPHP-CDC-Robert Wood Foundation***

UNIVERSITY OF WISCONSIN-MADISON AND STATE OF WISCONSIN (active in bold)

1974-2009	Infection Control Committee (Chair and Hospital Epidemiologist, 1974-2009) University of Wisconsin Hospital and Clinics
1974-91, 1996 -	<b>Pharmacy and Therapeutics Committee</b> <b>University of Wisconsin Hospital and Clinics</b>
1974-79	Clinical Affairs Committee, Department of Medicine University of Wisconsin
1975-76, 79-81, 89-90	Search Committee for Chairman of Medical Microbiology University of Wisconsin Medical School
1975-76	Dean's Committee to Review Basic Science Departments University of Wisconsin Medical School
1976-79, 80-84	Student Awards Committee (Chairman, 1978-79) University of Wisconsin Medical School
1977-78	Search and Screen Committee for Dean of the Medical School University of Wisconsin-Madison
1978-81	University Hospital Board University of Wisconsin Center for Health Sciences
1979-80, 1995-99	Medical School Clinical Practice Committee University of Wisconsin Center for Health Sciences
1979-80	Search and Screen Committee for Associate Dean, University of Wisconsin School of Veterinary Sciences
1980-82	Clinical Years Committee (Chairman) University of Wisconsin Medical School
1980-83, 1992-95	Faculty Advisory Committee to the Dean( by vote of the faculty) University of Wisconsin Medical School
1980-83, 1988-93	Educational Policy Council University of Wisconsin Medical School
1980-84	Critical Care Policy Committee University of Wisconsin Hospitals
1980-86	Promotions II Committee [Chairman 1983-84] University of Wisconsin Medical School
1980-86	Critical Care Coordinating Committee University of Wisconsin Hospitals
1981-92	Fourth-Year Committee [Chairman] University of Wisconsin Medical School
1981-89	Executive Committee, Department of Medical Sciences University of Wisconsin Veterinary School
1983-85	Helicopter Transport Committee University of Wisconsin Hospitals
1983-85	Ad Hoc IV Therapy Review Committee University of Wisconsin Hospitals
1982-2006	Ad Hoc Department of Medicine committees to review qualifications of departmental nominees for academic promotion
1983-88	Board of Directors, <i>Health Line</i> University of Wisconsin Medical School
1985-86	Governor's Task Force on AIDS State of Wisconsin
1985-87	Promotions and Tenure Appointments Committee University of Wisconsin Medical School
1986-95	University AIDS Task Force (Chairman) University of Wisconsin-Madison
1986-89	University Hospital Internists Committee University of Wisconsin Medical School
1987-99	Governor's Advisory Council on AIDS State of Wisconsin
1987-88	Long Range Planning Committee, Department of Medicine University of Wisconsin Medical School

**UW AND STATE COMMITTEE SERVICE, Continued****Dennis G Maki, MD**

1988-90 Universal Precautions Task Force  
University of Wisconsin Hospital

1988-1997 Continuing Medical Education Committee  
University of Wisconsin Medical School

1988-2010 Department of Medicine Internship and Residency Committee,  
University of Wisconsin Medical School

1988-93 Course Review Oversight Committee  
University of Wisconsin Medical School

1988-1995 Board of Directors, Oscar Rennebohm Foundation  
Madison, Wisconsin

1989-91 Biomedical Waste Disposal Planning Committee  
University of Wisconsin-Madison

1992-9 Task Force for New Technology to Prevent Biohazardous Injuries,  
University of Wisconsin Hospital and Clinics

1991-96 AIDS Task Force  
University of Wisconsin Hospital and Clinics

1992-93 Tuberculosis Task Force (Chair)  
University of Wisconsin Hospital and Clinics

1993-98 Department of Medicine Research Committee

1993-98 Consultant to the Secretary  
Wisconsin Division of Health and Human Services

1993-94 Search Committee for Head, Section of Cardiology (Chair)  
Department of Medicine, University of Wisconsin Medical School

1995-2003 Consultant to Wisconsin MetaStar, HCFA Quality Improvement Program  
State of Wisconsin

1995-1998,  
2002-5 Academic Policy Council (by vote of the faculty)  
University of Wisconsin Medical School

1985- **Co-author, *Annual Antimicrobial Guidelines***  
**University of Wisconsin Hospital and Clinics**

1996-99 Executive (Promotions) Committee, Division of Biologic Sciences  
University of Wisconsin-Madison (by vote of the faculty)  
(Vice-chair 1997-98, Chair 1998-99).

1999- **Advisor, Chartwell Inc. Home Intravenous Therapy Program**

1999-2003 Dean's HealthStar Leadership Task Force  
University of Wisconsin-Madison

2000 Search Committee, Executive Director, UW Medical Alumni Association

2000- **UWHC Antimicrobial Subcommittee**  
**University of Wisconsin Hospital and Clinics**

2000-9 Disaster Response Committee  
University of Wisconsin Hospital and Clinics

2001-2003 Governor's Task Force on Emergency Preparedness  
State of Wisconsin

2001-2003 Wisconsin State Medical Society Emergency Preparedness Task Force (Chair)  
State of Wisconsin

2001-7 Department of Medicine Executive Committee

2001-2003 Consultant, Wisconsin Antibiotic Resistance Network,  
State of Wisconsin

2002-2004 Member, Chancellor's Task Force on Chronic Wasting Disease  
University of Wisconsin-Madison

2002 Member, Computerized Surveillance System Advisory Committee,  
State of Wisconsin Department of Health and Family Services

2002 Member, State Bioterrorism Surveillance and Epidemiology Work Group,  
State of Wisconsin Department of Health and Family Services

2002-4 Co-chair, Chancellor's Create the Future Campaign  
University of Wisconsin-Madison



**UW AND STATE COMMITTEE SERVICE, Continued**

**Dennis G Maki, MD**

- 2004-12**            **Member, National Advisory Council, Marshfield Clinic (Chair, Independent Compensation Committee)**  
**University of Wisconsin School of Medicine and Public Health**
- 2004-6**            Member, Taskforce to Review Security of Containment Procedures in UW-Madison Research on 1918-like Influenza A Virus  
University of Wisconsin-Madison and advise the Chancellor
- 2006-7**            Member, Taskforce to Advise Chancellor on National Bio-Agro Defense Center, University of Wisconsin-Madison.
- 2007-10**            University Committee (Executive Committee of the UW-Madison Faculty Senate), University of Wisconsin-Madison (by vote of the UW-Madison faculty)
- 2007-10**            Member, Board of Directors, PROFS (by membership on University Committee) University of Wisconsin-Madison
- 2007-8**            Consultative Committee on Financial Emergencies (Chair), University of Wisconsin-Madison
- 2008-11**            Member, Retirement Committee,  
University of Wisconsin Medical Foundation (by vote of the membership)
- 2008-10**            Member, Chancellor's Committee on the Great People Scholarship Program  
University of Wisconsin-Madison
- 2009-10**            Member, Department of Medicine ad hoc Advisory Committee to Evaluate the Structure of Attending Physician Coverage for Inpatient General Medicine.
- 2010-14**            Member, Awards and Honors Committee,  
University School of Medicine and Public Health
- 2010-12**            Member, Fundraising Committee for Great people Scholairships,  
University of Wisconsin-Madison

**Ad Hoc Reviewer for Manuscripts 1974-present**

<i>Acta Paediatrica Scandinavia</i>	<i>Heart and Lung</i>
<i>American Journal of Diseases of Children</i>	<i>Intensive Care Medicine</i>
<i>American Journal of Infection Control</i>	<i>Investigative Dermatology</i>
<i>American Journal of Medical Sciences</i>	<i>Journal of the American Medical Association</i>
<i>American Journal of Medicine</i>	<i>Journal of Investigative Dermatology</i>
<i>American Journal of Neuroradiology</i>	<i>Journal of Intensive Care Medicine</i>
<i>Annals of Internal Medicine</i>	<i>Journal of Investigative Surgery</i>
<i>Annals of Surgery</i>	<i>Journal of Laboratory and Clinical Medicine</i>
<i>Antimicrobial Agents and Chemotherapy</i>	<i>Journal of Pediatrics</i>
<i>Archives of Internal Medicine</i>	<i>Mayo Clinic Proceedings</i>
<i>Archives of Surgery</i>	<i>McMaster PLUS, PIER, BMJ Updates and the</i>
<i>Biomedical Monitor</i>	<i>Evidence-Based Journals</i>
<i>Biomedical Central</i>	<i>New England Journal of Medicine</i>
<i>Chest</i>	<i>Obstetrics and Gynecology</i>
<i>Clinical Anesthesia</i>	<i>Pediatric Infectious Disease</i>
<i>Critical Care Medicine</i>	<i>Pediatrics</i>
<i>European Journal of Clinical Microbiology</i>	<i>PLOS ONE</i>
<i>and Infectious Disease</i>	<i>Resident and Staff Physician</i>
<i>European Journal of Intensive Care</i>	<i>Science</i>
	<i>Swiss Medical Letter</i>

**Editorial Boards**

<i>Infection Control and Hospital Epidemiology</i> (Associate Editor, 1979-93), 1979-2003	<i>Critical Care Medicine</i> , 1989-2003
<i>Journal of Laboratory and Clinical Medicine</i> , 1980-86	<i>Resident and Staff Physician</i> , 2003-6
<i>Critical Care Monitor</i> , 1982-85	<i>Mayo Clinic Proceedings</i> , 2003-7
<i>Journal of Critical Care</i> , 1985-95	<i>Biomedical Central</i> , 2003-
<i>Journal of Infectious Diseases</i> , 1988-90	<i>Morbidity and Mortality Weekly Report</i> , 2004-
	<i>McMaster PLUS, PIER, BMJ Updates and the</i> <i>Evidence-Based Journals</i> , 2005-

## HONORS AND AWARDS

Dennis G Maki, MD

- 1958** Valedictorian  
Edgar Public High School, Edgar, WI
- 1960-62** General Motors Scholar  
University of Wisconsin-Madison
- 1960** Ingersoll Award in Physics  
University of Wisconsin-Madison
- 1962** Phi Kappa Phi  
University of Wisconsin-Madison
- 1965** Mosby Award  
University of Wisconsin Medical School
- 1967** Alpha Omega Alpha  
University of Wisconsin Medical School
- 1971** Commendation Medal  
Center for Disease Control
- 1972** Outstanding Senior Medical Resident Award  
Massachusetts General Hospital
- 1975** Outstanding Clinical Teacher Award  
University of Wisconsin Medical School  
Awarded endowed Ovid O. Meyer Chair in Medicine  
University of Wisconsin-Madison
- 1976** Kiekhofer Award for Distinguished Teaching  
University of Wisconsin-Madison  
Medical Alumni Teaching Award  
University of Wisconsin Medical School  
First Award for Excellence in Teaching Medical House Officers  
University of Wisconsin Department of Medicine
- 1978** Macklin Memorial Lecture  
U.S. Naval Medical Center, Portsmouth, VA
- 1980** Medical Alumni Teaching Award  
University of Wisconsin Medical School  
Moulache Memorial Lecture  
University of Pittsburgh Medical School  
Award for Distinguished Achievement in Antibiotic Review  
Second National Conference on Antibiotic Review  
Award for Most Outstanding Research Paper  
Annual Meeting of the Association for Practitioners in Infection Control
- 1981** Listed in ***Best Doctors in the United States***,  
Pekkanen J., Harper and Row, New York, 1981
- 1982** Award for Outstanding Teaching, Second Year Class,  
University of Wisconsin Medical School
- 1983** Milford O. Rouse Memorial Lecture  
Baylor University Medical Center, Dallas  
Wisconsin Medical Alumni Teaching Award  
University of Wisconsin Medical School
- 1983-88** Board of Directors,  
National Medical Honor Society, Alpha Omega Alpha
- 1984** Paper, Infection Control in Infusion Therapy, ***Ann Intern Med* 79:867-887 (1973)**, recognized in  
***Current Contents* 33:22 (1984)** as "Citation Classic," one of most heavily cited biomedical  
papers during 1974-84
- 1985** Listed in, ***Who's Who in the United States***,  
Marquis *Who's Who*
- 1986** Edward J.L. Lowbury Lecture  
British Hospital Infection Society, London
- 1987** Investiture Marshal, Graduating Medical Class (by vote of the class)  
University of Wisconsin Medical School  
Outstanding Speaker Award, American Society of Clinical Chemistry  
Cited in, Sunshine L and Wright JW, ***The Best Hospitals in America***
- 1987-94** Scientific Program Committee, Interscience Conference on Antimicrobial  
Agents and Chemotherapy, American Society for Microbiology

## HONORS AND AWARDS, Continued

Dennis G Maki, MD

- 1988-91** Vice-president, President-Elect, President, Past-President  
Society of Hospital Epidemiologists of America
- 1988-95** Board of Directors  
Oscar Rennebohm Foundation
- 1988** Convocation Lecturer  
Lawrence University  
Harry Shubin Memorial Lecture  
University of Southern California Annual Critical Care Symposium  
National Health Care Cost-containment Professional of the Year Award  
McFauls and Lyons, Inc.  
National Foundation for Infectious Diseases Lectureship  
Annual Meeting of the Association for Professionals in Infection Control, Dallas  
Distinguished Service Award, Metropolitan School District  
Madison, Wisconsin
- 1989** Harry F. Dowling Lecture and Visiting Professorship  
University of Illinois College of Medicine
- 1989-95** American Board of Internal Medicine  
Test Committee on Critical Care Medicine
- 1989-90** Scientific Program Committee, Third International CDC Conference on Nosocomial Infections,  
Atlanta
- 1990** Harshfield Memorial Lecture, Swedish American-Medical Center,  
University of Illinois College of Medicine  
Dascomb Visiting Professorship and Lecture,  
Louisiana State University Medical School  
Advisory Board, Second International Symposium on Nosocomial Infection Control in Intensive  
Care, Freiburg, Germany
- 1991** Medical Alumni Teaching Award  
University of Wisconsin Medical School  
Harry Shubin Memorial Lecture  
University of Southern California - Chicago Medical School,  
Annual Critical Care Symposium, Las Vegas  
Cited in, ***The Best Doctors in America***, Woodward/White Inc., Aiken, SC  
Johnson and Johnson Visiting Professorship, Baylor University College of Medicine - Methodist  
Hospital Medical Center, Houston
- 1992** Trustbank - Canterbury Visiting Professorship, Otago Medical School and Christchurch Hospital,  
Christchurch, New Zealand
- 1992-95** Member of the Council,  
Infectious Diseases Society of America
- 1993** Cited in, ***Madison Magazine*** (April 1993) as "Top Doctor in Dane County," based on survey of  
practicing physicians  
Induction into Edgar High School Alumni Hall of Fame, Edgar, Wisconsin  
Balfour Visiting Professorship and Memorial Lecture, Mayo Clinic  
Keynote Speaker, 18th Annual Meeting of the Australian and  
New Zealand Intensive Care Society
- 1994** Harry Shubin Memorial Lecture  
University of Southern California Annual Critical Care Symposium  
Hickman-Broviac Award of Excellence,  
National Association of Vascular Access Networks (NAVAN)  
Medical Alumni Teaching Award  
University of Wisconsin Medical School  
Biennial CIPI Award of the International Congress on Infection Control,  
Societe de Pathologie Infectieuse de Langue Francaise,  
World Health Organization and the U.S. Centers for Disease Control, for exceptional  
contributions to the prevention of infection, Nice, France  
Keynote Address, Annual Meeting of the Australian Society for Microbiology,  
Melbourne, Australia
- 1995** Ralph White Memorial Lecture  
Georgia Baptist Medical Center, Atlanta, GA

## HONORS AND AWARDS, Continued

Dennis G Maki, MD

- 1996** Johnson and Johnson Visiting Professorship  
Rush Medical College  
Listed in, ***The Best Doctors in America***,  
Woodward/White Inc., Aiken, SC  
Keynote Address,  
Annual Meeting of the Norwegian Forum for Hospital Infection Control, Oslo, Norway  
Keynote Speaker, White Coat Investiture Ceremony,  
University of Wisconsin Medical School  
Laureate Award,  
Wisconsin Chapter, American College of Physicians  
Cited in "Leading Physicians in Dane County,"  
***Madison Magazine***,  
Listed in, ***American Men and Women of Science***  
Clara Franks Memorial Lecture, Thirteenth Annual Conference of the Deborah Heart and Lung  
Center, Atlantic City  
Dean's Medical Communications Award  
University of Wisconsin Medical School
- 1997** Friend of APIC Award, Wisconsin Chapter, Association for Professionals in Infection Control, for  
career contributions to infection control in Wisconsin.  
Award for Outstanding Research Paper to fellow, Paul Tambyah, MBBS,  
Annual Meeting of the Infectious Disease Society of America  
Pfizer National Visiting Professorship  
University of Oklahoma Medical Center  
The Sir Stanley Davidson Memorial Lecture  
Royal College of Physicians, Edinburgh, Scotland
- 1998** Investiture Marshal, Graduating Medical Class (by vote of the class)  
University of Wisconsin Medical School  
AMWA Gender Equity Award  
University of Wisconsin Medical School  
Listed in, ***Who's Who in Science and Engineering***,  
Marquis *Who's Who*
- 1999** Centennial Perspectives Speaker, "Medical and Scientific Advances and the State of Healthcare in  
the Late 20th Century: the Benefit of Good Science", Madison Downtown Rotary Club  
SHEA Lecture,  
Society for Healthcare Epidemiology in America, San Francisco,  
Outstanding SHEA Research Trainee Award to Fellow, Paul Tambyah, MBBS,  
Annual Meeting of the Society for Healthcare Epidemiology of America  
Elected to Fellowship, American Academy of Microbiology  
Keynote Address, Annual Meeting of the Canadian Hospital Infection Control Association, Moncton,  
New Brunswick
- 2000** Named Master, American College of Physicians  
Keynote Speaker, Inaugural Initiation Ceremony of UW-Madison Chapter,  
Alpha Epsilon Delta, National Premedical Honor Society  
Erwin R. Schmidt Interstate Teaching Award  
Wisconsin State Medical Society  
Theodor Lang Memorial Lecture  
St. Anthony Hospital, Rockford, IL  
Harry Shubin Memorial Lecture  
University of Southern California Annual Critical Care Symposium  
Society Citation for Outstanding Achievements in Infectious Disease Research  
Annual Meeting of the Infectious Disease Society of America  
Cited in, ***Madison Magazine*** (October 2000), as "Top Infectious Disease Doctor" in Dane County,  
based on survey of 800 practicing physicians  
Invited Faculty, UW-Madison Alumni University 2000  
Elected to Honorary Membership, Wisconsin Dental Forum  
Clinical Teaching Award  
UW Medical School Class of 2000  
Pfeifferberger Memorial Lecture  
Annual Meeting of the Interstate Postgraduate Medical Association, San Francisco, CA

- 2001**
- Hilldale Award for Distinguished Contributions in Teaching, Research and Service, University of Wisconsin-Madison Division of Biological Sciences
  - Folkert R. Belzer Award for Outstanding Contributions in Academic Medicine, University of Wisconsin Medical School
  - Abbott Epidemic (***Am J Med* 60:471-85 (1978)**) cited by CDC as one of 10 most important epidemics investigated by CDC during the past 50 years
  - Invited Speaker, Fiftieth Anniversary Celebration, CDC Epidemic Intelligence Service
  - McCracken Award for Outstanding Research Paper to Fellow, Nasia Safdar, MD
  - 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL
- 2002**
- Charles J. Hatem Visiting Professorship
  - Mt. Auburn Hospital, Harvard Medical School
  - Award for Outstanding Research Paper
  - Fifth Joint Annual Meeting of the AANS/CNS Section on Cerebro-vascular Surgery and the American Society of Interventional and Therapeutic Neuroradiology
  - Guest Speaker,
  - 40th Reunion of Class of 1962, University of Wisconsin-Madison
  - Cited in ***Madison Magazine*** (October 2002),
  - “Top Infectious Disease Doctor” in Dane County, based on survey of community physicians.
  - Cited in ***The Best Doctors in America***,
  - Woodward/White, Inc., Aiken, SC (2002)
  - Harry Shubin Memorial Lecture
  - University of Southern California Annual Critical Care Symposium, Las Vegas
  - Michael Rytel Memorial Lecture
  - Southeast Wisconsin Infectious Diseases Society, Milwaukee, WI
  - Theodor Lang Memorial Lecture
  - St. Anthony Hospital, Rockford, IL
  - J. Robert Funderburg Memorial Lecture
  - University of Illinois-Rockford, Rockford Memorial Hospital
  - President-elect, Interstate Post-graduate Medical Association of North America
  - McCracken Award for Outstanding Research Paper to fellow, Nasia Safdar, MD
  - 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA
  - Pfeiffenbarger Memorial Lecture
  - Annual Meeting of the Interstate Postgraduate Medical Association, Anaheim, CA
  - Appointed to Editorial Board,
  - Mayo Clinic Proceedings*
- 2003**
- Annual SHEA Outstanding Research Trainee Award to Fellow, Nasia Safdar, MD
  - Annual Meeting of the Society for Healthcare Epidemiology of America
  - 3M/SHEA Research Fellowship Award to Fellow, Christopher Crnich, MD
  - Annual Meeting of the Society for Healthcare Epidemiology of America
  - Cited in “UW Hospital’s Best Doctors, ”
  - In Business***, May 2003
  - Cited in ***America’s Top Doctors, 3rd Edition***
  - Cooper and Connelly Medical Ltd., April 2003
  - Pfizer National Visiting Professorship
  - Texas A and M Medical School
  - JFICM Lecture, Annual Meeting of the Australian and New Zealand College of Anesthesiology and Joint Faculty for Intensive Care Medicine, Gold Medal, Australian and New Zealand College of Anesthesiology, Hobart, Australia
  - Theodor Lang Memorial Lecture
  - St. Anthony Hospital, Rockford, IL
  - Pfeiffenbarger Memorial Lecture
  - Annual Meeting of the Interstate Postgraduate Medical Association, Anaheim, CA
  - President,
  - Interstate Postgraduate Medical Association
  - Elected to Fellowship,
  - Wisconsin Academy of Sciences Arts and Letters
  - 2003 Division L Lecture
  - 103rd Annual Meeting of the American Society of Microbiology, Washington, DC

- 2003 Professionalism Award,  
University of Wisconsin Department of Medicine Housestaff
- George G. Ruder Annual Lecture,  
Communication Foundation of North Central Wisconsin, Wausau, WI
- 2004** Appointed to Editorial Board, ***Morbidity and Mortality Weekly Report***,  
Centers for Disease Control and Prevention
- Keynote Address, Second International Congress of the Asia-Pacific Society of Infection Control,  
Singapore
- George Funderberg Lecture, Rockford Memorial Hospital,  
University of Illinois-Rockford
- Keynote Address, Research Day,  
University of Illinois-Rockford College of Medicine
- Cited in ***Madison Magazine*** as “Top Infectious Disease Doctor” in Dane County,  
based on survey of community physicians.
- Appointed to Marshfield Clinic National Advisory Council and Research Foundation,  
Marshfield Clinic and Research Foundation
- Listed in ***America’s Top Doctors 2004***,  
Castle-Connolly Medical Ltd
- Arthur White Annual Lecture and Visiting Professorship  
University of Indiana Medical Center
- Interviewed for University of Wisconsin-Madison Oral history Archive  
<http://archives.library.wisc.edu/ORAL/guide/set66.htm#ohno656>
- 2005** Listed in ***Who’s Who in America 2005 (59th Edition)***,  
Marquis *Who’s Who*
- Robert Glaser Clinical Star Visiting Professor,  
Washington University-Barnes-Jewish Medical Center, St Louis
- Listed in ***Who’s Who in Medicine 2005 (5th Edition)***,  
Marquis *Who’s Who*
- 2005 Plato Lecture,  
Wisconsin Academy of Arts, Sciences and Letters
- Keynote Address, 5<sup>th</sup> International IV Therapy Conference,  
Oxford, U.K.
- Listed in ***Who’s Who in American Education 2006-2007***,  
Marquis *Who’s Who*
- Investiture Marshal, Graduating Medical Class (by vote of the members)  
University of Wisconsin Medical School
- Keynote Address and Felix Pifano Memorial Lecture,  
13<sup>th</sup> Annual Congress of the Venezuelan Society  
of Internal Medicine–American College of Physicians
- Listed in ***America’s Top Doctors 2005***,  
Castle-Connolly Medical Ltd.
- Theodor Lang Memorial Lecture  
St. Anthony Hospital, Rockford, IL
- 2006** Listed in ***America’s Top Doctors 2006***,  
Castle-Connolly Medical Ltd
- Keynote Address, 6<sup>th</sup> International IV Therapy Conference,  
Oxford, U.K.
- Keynote Address, 4<sup>th</sup> Vascular Infusion Technology Symposium,  
Waljik, Netherlands
- Theodor Lang Memorial Lecture  
St. Anthony Hospital, Rockford, IL
- Cited in ***Madison Magazine*** as “Top Infectious Disease Doctor” in Dane County and  
Service to the Profession Award, based on survey of county physicians.
- Evans-Glassroth Teaching Award for excellence in educating residents and fellows,  
University of Wisconsin Department of Medicine
- National Heros of Infection Control Award: The University of Wisconsin Team,  
Annual Conference of the Association of Practitioners in Infection Control, Phoenix
- 2007-9** Scientific Program Committee,  
Annual Meeting of the American College of Physicians

## HONORS AND AWARDS, Continued

Dennis G Maki, MD

- 2007-10** Member, University Committee (by vote of the Faculty),  
Executive Committee of the Faculty Senate, University of Wisconsin-Madison
- 2007** Harry Shubin Memorial Lecture  
University of Southern California Annual Critical Care Symposium, Las Vegas  
Commencement Speaker (by vote of the Graduating Class)  
University of Wisconsin School of Medicine and Public Health  
Invited Faculty,  
UW-Madison Alumni University 2007  
Rutala Award for outstanding research paper on environmental aspects of infection control,  
Annual Conference of the Association of Practitioners in Infection Control, Phoenix, AZ  
Angelo P. Creticos Lecture and Visiting Professorship,  
University of Illinois College of Medicine—Masonic Medical Center, Chicago  
Listed in ***America's Top Doctors 2007***  
Castle-Connolly Medical Ltd  
Keynote Address,  
Finnish National Conference for Anesthesiology and Surgery--*Operatiiviset päivät*, Helsinki  
Listed in ***Best Doctors in America, 2007-8***  
<http://www.bestdoctors.com/bd/index.php>  
Listed in ***Who's Who in American Education, 2007-2008***  
Marquis' *Who's Who*  
Harry Beamis Lecture and Visiting Professorship,  
Lahey Clinic, Tufts Medical School
- 2008** Harry Shubin Memorial Lecture  
University of Southern California Annual Critical Care Symposium, Las Vegas  
Theodur Lang Memorial Lecture  
St. Anthony Hospital, Rockford, IL  
Keynote address  
Joint International Symposium on Infectious Diseases of the University of Illinois and the Pan  
American Infectious Diseases Society. Chicago, IL  
Cited in ***Madison Magazine*** as "Top Infectious Disease Doctor" in Dane County,  
based on survey of community physicians.  
Keynote address  
25<sup>th</sup> Annual Meeting of Scandanavian Society for Antimicrobial Chemotherapy, Copenhagen
- 2009** Listed in ***Who's Who in America, 2009***  
Marquis' *Who's Who*  
Listed in ***America's Top Doctors 2009***  
Castle-Connolly Medical Ltd  
Public Health Leadership Award,  
Department of Public Health for Madison and Dane County, Wisconsin  
Distinguished Alumni Award,  
University of Wisconsin Medical Alumni Association  
Harry Shubin Memorial Lecture  
University of Southern California Annual Critical Care Symposium, Palm Springs  
Keynote Adress, Fourth International Congress of the Asia-Pacific Society of Infection Control,  
Macau, China  
Singapore Ministry of Health 2009 Visiting Professor,  
Singapore General Hospital and Singapore National University Hospital  
2009 Heritage Foundation Award,  
Marshfield Clinic Heritage Foundation, Marshfield, Wisconsin  
The Dennis G Maki MD University of Wisconsin Infectious Disease Symposium,  
Wisconsin Dells, WI
- 2010** Listed in ***Best Doctors in America 2010-11***  
[www.bestdoctors.com](http://www.bestdoctors.com)  
Listed in ***Who's Who in America, 2010***,  
Marquis *Who's Who*  
Listed in ***Who's Who in Healthcare, 2010***,  
Marquis *Who's Who*  
Listed in ***America's Top Doctors 2010***, 9<sup>th</sup> Edition,  
Castle-Connolly Medical Ltd



- Investiture Marshal, Graduating Medical Class (by vote of the members)  
University of Wisconsin School of Medicine and Public Health  
Keynote address, World Congress of Vascular Access,  
Amsterdam, Netherlands
- Outstanding Off-Service Faculty Teaching Award,  
University of Wisconsin Department of Emergency Medicine  
Cited in **Madison Magazine** as "Top Infectious Disease Doctor" in Dane County,  
based on survey of community physicians.
- The International Lecture,  
Annual UK NHS HCAI Annual Conference, London, UK.
- 2011** Commencement Speaker (by vote of the graduating residency class),  
Graduation Banquet of the University of Wisconsin Internal Medicine Residency Program.  
Listed in **Who's Who in America, 2011**,  
Marquis *Who's Who*  
Listed in **America's Top Doctors 2011**, 10th Edition,  
Castle-Connolly Medical Ltd  
2011 American Society of Microbiology Lecturer,  
Annual Congress of the Japanese Association for Infectious Disease, Tokyo  
Evans-Glassroth teaching Award,  
University of Wisconsin Department of Medicine  
Keynote Address,  
Chilean Society for Hospital Infection Control -- VI Curso IASS, Santiago, Chile,  
Keynote presentation,  
The Dennis G Maki MD University of Wisconsin Infectious Disease Symposium,  
Wisconsin Dells, WI
- 2012** Harry Shubin Memorial Lecture  
Weil Annual Critical Care Symposium, Las Vegas  
Listed in **Who's Who in America, 2012**,  
Marquis *Who's Who*  
Investiture Marshal, Graduating Medical Class (by vote of the class)  
University of Wisconsin School of Medicine and Public Health  
Listed in **America's Top Doctors 2012**, 11th Edition,  
Castle-Connolly Medical Ltd  
Cited in **Madison Magazine** as "Top Infectious Disease Doctor" and "Top Critical Care Physician" in  
Dane County, based on survey of community physicians.  
Listed in **Best Doctors in America 2012-13**  
[www.bestdoctors.com](http://www.bestdoctors.com)
- 2013** Keynote Lecture, Legacy of Life Symposium honoring Professor John Burke  
University of Utah School of Medicine  
Listed in **Who's Who in America, 2013**,  
Marquis *Who's Who*  
Max Harry Weil Memorial Lecture  
Weil Annual Critical Care Symposium, Las Vegas  
Named Honorary Resident of the University of Wisconsin Hospital and Clinics Pharmacy  
Graduate and Residency Program at its 50<sup>th</sup> Anniversary Celebration
- 2014** Listed in **Who's Who in America, 2014**,  
Marquis *Who's Who*  
Listed in **America's Top Doctors 2014**, 12th Edition,  
Castle-Connolly Medical Ltd  
Listed in **Best Doctors in America 2013-14**  
[www.bestdoctors.com](http://www.bestdoctors.com)  
Keynote Speaker at opening session symposium, *Four Decades of Difference*,  
40th Annual Conference of the Association for Professionals in Infection Control  
Keynote Medical Presentation, Dedication of Sauk-Prairie Hospital  
Sauk-Prairie, Wisconsin  
Investiture Marshal, Graduating Medical Class (by vote of the class)  
University of Wisconsin School of Medicine and Public Health  
Cited in **Madison Magazine** as "Top Infectious Disease Doctor" in Dane County,  
based on survey of community physicians.

## HONORS AND AWARDS, Continued

Dennis G Maki, MD

2015

Listed in *Who's Who in America, 2015*,

Marquis *Who's Who*

Listed in *America's Top Doctors 2015*, 13th Edition,

Castle-Connolly Medical Ltd

Listed in *Best Doctors in America 2014-15*

[www.bestdoctors.com](http://www.bestdoctors.com)

Keynote Lecture,

3<sup>rd</sup> International Conference on Prevention and Infection Control (ICPIC), Geneva, Switzerland.

1. **Maki DG.** Oropharyngeal ecology (Letter to the Editor). *New Engl J Med* 282:814-5 (1970).
2. Bennett JV, Scheckler WE, **Maki DG**, Brachman PS. Surveillance of nosocomial infections, in *Proceedings of the 1st International Conference on Nosocomial Infections*, Center for Disease Control, Brachman PS, Eickhoff TE (Editors), Chicago, American Hospital Association, 1971, pp 42-9.
3. Garner JS, Bennett JV, Scheckler WE, **Maki DG**, Brachman PS. Surveillance of nosocomial infections, in *Proceedings of the 1st International Conference on Nosocomial Infections*, Center for Disease Control, Brachman PS, Eickhoff TE (Editors), Chicago, American Hospital Association, 1971, pp. 277-81.
4. **Maki DG**, Hennekens CH, Bennett JV. Prevention of catheter-related urinary tract infection: An additional measure. *JAMA* 221:1270-1 (72).
5. Goldmann DA, **Maki DG**. A rational approach to the problem of sepsis in hyperalimentation therapy. *Symposium on Total Parenteral Nutrition*, Nashville, 1972, American Medical Association, pp. 132-40.
6. **Maki DG**, Rhame FS, Mackel DC, Bennett JV. The infection hazard posed by contaminated intravenous infusion fluid. *Bacteremia--Laboratory and Clinical Aspects*, **Sonenwirth AC (Editor)**, Springfield, IL, Charles C. Thomas Co., 1973, pp. 76-91.
7. Bloch KJ, **Maki DG**. Hyperviscosity syndromes associated with immunoglobulin abnormalities. *Semin Hematol* 10:113-24 (73).
8. Goldmann DA, **Maki DG**. Infection control in total parenteral nutrition. *JAMA* 223:1360-4 (73).
9. **Maki DG**, Hennekens CG, Phillips CW, Shaw WV, Bennett JV. Nosocomial *Serratia marcescens* urinary tract infection: an epidemiologic study. *J Infect Dis* 128:579-87 (73).
10. **Maki DG**, Goldmann DA, Rhame FS. Infection control in intravenous therapy. *Ann Intern Med* 79:867-87 (73).  
Cited in *Current Contents* 33:24 (1984) as "Citation Classic".
11. Goldmann DA, **Maki DG**, Rhame FS, Kaiser AB, Tenney JH, Bennett JV. Guidelines for infection control in intravenous therapy. *Ann Intern Med* 79:848-50 (73).
12. Goldmann DA, **Maki DG**. Contamination of fluid for parenteral nutrition (Letter to the Editor), *N Engl J Med* 290:1437-8 (74).
13. **Maki DG**, Anderson RL, Shulman JA. A study of in-use contamination of intravenous infusion fluid. *Appl Microbiol* 28:778-84 (74).
14. Goldmann DA, **Maki DG**. The problem of sepsis in total parenteral nutrition. *Total Parenteral Nutrition*, White PL, Nagy ME (Editors), Publishing Sciences Group, Inc., 1974, pp. 319-28.
15. **Maki DG**, Martin WT. Nationwide epidemic of septicemia caused by contaminated infusion products. IV. Growth of microbial pathogens in fluids for intravenous infusion. *J Infect Dis* 131:267-72 (75).
16. **Maki DG**, Drinka PJ. Suppurative phlebitis of an arm vein from a "scalp vein needle". *N Engl J Med* 292:1116-7 (75).
17. **Maki DG**. Intramedullary vs. intra-arterial infusion – reply (Letter). *N Engl J Med* 293:309-10 (75).
18. **Maki DG**. Scalp-vein needle and infection -- reply (Letter). *N Engl J Med* 293:560 (75).
19. **Maki DG**. Infection control and the IV therapist. *Am J IV Therapy* 2:24-7 (75).

**PUBLICATIONS, Continued****Dennis G Maki, MD**

20. Mackel DC, **Maki DG**, Anderson RL, Bennett JV. Nationwide epidemic of septicemia caused by contaminated intravenous products. III. Mechanisms of contamination during manufacture. *J Clin Microbiol* 2:486-96 (75).
21. **Maki DG**, Rhame FS, Mackel DC, Bennett JV. Nationwide epidemic of septicemia caused by contaminated intravenous products. I. Epidemiological and clinical features. *Am J Med* 60:471-85 (76).
22. **Maki DG**. Final filters in IV therapy. *Hosp Infect Control* 3:22-3 (76).
23. **Maki DG**. Septic Thrombophlebitis: I. Pathophysiology, diagnosis and management. *Hosp Medicine* 12(12):36-49 (76).
24. **Maki DG**. Septic Thrombophlebitis: II. Pelvic thrombophlebitis, pyelophlebitis, and septic thrombophlebitis related to IV therapy. *Hosp Medicine* 13(1):6-29 (76).
25. Rhame FS, **Maki DG**. Non-suppurative septic thrombophlebitis (Letter to Editor). *Arch Surg* 111:832 (76).
26. **Maki DG**. Lister Revisited--surgical antisepsis and asepsis (Editorial). *N Engl J Med* 294:1286-7 (76).
27. **Maki DG**. Preventing infection in intravenous therapy. *Hosp Practice* 11(4):95-104 (76).  
Republished in *Anesth Analg* (Cleve.) 56:141-53 (77).
28. **Maki DG**. Preventing infusion-related infections. *Drug Therapy* 2(1):37-46 (77).
29. **Maki DG**. Growth properties of microorganisms in infusion fluid and methods of detection. *Microbiologic Hazards of Intravenous Therapy*, Phillips I (Editor), MTP Press Ltd., Lancaster, England, 1977, pp. 13-47.
30. **Maki DG**. Sepsis arising from extrinsic contamination of the infusion and measures for control. *Microbiologic Hazards of Infusion Therapy*, Phillips I (Editor), MTP Press Ltd., Lancaster, England, 1977, pp. 99-141.
31. **Maki DG**, Weise CE, Sarafin HW. A semiquantitative method for identifying intravenous catheter-related infection. *N Engl J Med* 296:1305-9 (77).  
Reviewed and abstracted in *Yearbook of Medicine, 1978*.
32. **Maki DG**, Jarrett F, Sarafin HW. A semiquantitative culture method for identification of catheter-related infection in the burn patient. *J Surg Res* 22:513-20 (77).  
Reviewed and abstracted in *Yearbook of Plastic Surgery, 1978*.
33. Helstad AG, Kimball JL, **Maki DG**. Recovery of anaerobic and aerobic bacteria from clinical specimens in three anaerobic transport systems. *J Clin Microbiol* 6:564-9 (77).
34. **Maki DG**. Nosocomial infections (Editorial). *The Double Helix* 5:2-4 (77).
35. **Maki DG**. Book Review: "Total Parenteral Nutrition," Edited by J. Fischer, Little, Brown and Company, 1976. *Chest* 71:22-4 (77).
36. Agger WA, **Maki DG**. Septicemia from heparin-lock needles (Comments Section). *Ann Intern Med* 86:657 (77).
37. Hanson PG, Standridge J, Jarrett F, **Maki DG**. Fresh water wound infection due to *Aeromonas hydrophila* *JAMA* 238:1053-4 (77).
38. **Maki DG**, Agger WA. Ludwig's angina. *Morbidity Mortality Weekly Rep* 26:199-200 (77).

**PUBLICATIONS, Continued****Dennis G Maki, MD**

39. **Maki DG.** Identification of catheter-related infection -- reply (Letter). *N Engl J Med* 297:617 (77).
  40. **Maki DG.** The epidemiology of surgical wound infections--guidelines for prevention. *J Surg\_Practice* 6:10-30 (77).
  41. Agger WA, Caplan RH, **Maki DG.** Ocular sporotrichosis mimicking mucormycosis in a diabetic. *Ann Ophthalmol* 10:543-8 (78).
  42. Goldmann DA, Fulkerson CC, Dixon RE, **Maki DG,** Bennett JV. Nationwide epidemic of septicemia caused by contaminated intravenous products. II. Assessment of the problem by a national nosocomial infection surveillance system. *Am J Epidemiol* 108:207-13 (78).
  43. **Maki DG,** Schuna AA. A study of antimicrobial misuse in a university hospital. *Am J Med Sci* 275:271-82 (78).
  44. Jarrett F, **Maki DG,** Chan C. Septic thrombosis of the inferior vena cava caused by *Candida*. *Arch Surg* 113:637-9 (78).
  45. Agger WA, **Maki DG.** Mucormycosis. A complication of critical care. *Arch Intern Med* 138:925-7 (78).
  46. **Maki DG.** Q fever. *Current Therapy*, Conn HF (Editor), W.B. Saunders, Philadelphia. 1978, pp. 52-4.
  47. Agger WA, **Maki DG.** Efficacy of the direct gram stain in differentiating staphylococci from streptococci in blood cultures positive for gram-positive cocci. *J Clin Microbiol* 7:111-3 (78).
  48. Ferguson EE, **Maki DG.** A baffling hyperpyrexia. *Hosp Practice* 13(3): 111-24 (78).
  49. Garfield MD, Ershler WB, **Maki DG.** Malaria Transmission by platelet concentrate transfusion. *JAMA* 240:2285-6 (78).
  50. **Maki DG,** Kurzynski TA, Agger WA. Carbenicillin for treatment of *Bacteroides fragilis* infections. Why not penicillin G? *J Infect Dis* 138:859-64 (78).
  51. **Maki DG.** Non-infective complications of infusion therapy. *Infusion* 2:89-107 (78).
  52. **Maki DG.** Control of colonization and transmission of pathogenic bacteria in the hospital. *Ann Intern Med* 89(Part 2):777-80 (78).
  53. **Maki DG,** Band JD. Septicemia from disposable pressure-monitoring chamber domes--"Beware of Greeks Bearing Gifts" (Editorial). *Chest* 74:486-7 (78).
  54. Rhame FS, **Maki DG,** Bennett JV. IV cannula-associated infections. *Hospital Infections*, Bennett JV, Brachman PS (Editors), Little, Brown & Co., Boston, 1979, pp. 433-42.
  55. Goldmann DA, **Maki DG,** Bennett JV. Intravenous infusion associated infections. *Hospital Infections*, Bennett JV, Brachman PS (Editors), Little, Brown & Co., Boston, 1979, pp. 443-52.
  56. **Maki DG,** McCormick RD, Wirtanen GW. Septic endarteritis due to intra-arterial catheters for cancer chemotherapy. I. Evaluation of an outbreak. II. Risk factors, clinical features and management. III. Guidelines for prevention. *Cancer* 44:1228-40 (79).
- Reviewed and abstracted in *Yearbook of Oncology, 1980.*
57. **Maki DG,** Craig WA, Agger WA. A comparative clinical trial of sisomicin and gentamicin in major gram-negative infections. *Infection* 7(Suppl 3):298-300 (79).

**PUBLICATIONS, Continued****Dennis G Maki, MD**

58. Karchmer A, Moellering R, **Maki DG**, Swartz M. Single antibiotic therapy of streptococcal endocarditis. *JAMA* 241:1801-6 (79).
59. Band JD, **Maki DG**. Safety of changing intravenous delivery systems at longer than 24-hour intervals. *Ann Intern Med* 91:173-8 (79).
- Reviewed in *Yearbook of Medicine, 1980*.
60. **Maki DG**. Infectious complications of infusion therapy and prevention. *Modern IV Practices*, Chicago, IL, Medical Directions Inc., 1979 pp. 1-50.
61. **Maki DG**. Microbiologic surveillance. *Modern IV Practices*, Chicago, IL, Medical Directions Inc., 1979, pp. 1-31.
62. **Maki DG**. Evaluation of a suspected epidemic. *Modern IV Practices*, Chicago, IL, Medical Directions Inc., 1979, pp. 1-26.
63. **Maki DG**. The consequences of antibiotic overuse: Ammunition for a hospital program of improvement. *Practical Aspects of Antibiotic Review. Proceedings of the First National Conference on Antibiotic Review*, Atlanta, GA, American Health Consultants, Inc., 1979 pp. 31-40.
64. **Maki DG**. The carrot or the stick: Constructing antibiotic education and restriction programs. *Practical Aspects of Antibiotic Review. Proceedings of the First National Conference on Antibiotic Review*, Atlanta, GA, American Health Consultants, Inc., 1979 pp. 193-211.
65. Band JD, **Maki DG**. A semiquantitative culture technique for identifying infection due to steel needles used for intravenous therapy. *Am J Clin Pathol* 72:980-4 (79).
66. Drow DL, Manning DD, **Maki DG**. Indirect sandwich enzyme-linked immunosorbent-assay for rapid detection of *Haemophilus influenzae* Type b infection. *J Clin Microbiol* 10(4):442-50 (79).
67. Band JD, **Maki DG**. Infections caused by arterial catheters used for hemodynamic monitoring. *Am J Med* 67:735-41 (79).
- Reviewed and abstracted in *Yearbook of Medicine, 1980*.
68. **Maki DG**. The Hospital Epidemiologist. *Proceedings of the Sixth Annual Meeting of the Association of Practitioners in Infection Control*, Association for Practitioners in Infection Control, Inc., 1979, pp. 32-9.
69. **Maki DG**, Helstad AG, Kimball JL. Penicillin susceptibility of *Streptococcus pneumoniae* in 1978. Screening for resistance by disk testing. *Am J Clin Pathol* 73:177-82 (80).
70. **Maki DG**. Through a glass darkly, nosocomial pseudoepidemics and pseudobacteremias (Editorial). *Arch Intern Med* 140:26-8 (80).
71. Band JD, **Maki DG**. Steel needles used for intravenous therapy: Morbidity in patients with hematologic malignancy. *Arch Intern Med* 140:31-4 (80).
72. **Maki DG**. *Sepsis associated with infusion therapy. Controversies in Surgical Sepsis: Proceedings of an International Symposium*, Karran S (Editor), London, Praeger, 1980, pp. 207-53.
73. **Maki DG**, Nauseef WN. Simple protective isolation in patients with granulo-cytopenia. *Proceedings of the 11th International Congress of Chemotherapy, Current Chemotherapy and Infectious Disease*, Nelson JC, Grassi C (Editors), Washington, D.C., American Society for Microbiology, 1980, pp. 1091-2.

**PUBLICATIONS, Continued****Dennis G Maki, MD**

74. **Maki DG**, Zilz MA, Alvarado CJ. Evaluation of the anti-bacterial efficacy of four agents for handwashing. *Current Chemotherapy and Infectious Disease Proceedings of the 11th International Congress on Chemotherapy and the 19th ICAAC*, Nelson JC, Grassi C (Editors), Washington, D.C., American Society for Microbiology, 1980, pp. 1089-90.
75. Reich R, **Maki DG**. Anaerobic bacterial meningitis. *Proceedings of the 11th International Congress on Chemotherapy, Current Chemotherapy and Infectious Disease*, Washington, D.C., American Society for Microbiology, 1980, pp. 886-8.
76. **Maki DG**. Lifelines gone bad. *Back to Basics. Common Emergencies in Daily Practice*, New York, EM Books, 1980, pp. 177-86.
77. **Maki DG**. The prevention and management of device-related infection in infusion therapy. *J Med* 11:239-53 (80).
78. **Maki DG**. The prevention and management of device-associated infections in infusion therapy. *J Med* 1980;11:239-250.
79. **Maki DG**. Epidemic Nosocomial Bacteremias. *Handbook of Hospital Infections*, Wenzel RR (Editor), C.R.C. Press, Inc., West Palm Beach, 1981, pp. 371-512.
80. Jaffe J, **Maki DG**. Lung biopsy in immunocompromised patients--One institution's experience and an approach to management of pulmonary disease in the compromised host. *Cancer* 44:1144-53 (81).
81. Nauseef WN, **Maki DG**. A study of the value of simple protective isolation in patients with granulocytopenia. *N Engl J Med* 304:448-53, (81).  
  
Reviewed and abstracted in the *Yearbook of Medicine, 1982*.
82. **Maki DG**. Nosocomial bacteremia. An epidemiologic overview. *Am J Med* 70:719-32 (81).
83. **Maki DG**, Hassemer CA. Endemic rate of fluid contamination and related septicemia in arterial pressure monitoring. *Am J Med* 70:733-8 (81).
84. **Maki DG**, Band JD. A comparative study of polyantibiotic and iodophor ointments in prevention of vascular catheter-related infection. *Am J Med* 70:739-44 (81).
85. McCormick R, **Maki DG**. Epidemiology of needle-stick injuries in hospital personnel. *Am J Med* 70:928-32 (81).
86. **Maki DG**. The epidemiology of surgical wound infection. *Surgical Infections*. Condon R, Gorbach S (Editors), Williams and Wilkins, Baltimore, 1981, pp. 166-76.
87. **Maki DG**, Alvarado CJ, Hassemer CA. False-positive results of spore tests in ethylene oxide sterilizers--Wisconsin. *Morbidity and Mortality Weekly Report* 30:238-40 (81).
88. **Maki DG**, Nauseef WM. Simple protective isolation in patients with granulocytopenia -- reply (Letter). *N Engl J Med* 304:1493-4 (81).
89. **Working Group, (Maki DG, member)**. Guidelines for prevention of intravenous therapy-related infections. *Guidelines for the Prevention and Control of Nosocomial Infections*. U.S. Department of Health and Human Services--DHS, Center for Disease Control, Atlanta, GA, *Infect Control* 3:62-79, 1981.
90. Working Group, (Maki DG, member). Guidelines for prevention of infections related to intravascular pressure-monitoring systems. *Guidelines for the Prevention and Control of Nosocomial Infections*. U.S. Department of Health and Human Services--DHS, *Infect Control* 3:68-72, 1981.
91. **Maki DG**. Nosocomial bacteremia. An epidemiologic overview. *Nosocomial Infections*, Dixon RE (Editor), Yorke Medical Books, 1981, pp. 183-96.

92. **Maki DG**, Hassemer CA. Endemic rate of fluid contamination and related septicemia in arterial pressure monitoring. **Nosocomial Infections**, Dixon RE (Editor), Yorke Medical Books, 1981, pp. 201-6.
93. **Maki DG**, Band JD. A comparative study of polyantibiotic and iodophor ointments in prevention of vascular catheter-related infection. **Nosocomial Infections**, Dixon RE (Editor), Yorke Medical Books, 1981, pp. 207-12.
94. McCormick R, **Maki DG**. Epidemiology of needle-stick injuries in hospital personnel. **Nosocomial Infections**, Dixon RE (Editor), Yorke Medical Books, 1981, pp. 302-8.
95. **Maki DG**, Reich R. Infectious mononucleosis in the athlete--complications, diagnosis and management. **Am J Sports Med** 10:162-73 (82).
96. **Maki DG**. Infections associated with intravascular lines. **Current Topics in Clinical Infectious Disease**, Swartz M, Remington J (Editors), McGraw-Hill, Inc., New York, 1982, pp. 309-63.
97. **Maki DG**, Alvarado CJ. The role of the clinical microbiology laboratory in diagnosis of infusion-related sepsis. **Clin Microbial Newsletter** 4(13):89-94, (82).
98. England AC, Miller SA, **Maki DG**. Ocular findings of acute cytomegalovirus infection in an immunologically competent adult. **N Engl J Med** 307:94-5 (82).
99. **Maki DG**, Aughey D. Comparative study of cefazolin, cefoxitin, and ceftizoxime for surgical prophylaxis in colorectal surgery. **J Antibiotic Chemother** 10(Suppl C):281-7 (82).
100. **Maki DG**, Alvarado CJ, Hassemer CA, Zilz MA. Relationship of the inanimate hospital environment to endemic nosocomial infection. **N Engl J Med** 307:1562-6 (82).
- Reviewed and abstracted in **Yearbook of Medicine, 1984**.
101. **Maki DG**, England AC, Miller SA. Ocular findings in cytomegalovirus infection (Letter to the Editor). **N Engl J Med** 307:1584 (82).
102. **Maki DG**. Intravenous therapy related infections: Their sources and the new CDC guidelines for their prevention. **Proceedings of an Association for the Advancement of Medical Instrumentation Technology Assessment Conference, Infusion Technology, and Therapy**, Association for the Advancement of Medical Instrumentation, Arlington, VA, No. 5, 1983, pp. 25-31.
103. **Maki DG**. Workshop summary and guidelines for preventing contamination of enteric feedings. **Proceedings of the Ross Laboratories Workshop, Contamination of Enteral Feeding Products During Clinical Usage**, Ross Laboratories, 1983, pp. 38-42.
104. **Maki DG**, Alvarado CJ, Hassemer CA, Zilz MA. Nosocomial infections -- reply (Letter). **N Engl J Med** 307:1540-1 (83).
105. **Maki DG**. Prevention of bacteremic infections due to intravascular medical devices. **Proceedings of the Second Annual Middle East Symposium, Nosocomial Infection and Its Control**, Barker Publications Ltd., The Green, Richmond, Surrey, England, 1983, pp. 59-64.
106. **Maki DG**, Lammers JL, Aughey DR. Comparative studies of multiple-dose cefoxitin vs. single-dose cefonicid for surgical prophylaxis in patients undergoing biliary tract operations and hysterectomy. **Rev Infect Dis** 6(Suppl 4): S887-96 (84).
107. Nichols L, Gudmundsson S, **Maki DG**. Experience with cefsulodin therapy for lower respiratory tract infections caused by *Pseudomonas aeruginosa* in adults without cystic fibrosis or granulocytopenia. **Rev Infect Dis** 6(Suppl 3):S711-20 (84).
108. **Maki DG**. "Citation Classic": Infection control in infusion therapy. **Curr Cont** 33:22 (84).



109. Stark RP, **Maki DG**. Bacteriuria in the catheterized patients. What level of bacteriuria is relevant? *N Engl J Med* 311:560-4 (84).  
Reviewed and abstracted in *Yearbook of Medicine, 1985*.
110. Nichols L, **Maki DG**. The emergence of resistance to beta-lactam antibiotics during treatment of *Pseudomonas aeruginosa* lower respiratory tract infections: Is combination chemotherapy the solution? *Chemoterapia* 4:102-9 (85).
111. Strinden W, Helgerson R, **Maki DG**. Septic thrombosis of the great central veins caused by candida. Clinical features, natural history, and management. *Ann Surg* 202:653-8 (85).
112. **Maki DG**. Skin as a source of nosocomial infection. *Infect Control* 7(Suppl.):113-7 (86).
113. Hamill RJ, **Maki DG**. Endotoxic shock in the human caused by gram-negative bacilli. Etiology, clinical features, diagnosis, natural history, and prevention. *Handbook of Endotoxin, Vol. 4: Clinical Aspects of Endotoxic Shock*, Proctor, R. (Editor), Elsevier Science Publishers, B.V., Amsterdam 1986, pp. 55-126.
114. **Maki DG**. Infections due to infusion therapy. *Hospital Infections*, Bennett JV, Brachman PS (Editors), Second Edition, Little Brown and Co., Boston, 1986, pp. 580-601.
115. Peckham BM, **Maki DG**, Patterson JJ, Hafez G. Focal vulvitis-A characteristic syndrome and cause of dyspareunia. *Am J Obstet Gynecol* 154:855-64 (86).
116. Pirsch JD, **Maki DG**. Infectious complications of bone marrow transplantation of adults with T-cell depletion of donor marrow. *Ann Intern Med* 104:619-31 (86).
117. Warner TF, Crass B, Gable C, **Maki DG**, Highways GR, Golubjatnikov R. Diagnosis of HTLV-III infection by ultrastructural examination of germinal centers of lymph nodes. *AIDS Research* 2:43-50 (86).
118. **Maki DG**, Alvarado C, Hassemer C. Double-bagging of items from isolation rooms is unnecessary as an infection control measure. A comparative study of surface contamination with single- and double-bagging. *Infect Control* 7:535-7 (86).
119. Governor's AIDS Task Force (**Maki DG**, member). **Information and Recommendations for Preventing the Transmission of HTLV-III**. State of Wisconsin, Dept. of Health and Social Services, Madison 1986.  
Recommendations for Schools (18 pp.)  
Recommendations for Prisons (32 pp.)  
Recommendations for Jails (29 pp.)  
Recommendations for Hospitals (60 pp.)  
Recommendations for Nursing Homes (58 pp.)  
Recommendations for DCTF and Mental Health Institutions (86 pp.)  
Recommendations for the Work Place (Health Care, Personal Service, Food Service) (25 pp.)  
Recommendations for Funeral Directors and Pathologists (60 pp.)  
Recommendations for Emergency Medical Service Personnel (60 pp.)  
Recommendations for Dental Personnel (22 pp.)  
Recommendations for Home Care (49 pp.)  
Recommendations for Child Care (Day Care, Foster Care and Adoption) (50 pp.)  
Recommendations for Serologic Screening (25 pp.)  
Recommendations for Contact Notification (10 pp.)  
Recommendations for Health Care Services for the Chronically Ill (30 pp.)  
Recommendations for Neuropsychiatric Aspects of AIDS (42 pp.)  
Recommendations for Public Education Issues (6 pp.)  
Recommendations for Professional Education Issues (12 pp.)  
Summary Report: Public Health Task Force on Acquired Immunodeficiency Syndrome (AIDS) (72 pp.)
120. **Maki DG**, Hassemer CA. Flash sterilization--carefully measured haste (Editorial). *Infect Control* 8:307-10 (87).

121. **Maki DG**, Botticelli JT, Leroy ML, Thielke TS. Prospective study of replacing administration sets for intravenous therapy at 48-hour versus 72-hour intervals. 72 hours is safe and cost-effective. *JAMA* 258:1777-81 (87).
- Republished in *JAMA - Southeast Asia Edition*.  
Reviewed and abstracted in *Yearbook of Medicine, 1989*.
122. **Maki DG**, Ringer M. Evaluation of four dressing regimens for peripheral venous catheters, including gauze, a transparent dressing, and an iodophor-impregnated transparent dressing. *JAMA* 258:2396-403 (87).
- Reviewed and abstracted in *Yearbook of Medicine, 1989; Yearbook of Anesthesiology, 1990; Yearbook of Critical Care Medicine, 1989*.
123. **Maki DG**, McCormack KN. Defatting catheter insertion sites with acetone is of no value as an infection control measure in total parenteral nutrition. A comparative trial. *Am J Med* 83:833-40 (87).
- Reviewed and abstracted in *Yearbook of Critical Care Medicine, 1989*.
124. Oh C, Stratta RJ, Fox BC, Sollinger HW, Belzer FO, **Maki DG**. Increased infections associated with OKT3 for treatment of steroid-resistant rejection in renal transplantation. *Transplantation* 45:68-73 (88)
125. Gillum MH, **Maki DG**. Tuberculin testing, BCG in pregnancy. *Infect Control and Hosp Epidemiol* 9:119-21 (88).
126. Hamill RJ, **Maki DG**. Infectious complications of heart transplantations, In *Heart Transplantation*, Myerowitz PD (Editor), Mount Kisco, NY, Future Publishing Co., 1988, pp. 309-88.
127. **Maki DG**. IV catheter-related infection -- reply (Letter to the Editor). *JAMA* 259:1498-9 (88).
128. Alvarado C, **Maki DG**. Book review: *Infectious Disease Handbook for Emergency Care Personnel*, West KH, JB Lippincott, Philadelphia, 1987, 114 pp., *Infect Control and Hospital Epidemiol* 9:221-2 (88).
129. **Maki DG**, Agger WA. Enterococcal bacteremia. Natural history, the risk of endocarditis, and management. *Medicine* 67:248-69 (88).
- Reviewed and abstracted in *Yearbook of Medicine, 1989*.
130. **Maki DG**, Cobb L, Garman JK, Shapiro J, Ringer M, Helgerson RB. An attachable silver-impregnated cuff for prevention of infection with central venous catheters. A prospective randomized multi-center trial. *Am J Med* 85:307-14 (88).
- Reviewed and abstracted in *Yearbook of Critical Care Medicine, 1990*.
131. Golenbock DT, Guerra J, Pfister J, Golubjatnikov R, Abelardo T, Abugattas J, Kemper R, **Maki DG**. Absence of infection with human immunodeficiency virus in Peruvian prostitutes. *AIDS Res\_and Retroviruses* 4:493-9 (88).
132. **Maki DG**. Risk factors for nosocomial infection in intensive care. Devices versus nature and goals for the next decade. *Arch Intern Med* 149:30-5 (89).
133. Mermel LA, **Maki DG**. Epidemic bloodstream infections from hemodynamic monitoring: Signs of the times (Editorial). *Infect Control and Hosp Epidemiol* 10:47-53 (89).

**PUBLICATIONS, Continued****Dennis G Maki, MD**

134. **Maki DG.** Dexamethasone as adjunctive therapy for bacterial meningitis (Letter to the Editor) **N Engl J Med** 320:464-5 (89).
135. D'Alessandro AM, Stratta RJ, Pirsch JD, Sollinger HW, Kalayoglu M, **Maki DG**, Belzer FO. OKT3 Salvage therapy in a quadruple immunosuppressive protocol. **Transplantation** 47:297-300 (89).
136. **Maki DG.** Pathogenesis, prevention, and management of infections due to intravascular devices used for infusion therapy. In **Infections Associated with Indwelling Medical Devices**, Bisno A, Waldvogel F. (Editors), Washington, D.C., American Society for Microbiology, 1989, pp. 161-77.
137. **Maki DG.** The use of antiseptics for handwashing by medical personnel. **J Chemother** 1(Suppl 1):3-11 (89)
138. Rhame FS, **Maki DG.** The case for wider use of HIV testing. **N Engl J Med** 320:1248-54 (89).  
Reprinted in **The AIDS Crisis**, CP Cozic (Ed), Greenhaven Press, San Diego, 1991, pp 112-7
139. Klein BS, Perloff WH, **Maki DG.** Reduction of nosocomial infection during pediatric intensive care by protective isolation. **N Engl J Med** 320:1714-21 (89).
140. **Maki DG.** AIDS: Serologic testing for the Human Immunodeficiency Virus -- To screen or not to screen. **Infect Control and Hosp Epidemiol** 10:243-7 (89).
141. **Maki DG.** Forward for **Asepsis, The Right Touch**, Crowe S., Everette Pub., Bosier City, LA, 1989, pp. v-vii.
142. Pirsch JD, Armburst MJ, Stratta RJ, D'Alessandro AM, Sollinger HW, Belzer FO, Kalayoglu M, **Maki DG.** Perioperative infections in liver transplant recipients under a quadruple immunosuppression protocol. **Transplantation Proceedings** 21:3559 (89).
143. Rhame FS, **Maki DG.** Wider use of testing for HIV infection -- reply (Letter). **N Engl J Med** 321:1266-7 (89).
144. **Maki DG**, McGowan JE. Questions raised about the June issue (Letter). **Infect Control Hosp Epidemiol** 1989;10:500-502.
145. **Maki DG.** To test or not to test (Letter to the Editor) **Infect Control and Hosp Epidemiol** 10:500-1 (89).
146. Klein B, Perloff WH, **Maki DG.** Reduction of nosocomial infection during pediatric care by protective isolation -- reply (Letter). **N Engl J Med** 322:553 (90).
147. Mermel LA, **Maki DG.** Bacterial pneumonia in the solid organ transplant recipient. **Semin Resp\_Infect** 5:10-29 (90).
148. **Maki DG.** Nosocomial infections. In: **Current Therapy in Critical Care**, Parrillo JE (Editor), Saunders, New York, 1990, pp. 208-14.
149. Beam TR, Farr BM, Goodman E, **Maki DG**, Mayhall G. Preventing central venous catheter-related complications. A roundtable discussion. **Infect In Surg** 9:9-42 (90).
150. Wenzel RP, **Maki DG**, Crow S, Schaffner W, McGowan JE. Duplicate publication of a manuscript (Editorial). **Infect Control and Hosp Epidemiol** 11:341-2 (90).
151. Fox BC, Sollinger HW, Belzer FO, **Maki DG.** A prospective randomized double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation. Clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects in the microflora and the cost-benefit of prophylaxis. **Am J Med** 89:255-74 (90).

Reviewed and abstracted in **Yearbook of Nephrology, 1992; Yearbook of Transplantation, 1992.**

**PUBLICATIONS, Continued****Dennis G Maki, MD**

152. **Maki DG**, Klein B, McCormick R, Alvarado C, Gould J, Zilz M, Liegel A. *Pseudomonas pickettii* bacteremias traced to contaminated fentanyl. A case for selective drug screening of medical personnel. **JAMA** 265:981-6 (91).
153. **Maki DG**, Ringer M. Risk factors for phlebitis with peripheral venous catheters. A prospective study. **Ann Intern Med** 114:845-54 (91).
154. **Maki DG**, Alvarado CJ, Ringer M. A prospective, randomized trial of povidone-iodine, alcohol and chlorhexidine for prevention of infection with central venous and arterial catheters. **Lancet** 338:339-43 (91).
155. Alvarado CJ, Stolz SM, **Maki DG**, Fraser V. Nosocomial infection and pseudoinfection from contaminated endoscopes and bronchoscopes. **Morbidity Mortality Weekly Report** 40:676-8 (91).
156. Redington JJ, **Maki DG**. Infectious complications in cancer patients. **Current Therapy in Hematology-Oncology**, 4th Edition, Carbone PP (Ed). B.C. Decker, Philadelphia, 1991, pp. 427-42.
157. McCormick RP, Meisch M, Ircinck F, **Maki DG**. Epidemiology of hospital sharps injuries: a 14-year perspective in the pre-AIDS and AIDS eras. **Am J Med** 91(3B):301S-7S (91).
158. Mermel L, Stolz S, **Maki DG**. The pathogenesis and epidemiology of catheter-related infection with pulmonary artery Swan-Ganz catheters. A prospective study utilizing molecular subtyping. **Am J Med** 91(3B):197S-205S (91).
- Reviewed and abstracted in **Yearbook of Critical Care Medicine, 1992**.
159. Alvarado CJ, Stolz SM, **Maki DG**. Nosocomial *Pseudomonas aeruginosa* infections from contaminated endoscopes. A flawed commercial automated washer. An investigation using molecular epidemiology. **Am J Med** 91(3B):272S-80S (91).
160. **Maki DG**. Summary comments for the symposium, Hand Antiseptics - Efficacy or Acceptability. **J Hosp Infect** 18(Suppl. B):71 (91).
161. Therapy Panel (**Maki DG**, Member). Diagnosis and treatment of Lyme disease. NIH State-of-the-Art Conference. National Institute of Arthritis and Musculoskeletal and Skin Diseases - National Institute of Allergy and Infectious Diseases. **Clinical Courier** 9:1-8 (91).
162. **Maki DG**. Intravenous catheter sites and sepsis -- reply (Letter). **Lancet** 338:1218-9 (91).
163. Proctor M, Davis J, **Maki DG**, et al. **Recommendations for Control of Methicillin-resistant Staphylococcus aureus (MRSA) in Acute Care and Extended Care and for the Transfer Between Facilities of Patients Colonized With MRSA**. Wisconsin Division of Health-DHSS - Section of Acute and Communicable Disease Epidemiology, Madison, WI, 1991, pp. 1-35.
164. **Maki DG**. ICAAC Young Investigator Awards. **ASM News** 57:466-77 (91).
165. **Maki DG**. Biography: Spotlight on an Editorial Board Member--Henry Masur. **Crit Care Med** 20:450 (92).
166. **Maki DG**, Fox BC, Kuntz JR, Sollinger HW, Belzer FO. A prospective, randomized double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation. Side effects of trimethoprim-sulfamethoxazole, interactions with cyclosporine. **J Lab Clin Med** 119:11-24 (92).
167. Consensus Panel (**Maki DG**, member). Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. **Chest** 101:1644-55. (92).
168. **Maki DG**. Infection caused by intravascular devices: Pathogenesis, strategies for prevention. In: **Im-proving Catheter Site Care**, Royal Society of Medicine Services Ltd., London-New York, 1992, pp. 3-28.

## PUBLICATIONS

Dennis G Maki, MD

169. **Maki DG**, Stolz S, Wheeler S. A prospective randomized three-way clinical comparison of a novel, highly-permeable, polyurethane dressing with 206 Swan-Ganz pulmonary artery catheters. I. Cutaneous colonization under the dressing, catheter-related infection. In: **Improving Catheter Site\_Care**, Royal Society of Medicine Services Ltd., London-New York, 1992, pp. 61-66.
170. Wheeler S, Stolz S, **Maki DG**. A prospective randomized three-way clinical comparison of a novel, highly-permeable, polyurethane dressing with 206 Swan-Ganz pulmonary artery catheters. II. Effectiveness and tolerance as catheter dressings. In: **Improving Catheter Site Care**, Royal Society of Medicine Services Ltd., London-New York, 1992, pp. 67-71.
171. **Maki DG**. Infections due to intravascular devices. In: **Hospital Infections**, Bennett JV, Brachman PS (Editors), Third Edition, Little Brown and Co., Boston, 1992, pp. 849-99.
172. **Maki DG**, Bohn M, Stolz SM, Kroncke G, Acker CW, Myerowitz PD. Cefazolin, cefamandole and vancomycin for prophylaxis in cardiovascular surgery. A prospective double-blind trial. **J Thorac Cardiovasc Surg** 104:1423-34 (92).
173. Chang W, VanderHeyde H, **Maki DG**, Malkovsky M, Weidanz WP. Subset heterogeneity among  $\gamma\delta$  cells found in peripheral blood during *Plasmodium falciparum* malaria. **Immunol Lett** 32:273-4 (92).
174. **Maki DG**. ICAAC Young investigator awards. **ASM News** 59:456-7 (93).
175. Mermel LA, **Maki DG**. Surface antimicrobial activity of heparin-bonded and antiseptic-impregnated vascular catheters. **J Infect Dis** 167:920-4 (93).
176. Mermel LA, Stolz SM, **Maki DG**. Surface antimicrobial activity of heparin-bonded and antiseptic-impregnated vascular catheters (Letter). **J Infect Dis** 168:1342 (93).
177. Meyer KC, McManus EJ, **Maki DG**. Overwhelming pulmonary blastomycosis associated with ARDS. Clinical features, diagnosis and management. **New Engl J Med** 20:1231-4(93).
178. Mermel LA, **Maki DG**. Detection of bacteremia in adults: consequences of culturing an inadequate volume of blood. **Ann Intern Med** 119:270-72(93).  
Reviewed in an editorial in **Lancet** 342:1006(93).
179. Mermel LA, **Maki DG**. Infectious complications of Swan-Ganz pulmonary artery catheters: pathogenesis, epidemiology, prevention and management. State-of-the-art. **Am J Resp Ther Crit Care Med** 149:1020-1036(94).
180. **Maki DG**. Infection caused by intravascular devices used for infusion therapy: pathogenesis, prevention and management. In: **Infections Associated with Indwelling Medical Devices**, Second Edition, Bisno AL, Waldvogel FA, eds., American Society for Microbiology, Washington, D.C., 1994, pp 155-212.
181. **Maki DG**. Nosocomial infection in the intensive care unit. In: **Critical Care Medicine**, Parrillo J, Bone R, eds., Mosby, St. Louis, MO, 1994, pp. 893-954.
182. Eickhoff TC and members of the Clinical Practice Subcommittee, Health and Public Policy Subcommittee, HIV Committee and Council (**Maki DG**, member). Human immunodeficiency virus (HIV) infection. **Ann Intern Med** 120:310-19(94).
183. Fisher CJ, Dhainaut JFA, Opal SM, et al and members of the Study Group (**Maki DG**, member). Recombinant human interleukin-1 antagonist in the treatment of patients with the sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. **JAMA** 1994; 271: 1836-1843.
184. **Maki DG**. Epidemiology and prevention of intravascular device-related infections. In: **Proceedings of the Conference: Infection Control Symposium. Influence of medical device design**. US DHHS:Public Health Service, HSS, Food and Drug Administration, Center for Devices and Radiologic Health. Washington, D.C., January, 1995, pp. 27-34.

185. **CDC HICPAC (Maki DG, co-author)**. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). *MMWR* 44(RR-12)1-13, 1995.  
Also published in *Infect Control Hosp Epidemiol* 16:105-13(95) and *Fed Reg* 59:25758-61(94).
186. **Maki DG**. Yes, Virginia, aseptic technique is very important. Maximal barrier precautions during insertion reduces the risk of central venous catheter-related bacteremia (Editorial). *Infect Control and Hosp Epidemiol* 15:227-230 (94).
187. **Maki DG**. Universal maximal sterile barrier precautions may be unnecessary (Letter). *Infect Control Hosp Epidemiol* 15:685-6 (94).
188. **Maki DG, Stolz SS, Wheeler S, Mermel LA**. A prospective randomized trial of gauze and two polyurethane dressings for site care of pulmonary artery catheters: implications for catheter management. *Critical Care Medicine* 22:1-7(95).
189. **Maki DG**. Reactions associated with midline catheters for intravenous access (Editorial). *Ann Intern Med* 123:884-886 (95).
190. **Maki DG, Boyce J, Weinstein R**. Prevention and control of nosocomial infections caused by vancomycin-resistant enterococci. **CoMed Communications**, Philadelphia, PA, 1996.
191. Knaus WA, Harrell FE, LaBrecque JF, et al and members of the Study Group (**Maki DG, member**). Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. *Crit Care Med* 1996;24:46-56.
192. **Maki DG**. Management of life-threatening infection in the ICU. In: *Critical Care Medicine. Perioperative Management*. Murray MJ, Coursin DB, Perot RG, Prough DS (eds). Lippincott-Raven, Philadelphia, 1997, pp. 643-68.
193. Mermel LA, **Maki DG**. Infectious complications of Swan-Ganz pulmonary artery catheters and peripheral arterial catheters. In: *Infusion Therapy*, Seifert H, Jansen B, Farr BM (eds), Marcel-Decker, Inc., New York, 1997, pp. 259-306.
194. **Maki DG, Stolz SM, Wheeler S, Mermel LA**. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial. *Ann Intern Med* 127:257-66(97).  
Reviewed in an editorial in *Ann Intern Med*.
195. Rhame FS, **Maki DG, Bennett JV, Jarvis WR**. Epidemiologic notes and reports. Nosocomial bacteremias associated with intravenous fluid therapy - U.S.A. *MMWR* 48:1227-33(97).
196. **Maki DG, Rolandelli RH, Shronts EP, Warden GD**. Parenteral nutrition for the septic patient: timing of feeding and selection of formula. *J Crit Care Nutr* 4:(97).
197. **Maki DG, Mermel LA**. Infections due to infusion therapy. In: *Hospital Infections*, Bennett JV, Brachman PS (eds), Fourth Edition, Lippincott-Raven, Philadelphia, 1998, pp. 689-724.
198. O'Grady NP, Barie PS, Bartlett J, Bleck T, Garvey G, Jacobi J, Linden P, **Maki DG, Nam M, Pascule W, Pasquale MD, Tribett DL, Masur H**. Practice parameters for evaluating new fever in critically ill patients. *Crit Care Med* 26:392-408(98); *Clin Infect Dis* 26: 1042- 59 (1998);
199. Didier ME, Fisher S, **Maki DG**. Reconstituted recombinant Factor VIII can be safely infused continuously for at least 3 days: it is a poor microbial growth medium. *Blood Coag and Fibrinolysis* 9:227-32(98).

## PUBLICATIONS

Dennis G Maki, MD

200. Didier ME, Fisher S, **Maki DG**. Total nutrient admixture (TNA) solutions appear safer than lipid emulsions alone as regards microbial contamination. Growth properties of microbial pathogens at room temperature. *J Parent and Ent Nutr* 22:1-5 (98).
201. **Maki DG**. Complications of peripheral intravenous therapy. **Proceedings of the Fourth World Congress of Nurse Anesthetists**, Paris, 1998, in the **Cardiac Patient and Anesthesia, Intravenous Anesthesia, Anesthesia of Ambulatory Patients, Local-regional Anesthesia, Safety Conditions in Anesthesia, New Drugs, Venous Route Focus Session**. Arnette Inc., Paris, 1994; 313-29.
197. Wickline S, Wu KK, Didisheim P, Anderson JM, Buddinger TF, Fuster V, Harker LA, Kottke-Marchant K, **Maki DG**, Strauss W, Callahan H, Watson JT, Berson A. NHLBI/FDA Conference on thrombosis and infections with cardiovascular devices. *J Biomed Mat Res* 42:341-6 (1998).
198. Andes DR, Urban AW, Acher CW, **Maki DG**. Septic thrombosis of the basilic, axillary and subclavian veins caused by peripherally-inserted central venous catheter. Report of a case and mini-review. *Am J Med* 105:446-50 (1998).
199. Mejicano GC, **Maki DG**. Infections acquired during cardiopulmonary resuscitation: estimating the risk, defining the strategies for prevention. *Ann Intern Med* 129:813-28 (1998).
200. **Maki DG**. Other infections in the ICU. *Multidisciplinary Critical Care Board Review Course Text*. Society of Critical Care Medicine, Chicago, 1998, pp. 569-594.
201. **Maki DG**. Antibacterial agents in the ICU. *Multidisciplinary Critical Care Board Review Course Text*. Society of Critical Care Medicine, Chicago, 1998, pp. 549-554.
202. **Maki DG**. Use of antiseptics for prevention of infection during intravascular access. In: *Disinfection, Sterilization and Antisepsis in Health Care*, Rutala WA, ed. Association for Professionals in Infection Control and Epidemiology, Inc. Washington, DC, 1998, pp. 281.
203. Mejicano G, **Maki DG**. Infections acquired during cardiopulmonary resuscitation: risk and prevention. In: *Resuscitation of the Arrested Heart*, Weil MH, Tang W, eds. Saunders and Co., Orlando, FL. 1999, pp. 229-54.
204. Tambyah PA, **Maki DG**. A prospective study of the pathogenesis of catheter-associated urinary tract infection. *Mayo Clin Proc* 74:131-6 (1999).
205. Buchman JG, Bertino JS, Breiman RF, Cassell GH, Charach T, Doern GD, File TM, Fine MJ, Greenberg RM, Greenberg SB, Hammerschlag MR, **Maki DG**, Massoud N, Masur H, Murphy TF, Plouffe JF, Talan DA, Tomasz E, Teanor J, Weiser JN, Whitney CG, Yoshikawa TT. Hospitalized patient with community-acquired pneumonia. In: *Community-Acquired Pneumonia in Adult and Elderly Populations*. *Clinical Courier* 16:1-16 (1999).
206. **Maki DG**. Infection control strategies. *New Strategies in Critical Care*. Tuscany Critical Care Group, Florence, Italy, 1999, pp. 16-17.
207. Tambyah PA, **Maki DG**. The relationship between pyuria and infection in patients with indwelling urinary catheters. Results of a prospective study of 761 patients. *Arch Intern Med* 160:7637 (2000).
208. Tambyah PA, **Maki DG**. Catheter-associated urinary tract infection is rarely symptomatic. A prospective study of 1497 catheterized patients. *Arch Intern Med* 160:678-82 (2000).
209. Buchman JG, Bertino JS, Breiman RF, Cassell GH, Charach T, Doern GD, File TM, Fine MJ, Greenberg RM, Greenberg SB, Hammerschlag MR, **Maki DG**, Massoud N, Masur H, Murphy TF, Plouffe JF, Talan DA, Tomasz E, Teanor J, Weiser JN, Whitney CG, Yoshikawa TT. Community-acquired pneumonia in adult and elderly populations. *Clinician* 17:1-28 (2000).

## PUBLICATIONS

Dennis G Maki, MD

210. McCormick RA, Buchman T, **Maki DG**. Randomized trial of a novel barrier cream and an oil-containing hand lotion for protecting the hands of healthcare workers. *Am J Infect Control* 28:302-10 (2000).
211. Coursin DB, Updike S, **Maki DG**. Massive rhabdomyolysis, anemia, thrombocytopenia, renal and respiratory failure in an anicteric man with leptospirosis. *J Intensive Care Med* 26:808-12 (2000).
212. Eastman ME, Khorsand M, **Maki DG**, Williams E, KyungMann K, Sondel P, Schiller JH, Albertini MR. Central venous device-related infection and thrombosis in patients treated with moderate-dose continuous-infusion interleukin-2. *Cancer* 91:806-14 (2001).
213. Garland JS, Harris MC, Alex CT, Mueller CD, Otten D, Shivturi Chandra, Naples M, Pellegrini J, Buck RK, McCauliffe TL, Goldmann DA, **Maki DG**. A randomized trial comparing povidone-iodine and a chlorhexidine gluconate-impregnated antimicrobial dressing for prevention of central venous catheter infections in neonates. *Pediatrics* 107:1431-6 (2001).
214. Grohskopf LA, Sohn AH, Sinkowitz-Cochran RL, Jarvis WR, Goldmann DA, **Maki DG**. Reality check: Should we use vancomycin for the prophylaxis of intravascular catheter-associated infections? *Infect Control Hosp Epidemiol* 22:176-9 (2001).
215. O'Grady NP, Alexander M, Bellinger EP, Gerberding J, Heard SO, **Maki DG**, Masur H, McCormick R, Mermel L, Pearson M, Raad II, Randolph J, Weinstein R. HICPAC Guideline (Draft) for the prevention of intravascular catheter-related infection. *Fed Reg* 66:46801-12 (2001).
216. Bernard GR, Vincent J-L, Laterre P-F, et al. for the Recombinant Human Activated Protein C World-wide Evaluation and Serious Sepsis (PROWESS) Study Group (**Maki DG**, co-investigator). Efficacy and safety of recombinant human activated protein C for severe sepsis. *N Engl J Med* 344:699-709 (2001).
217. Maki DG. Antimicrobials incorporated into prosthetic materials to prevent infection. In: *International Symposium on Disinfection, Sterilization and Antisepsis*. Rutala WA (ed.), Association for Professionals in Infection Control and Healthcare for Epidemiology, Inc., Washington, D.C., (2001).
218. **Maki DG**, Tambyah PA. Engineering out the risk for infection with urinary catheters. *Emerg Infect Dis* 7:342-7 (2001).
219. Rose EA, Gelijns AC, Moskewitz AJ, et al, for the REMATCH Study Group (**Maki DG**, member, Morbidity and Mortality Committee). Long-term use of a left ventricular assist device for end-stage heart failure. *N Engl J Med* 345:1435-43 (2001).
220. **Maki DG**. Antimicrobial use and resistance: it's more than "bugs and drugs". In *Unintended Consequences: Antibiotic Use and Collateral Resistance*. MPE Communications, Inc., New York, NY pp. 20-26 (2001).
221. Safdar N, **Maki DG**. The commonality of risk factors for nosocomial infection with antimicrobial-resistant pathogens: methicillin-resistant, *Staphylococcus aureus*, vancomycin-resistant Enterococcus, extended-spectrum  $\beta$ -lactamase-producing gram-negative bacilli, *Clostridium difficile*, and Candida. *Ann Intern Med* 136:834-44 (2002).
222. Tambyah PA, Knasinski V, **Maki DG**. The direct costs of nosocomial catheter-associated urinary tract infection in the era of managed care. *Infect Control Hosp Epidemiol* 23:27-31 (2002).
223. Crnich CJ, **Maki DG**. New technology for reducing infection and resistance in the ICU. *J Crit Illness*, 17:48-51 (2002).
224. Maki DG, Weinstein RA. Nosocomial infection in the intensive care unit. In: *Critical Care Medicine Principles of Diagnosis and Management*, Second edition, Parrillo JE, Dellinger RP, eds. Mosby 981-1046 (2002).



## PUBLICATIONS

Dennis G Maki, MD

225. Fry BE, **Maki DG**, Malangoni MA, Solomkin JS. Antimicrobial prophylaxis in surgery: current controversies and debates. *Medical Crossfire-General Surgery Edition* 2:15-24 (2002).
226. Crnich CJ, **Maki DG**. The role of intravascular devices in sepsis. *Current Infectious Disease Reports*, 3:496-506 (2002).
227. Safdar N, Crnich CJ, **Maki DG**. Nosocomial infections in the intensive care unit associated with invasive medical devices. *Current Infectious Disease Reports*, 3:487-495 (2002).
228. **Maki DG**, Crnich CJ. Line sepsis in the granulocytopenic patient: prevention, diagnosis and management In: *Hematology 2001*. American Society of Hematology, Washington, DC, 119-26 (2002).
229. Safdar N, Love RB, **Maki DG**. Severe *Ehrlichia chaffeensis* infection in a lung transplant recipient: a review of ehrlichiosis in the immunocompromised patient. *Emerg Infect Dis*, 8:320-3 (2002).
230. **Maki DG**. Management of life-threatening infection in the ICU. In: *Critical Care: Perioperative Management*, Second Edition, Murray MJ, Coursin DB, Pearl RG, Prough DS, eds. Lippincott Williams and Wilkins, Philadelphia, 2002:616-48.
231. Crnich CJ, **Maki DG**. The promise of novel technology for prevention of intravascular device-related bloodstream infection, Part 1: pathogenesis and short-term devices. *Clin Infect Dis*, 34:1232-42 (2002).
232. Crnich CJ, **Maki DG**. The promise of novel technology for prevention of intravascular device-related bloodstream infection, Part 2: long-term devices. *Clin Infect Dis*, 34:1362-8 (2002).
233. Safdar N, Said A, Gangnon RE, **Maki DG**. Risk of hemolytic uremic syndrome after antibiotic treatment of *Escherichia coli* O157:H7 enteritis: a meta-analysis. *JAMA*. 288:996-1001 (2002).
234. Members of the Task Force, (**Maki DG**, member). **Final report: Governor's Task Force on Terrorism Preparedness**. State of Wisconsin, Department of Health and Family Services and Department of Emergency Management, Madison, WI (2002).
235. Safdar N, Kluger DM, **Maki DG**. A review of risk factors for catheter-related bloodstream infection caused by percutaneously inserted, non-cuffed central venous catheters. Implications for preventive strategies. *Medicine* 81:466-79 (2002).
236. Coursin DB, Ketzler JT, Kumar A, **Maki DG**. Bioterrorism may overwhelm medical resources. New and different patient safety challenges must be anticipated. *APSF Newsletter* 17:4-8 (2002).
237. Aiyanger A, Crone WC, Crnich CJ, **Maki DG**. Effect of ethanol on the mechanical properties of silicone and polyurethane catheters. *Proceedings of the SEM Conference on Experimental Mechanics* 127:14 (2002).
238. **Maki DG**, Safdar N. Risk of hemolytic uremic syndrome after antibiotic treatment of *Escherichia coli* O157:H7 enteritis: a meta-analysis – reply (Letter). *JAMA* 288:3112-3112 (2002).
239. Safdar N, **Maki DG**. Inflammation of the insertion site is not predictive of catheter-related infection with central venous catheters. *Crit Care Med* 30:2632-5 (2002).
240. **Maki DG**, Crnich CJ. Line sepsis in the ICU. *Seminars Respiratory and Crit Care Med* 24:23-36 (2002).
241. **Maki DG**. Conclusions: drotrecogin alfa (activated) – from bench to practical use at the bedside. *Am J Surg* 184(Suppl):S47-50 (2002).
242. Garland JS, Hendrickson K, **Maki DG**. The 2002 Hospital Infection Control Practices Advisory Committee Centers for Disease Control and Prevention Guideline for Prevention of Intravascular Device-related Infection. *Pediatrics* 110:1009-13 (2002)

## PUBLICATIONS

Dennis G Maki, MD

243. **Maki DG.** Infection in the intensive care unit. *Classic Papers in Intensive Care*, Hayes M, Soni N, Fink M (eds), ISIS Medical Media Ltd., Oxford (2003).
244. O'Grady NP, Alexander M, Dellinger EP, Gerberding JL, Heard SO, **Maki DG**, Masur H, McCormick RD, Mermel LA, Pearson ML, Raad II, Randolph A, Weinstein RA. Guidelines for the prevention of intravascular catheter-related infection. *MMWR* 51 (RR 10): 1-29, 2002 (Erratum 51 (RR10): 711, 2002). Also published in *Pediatrics* 110:e51, 2002 and *Clin Infect Dis* 35:1281-1307, 2002, *Am J Infect Control* 30:476-489, 2002, and *Infect Control Hosp Epidemiol* 23:759-769, 2002. Article summary in National Guidelines Clearinghouse.
245. Tambyah PA, **Maki DG.** Detection of urinary tract infection in the catheterized ICU patient. In: *Immunology and Infectious Diseases*, Doughty LA, Linden P, eds. Boston, MA: Kluwer Academic Publishers, 241-255 (2002).
246. Crnich CJ, Safdar N, **Maki DG.** Infections associated with implanted medical devices. In: *Antibiotic and Chemotherapy: Anti-Infective Agents and Their Use in Therapy*. 8th ed. Finch RG, Greenwood D, Norrby SR and Whitley RJ, eds. New York, N. Y.: Churchill Livingstone, 575-618 (2003).
247. Weinstein RA, **Maki DG.** ICU infections. In *Infectious Diseases, 2nd edition*. Cohen J, Powderly WG, Berkely SF, Calandra T, Clumeck N, Finch RG, Hammer SM, Holland SM, Kiehn TE, McAdam KP, **Maki DG**, Norrby SR, Opal SM, Ronald AR, Solberg CO, Verhoef J (eds), Elsevier Science, USA, Philadelphia, PA, 981-1046 (2003).
248. Crnich CJ, **Maki DG.** Infections of vascular devices. In *Infectious Diseases, 2nd edition*. Cohen J, Powderly WG, Berkely SF, Calandra T, Clumeck N, Finch RG, Hammer SM, Holland SM, Kiehn TE, McAdam KP, **Maki DG**, Norrby SR, Opal SM, Ronald AR, Solberg CO, Verhoef J (eds), Elsevier Science, USA, Philadelphia, PA, 722-43 (2003).
249. Crnich CJ, **Maki DG.** Practice point: Should all infected intravascular devices be removed? In *Infectious Diseases, 2nd edition*. Cohen J, Powderly WG, Berkely SF, Calandra T, Clumeck N, Finch RG, Hammer SM, Holland SM, Kiehn TE, McAdam KP, **Maki DG**, Norrby SR, Opal SM, Ronald AR, Solberg CO, Verhoef J (eds), Elsevier Science, USA, Philadelphia, PA, 769-82 (2003).
250. Safdar N, **Maki DG.** Practice point: when to do a lumbar puncture for evaluation of meningococcal meningitis. In *Infectious Diseases, 2nd edition*. Cohen J, Powderly WG, Berkely SF, Calandra T, Clumeck N, Finch RG, Hammer SM, Holland SM, Kiehn TE, McAdam KP, **Maki DG**, Norrby SR, Opal SM, Ronald AR, Solberg CO, Verhoef J (eds), Elsevier Science, USA, Philadelphia, PA, 331-34 (2003).
251. Opal SM, **Maki DG**, Garber GE, LaRosa SP, Freebairn RC, Graham DE, Nelson DR. Host responses to severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). *Clin Infect Dis* 37:50-8, (2003).
252. Dhainaut J-F, Laterre P-F, LaRosa SP, Levy H, Garber GE, Heiselman D, Kinasewitz GT, Light RB, Morris P, Schein R, Sollet JP, Bates BM, Utterback BG, **Maki DG.** The clinical evaluation committee in a large multi-center phase III trial for drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): role, methodology and results. *Crit Care Med* 31:2291-2301 (2003).
253. Albertson TE, Panacek EA, MacArthur RD, Johnson SB, Benjamin E, Matushak GM, Zaloga G, **Maki DG**, Silverstein J, Tobias JK, Haenftling K, Black G, Cowens JW for the MAB-T88 Sepsis Study Group. Multicenter evaluation of a human monoclonal antibody to enterobacteraceae common antigen in patients with gram-negative sepsis. *Crit Care Med* 31:419-27 (2003).
254. **Maki DG.** National preparedness for biologic warfare and bioterrorism. Smallpox and the ophthalmologist (Editorial). *Arch Ophthalmol* 121:1-3 (2003).

## PUBLICATIONS

Dennis G Maki, MD

255. **Maki DG.** SARS: 1918 revisited? The need for global collaboration in public health (Editorial). *Mayo Clin Proceed* 78:813-6 (2003).
256. Safdar N, Narans L, Gordon B, **Maki DG.** Comparison of culture screening methods for detection of nasal carriage of methicillin-resistant *Staphylococcus aureus*: a prospective study comparing 32 methods. *J Clin Microbiol* 41:3163-3166 (2003).
257. Safdar N, **Maki DG.** Quality of care and satisfaction among patients isolated for infection control *JAMA* 291:420-421 (2004).
258. Safdar N, **Maki DG.** The pathogenesis of catheter-related bloodstream infection with noncuffed short-term central venous catheters *Intens Care Med* 30:62-67 (2004).
259. Said A, Safdar N, Lucey MR, et al. Infected bilomas in liver transplant recipients, incidence, risk factors and implications for prevention. *Am J Transplant* 4:574-582 (2004).
260. Crnich CJ, **Maki DG.** Are antimicrobial-impregnated catheters effective? Don't throw out the baby with the bathwater. *Clin Infect Dis* 38:1287-1292 (2004).
261. Arbeit RD, **Maki DG,** Tally FP, Campanaro E, Eisenstein BI and the Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of Daptomycin for the treatment of complicated skin and skin-structure infections. *Clin Infect Dis* 38:1673–81 (2004)
262. **Maki DG.** Microbiologic diagnosis of blood culture-negative sepsis by hemofiltration (Editorial). *Crit Care Med* 32:1075-1077 (2004).
263. **Maki DG.** Pneumococcal bacteremia: Lessons learned, yet more to learn (Editorial). *Mayo Clin Proc* 79:599-603 (2004).
264. Rosenthal VD, **Maki DG.** Prospective study of the impact of open and closed infusion systems on rates of central venous catheter-associated bacteremia *Am J Infect Control* 32:135-141 (2004).
265. Safdar N, Mermel LA, **Maki DG.** Epidemiology of catheter-related infection in the critically ill. In: *Catheter-related Infection in the critically ill.* O'Grady NP, Pittet D (eds), Boston, MA: Kluwer Academic Publishers, 1-22 (2004).
266. Tambyah PA, Marx JA, Spiegel C, **Maki DG.** The epidemiology of nosocomial infection with vancomycin-dependent enterococci: A clinical and molecular study. *Emerg Infect Dis* 10:1277-1281 (2004).
267. Safdar N, Handelsman J, **Maki DG.** Does combination therapy reduce mortality in gram-negative bacteremia? A meta-analysis. *Lancet Infectious Diseases* 4:519-527 (2004).
268. Said A, Safdar N, Kalayoglu M, Knechtle SJ, D'Alessandro A, **Maki DG.** Post liver transplant infected fluid collections (bilomas). Management and outcomes. *Clin Infect Dis* 38:517-525 (2004).
269. **Maki DG.**SARS revisited: The challenge of controlling emerging infectious diseases at the local, regional, national and global levels (Editorial). *Mayo Clin Proceed* 79:1359-1366 (2004)
270. **Maki DG,** Safdar N. Combination antibiotic therapy for *Pseudomonas aeruginosa* bacteraemia—Authors' reply. *Lancet Infectious Diseases* 5: 193-4 (2005).
271. Safdar N, Fine JP, **Maki DG.** Diagnosis of intravascular device-related bloodstream infection. A meta-analysis. *Ann Intern Med* 142: 451-466 (2005).

## PUBLICATIONS

Dennis G Maki, MD

272. Safdar N, Crnich CJ, **Maki DG**. The pathogenesis of ventilator-associated pneumonia. Its relevance to developing effective preventive strategies. *Resp Care* 50: 725-41 (2005).
273. Crnich CJ, Safdar N, **Maki DG**. The role of the ICU environment in the pathogenesis and prevention of ventilator-associated infection. *Resp Care* 50: 813-38 (2005).
274. Garland JS, Alex CP, Hendrickson KJ, **Maki DG**. A vancomycin-heparin lock solution for prevention of nosocomial bloodstream infection in critically-ill neonates with peripherally-inserted central venous catheters. A prospective randomized trial. *Pediatrics*. 116: e198-205 (2005).
275. Laterre P-F, Garber G, Levy H, Kinasevitz GT, Sollet JP, **Maki DG**, Light RB, Bates B, Dhainaut J-F, for the PROWESS CEC Committee. Community-acquired pneumonia as the cause of severe sepsis: data from the PROWESS study. *Chest* 33: 952-61 (2005).
276. Mermel LA, **Maki DG**. Infectious complications of pulmonary artery catheters, cordis introducers and peripheral arterial catheters. In *Catheter-related Infections*, Seifert H, Jansen B, Farr BM (eds), Marcel-Dekker Inc., New York (In press).
277. Crnich CJ, **Maki DG**. Infections caused by intravascular devices: epidemiology, pathogenesis, diagnosis, prevention, and treatment. In: *APIC Text of Infection Control and Epidemiology*. 2<sup>nd</sup> ed. Vol. 1. Washington D.C.: Association for Professionals in Infection Control and Epidemiology, Inc., 2005: 24.1-24.26.
278. Safdar N, **Maki DG**. The risk of catheter-related bloodstream infection with peripherally-inserted central venous catheters used in the inpatient setting. *Chest* 128: 489-95 (2005).
279. Crnich CJ, Aiyanger A, Crone WC, **Maki DG**. Prolonged exposure to 70% ethanol does not alter the mechanical properties of polyurethane or silicone catheters. *Infect Control Hosp Epidemiol* 26: 708-14 (2005).
280. Crnich CJ, **Maki DG**. Are antimicrobial-impregnated catheters effective? When does repetition reach the point of exhaustion? *Clin Infect Dis* 41: 681-5 (2005).
281. Rupp ME, Lisco SJ, Lipsett, PA, Perl T, Keating K, Civetta J, Mermel LA, Dellinger EP, Donahoe M, Giles D, Pfaller MA, **Maki DG**, Sherertz R. Effect of a second-generation chlorhexidine/silver sulfadiazine-impregnated central venous catheter on catheter-related infections in intensive care unit patients. A randomized, double-blinded, controlled trial. *Ann Intern Med* 142: 570-80 (2005).
282. Rupp ME, Lisco SJ, Lipsett, PA, Perl T, Keating K, Civetta J, Mermel LA, Dellinger EP, Donahoe M, Giles D, Pfaller MA, **Maki DG**, Sherertz R. Effect of a second-generation chlorhexidine/silver sulfadiazine-impregnated central venous catheter on catheter-related infections in intensive care unit patients. A randomized, double-blinded, controlled trial (Letter). *Ann Intern Med* 143: 136 (2005).
283. **Maki DG**, Crnich CJ. History forgotten is history relived: nosocomial infection control is also essential in the outpatient setting (editorial). *Arch Intern Med* 165: 2565-7 (2005).
284. Safdar N, Crnich CJ, **Maki DG**. Infections associated with chemotherapy. In: Chang AE, Ganz PA, Hayes DF, Kinsella T, Pass HI, Schiller JH, Stone RM, Strecher V, eds. *Oncology - An Evidence-Based Approach*. New York, NY: Springer Science, 2006; 1363-1400.
285. Safdar N, **Maki DG**. Lost in translation (editorial). *Infect Control and Hosp Epidemiol* 27: 3-7 (2006).
286. Safdar N, **Maki DG**. The use of vancomycin lock solutions for prevention of intravascular-device-associated bloodstream infection. A meta-analysis. *Clin Infect Dis* 43:474-84 (2006).
287. Safdar N, Marx J, **Maki DG**. Preemptive barrier precautions for containing spread of MRSA in a burn unit. *Amer J Infect Control* 34:476-83 (2006).

**PUBLICATIONS****Dennis G Maki, MD**

288. Menyhay SZ, **Maki DG**. Disinfection of needless catheter connectors and access ports with alcohol may not prevent microbial entry. The promise of a novel antiseptic-barrier cap. *Infect Control Hosp Epidemiol* 27:23-27 (2006).
289. **Maki DG**, Safdar N, Kluger DM. The relative risk of intravascular device-related bloodstream infection. A systematic review of 197 published prospective studies. *Mayo Clinic Proceedings* 81:1159-71 (2006).
290. Rosenthal VD, **Maki DG**, Salomao R, Moreno CA, Mehta Y, Higuera F, Cuellar LE, Arikan OA, Abouqal R, Leblebicioglu H. International Nosocomial Infection Control Consortium. Device-associated nosocomial infections in 55 intensive care units of 8 developing countries. *Ann Intern Med* 145:582-91 (2006).
291. Safdar N, Crnich CJ, **Maki DG**. Selective decontamination of the digestive tract and ventilator-associated pneumonia (Letter). *Resp Care* 2006;51:70-72.
292. **Maki DG**. Don't eat the spinach--controlling foodborne infectious disease. *N Engl J Med* 355:1952-5 (2006).
293. **Maki DG**, Crnich CJ, Safdar N. Nosocomial infection in the intensive care unit. In: *Critical Care Medicine Principles of Diagnosis and Management*, Third edition, Parrillo JE, Dellinger RP, eds. Mosby, 2007; 1001-1069.
294. Safdar N, **Maki DG**. The Intensive Care Unit: Part B. Antibiotic Resistance, and Prevention of CVC-BSIs, Catheter-associated Urinary Tract Infections and *Clostridium difficile*. In: *Hospital Infections*, Jarvis W (ed), Fifth Edition, Lippincott-Raven, Philadelphia, 2007; 395-415.
295. **Maki DG**, Mermel L. Infections due to infusion therapy. In: *Hospital Infections*, Jarvis W (ed), Fifth Edition, Lippincott-Raven, Philadelphia, 2007; 611-647.
296. **Maki DG**. Protecting the ICU patient from secondary sepsis. *Clinical Focus. Sepsis, Glycemic Control, and Antithrombotics in Critical Care*. Society of Critical Care Medicine, Des Plaines, IL, 2007; 1-5.
297. **Maki DG**, Fish DN. Point-Counterpoint Debate: Antimicrobial Restriction is Imperative to Control Antibiotic Resistance. *Clinical Focus. Sepsis, Glycemic Control, and Antithrombotics in Critical Care*. Society of Critical Care Medicine, Des Plaines, IL, 2007; 23-26.
298. Raad I, Hanna H, **Maki DG**. Intravascular catheter-related infections: advances in diagnosis, prevention, and management. *Lancet Infect Dis*. 10:645-57 (2007).
299. **Maki DG**, Safdar N, Ebert SC. Prevalence, consequences, and solutions. *Pharmacotherapy*. 10 (Pt 2):121S-125S (2007).
300. **Maki DG**, Ebert SC, Rybak MJ. Case study and panel discussion. *Pharmacotherapy*. 10 (Pt 2):136S-143S (2007).
301. Garland JS, Alex CP, Sevallius JM, Murphy DM, Good MJ, Volberding AM, Hofer LL, Gordon BJ, **Maki DG**. Pathogenesis of catheter-related bloodstream infections in neonates with peripherally-inserted central venous catheters (PICCs): a cohort study with molecular epidemiology. *Infect Control Hosp Epidemiol*. 2008;29:243-9.
302. O'Grady NP, Barrie PS, Bartlett JG, Bleck T, Carroll K, Kalil KC, Linden P, **Maki DG**, Nierman D, Pasculle W, Masur H. Guidelines for evaluation of new fever in critically ill adult patients: 2008 update. *Clin Infect Dis* and *Crit Care Med* 2008;36:1330-49.
303. Fox BC, Shenk G, Peterson D, Spiegel C, **Maki DG**. Choosing more effective antimicrobial combinations for empiric antimicrobial therapy of serious gram-negative rod infections using a dual cross-table antibiogram. *Am J Infect Control* 2008;36 Supplement 1:S57-S61.
304. Rosenthal VD, **Maki DG**, Mehta A, Alvarez-Moreno C, Leblebicioglu H, Higuera F, Cuellar LE, Madani N, Mitrev Z, Dueñas L, Navoa-Ng JA, Garcell HG, Raka L, Hidalgo RF, Medeiros EA, Kanj SS, Abubakar S,

## PUBLICATIONS

Dennis G Maki, MD

- Nercelles P, Pratesi RD, for the International Nosocomial Infection Control Consortium Members. International Nosocomial Infection Control Consortium Report, Data Summary for 2002-2007, issued January 2008. *Am J Infect Control*. 2008;36:627-37.
305. Rosenthal VD, **Maki DG**, for the International Infection Control Consortium. International nosocomial infection control consortium system (INICC): Description of surveillance methods. *Am J Infect Control* 2008;36:e1-12.
306. **Maki DG**. Commentary for *ACP J Club*: Vasopressin versus norepinephrine infusion in patients with septic shock. *N Engl J Med* 2008;358:877-87. *Ann Intern Med* 2008;149:JC3-14.
307. Kritchevsky SB, Braun BI, Bush AJ, Bozikis MR, Kusek L, Burke JP, Wong ES, Jernigan J, Davis CC, Simmons B and the TRAPE Study Group (**Maki DG**, member). The effect of a quality improvement collaborative to improve antimicrobial prophylaxis in surgical patients: a randomized trial. *Ann Intern Med*. 2008;149:472-80.
308. **Maki DG**. Improving the safety of peripheral intravenous catheters (Editorial). *BMJ* 2008;337:a630.
309. **Maki DG**. Coming to grips with foodborne infection — peanut butter, peppers, and nationwide salmonella outbreaks. *N Engl J Med* 2009;360:949-52.
310. Raad I, Hanna H, **Maki DG**. Bacterial infectious disease issues: catheter-related infections. In: *Medical Care of Cancer Patients*. Yeung S-CJ, Escalante CP, Gagel RF (Eds). BC Decker Inc., Shelton, CN, 2009; 139-150.
311. Alvarado CJ, Anderson AG, **Maki DG**. Microbiologic assessment of sterile endoscopic sheaths to replace high-level disinfection in reprocessing. A prospective clinical trial with nasopharyngoscopes. *Am J Infect Control* 2009;37:408-13.
312. Crnich CJ, **Maki DG**. Infections caused by intravascular devices: epidemiology, pathogenesis, diagnosis, prevention, and treatment. In: *APIC Text of Infection Control and Epidemiology*. 3<sup>rd</sup> ed. Vol 1. Washington D.C.: Association for Professionals in Infection Control and Epidemiology, Inc., 2009; 24:1-24.26.
313. **Maki, DG**. Simulation studies of a silver-coated leuc-activated needleless connector for prevention of CRBSI. *Clin Infect Dis* 2010; 50:1580-87.
314. Kumar A, Zarychanski R, Light B, Parrillo JE, **Maki DG**, et al. Combination antimicrobial therapy yields improved survival compared to monotherapy in septic shock: A propensity-matched analysis. *Crit Care Med* 2010;38:1773-85.
315. Sprung CL, Cohen R, Adini B and European Society of Intensive Care Medicine's Task Force for intensive care unit triage during an influenza epidemic or mass disaster (**Maki DG, collaborator**). Chapter 1. Introduction. Recommendations and standard operating procedures for intensive care unit and hospital preparations for an influenza epidemic or mass disaster. *Intensive Care Med*. 2010;36 Suppl 1:S4-10.
316. Hick JL, Christian MD, Sprung CL and European Society of Intensive Care Medicine's Task Force for intensive care unit triage during an influenza epidemic or mass disaster (**Maki DG, collaborator**). Chapter 2. Surge capacity and infrastructure considerations for mass critical care. Recommendations and standard operating procedures for intensive care unit and hospital preparations for an influenza epidemic or mass disaster. *Intensive Care Med*. 2010;36 Suppl 1:S11-20.
317. Joynt GM, Loo S, Taylor BL, Margalit G, Christian MD, Sandrock C, Danis M, Leoniv Y, Sprung CL and European Society of Intensive Care Medicine's Task Force for intensive care unit triage during an influenza epidemic or mass disaster (**Maki DG, collaborator**). Chapter 3. Coordination and collaboration with interface units. Recommendations and standard operating procedures for intensive care unit and hospital preparations for an influenza epidemic or mass disaster. *Intensive Care Med*. 2010;36 Suppl 1:S21-31.

## PUBLICATIONS

Dennis G Maki, MD

318. Jandrock C and European Society of Intensive Care Medicine's Task Force for intensive care unit triage during an influenza epidemic or mass disaster (**Maki DG, collaborator**). Chapter 4. Manpower. Recommendations and standard operating procedures for intensive care unit and hospital preparations for an influenza epidemic or mass disaster. *Intensive Care Med.* 2010;36 Suppl 1:S32-7.
319. Sprung CL, Kesecioglu J and European Society of Intensive Care Medicine's Task Force for intensive care unit triage during an influenza epidemic or mass disaster (**Maki DG, collaborator**). Chapter 5. Essential equipment, pharmaceuticals and supplies. Recommendations and standard operating procedures for intensive care unit and hospital preparations for an influenza epidemic or mass disaster. *Intensive Care Med.* 2010;36 Suppl 1:S38-44.
320. Taylor BL, Montgomery HE, Rhodes A, Sprung CL and European Society of Intensive Care Medicine's Task Force for intensive care unit triage during an influenza epidemic or mass disaster (**Maki DG, collaborator**). Chapter 6. Protection of patients and staff during a pandemic. Recommendations and standard operating procedures for intensive care unit and hospital preparations for an influenza epidemic or mass disaster. *Intensive Care Med.* 2010;36 Suppl 1:S45-54.
321. Christian MD, Joynt GM, Hick JL, Colvin J, Danis M, Sprung CL and European Society of Intensive Care Medicine's Task Force for intensive care unit triage during an influenza epidemic or mass disaster (**Maki DG, collaborator**). Chapter 7. Critical care triage. Recommendations and standard operating procedures for intensive care unit and hospital preparations for an influenza epidemic or mass disaster. *Intensive Care Med.* 2010;36 Suppl 1:S55-64.
322. Zimmerman JL, Sprung CL and European Society of Intensive Care Medicine's Task Force for intensive care unit triage during an influenza epidemic or mass disaster (**Maki DG, collaborator**). Chapter 8. Medical procedures. Recommendations and standard operating procedures for intensive care unit and hospital preparations for an influenza epidemic or mass disaster. *Intensive Care Med.* 2010;36 Suppl 1:S65-9.
323. Richards GA, Sprung CL and European Society of Intensive Care Medicine's Task Force for intensive care unit triage during an influenza epidemic or mass disaster (**Maki DG, collaborator**). Chapter 9. Educational process. Recommendations and standard operating procedures for intensive care unit and hospital preparations for an influenza epidemic or mass disaster. *Intensive Care Med.* 2010;36 Suppl 1:S70-9.
324. Rosenthal VD, **Maki DG**, Jamulitrat S, Medeiros EA, Todi SK, Gomez DY, Leblebicioglu H, Abu Khader I, Miranda Novales MG, Berba R, Ramirez Wong FM, Barkat A, Pino OR, Dueñas L, Mitrev Z, Bijie H, Gurskis V, Kanj SS, Mapp T, Hidalgo RF, Ben Jaballah N, Raka L, Gikas A, Ahmed A, Thu le TA, Guzmán Siritt ME; INICC Members. International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003-2008, issued June 2009. *Am J Infect Control.* 2010;38:95-104.e2.
325. Rosenthal VD, **Maki DG**, Rodrigues C, Alvarez-Moreno C, Leblebicioglu H, Sobreyra-Oropeza M, Berba R, Madani N, Medeiros EA, Cuéllar LE, Mitrev Z, Dueñas L, Guanche-Garcell H, Mapp T, Kanj SS, Fernández-Hidalgo R. Impact of International Nosocomial Infection Control Consortium (INICC) Strategy on Central Line-Associated Bloodstream Infection Rates in the Intensive Care Units of 15 Developing Countries. *Infect Control Hosp Epidemiol.* 2010;31:1264-1272.
326. **Maki DG**, Rosenthal VD, Salomao R, Franzetti F, Rangel-Frausto MS. Impact of switching from an open to a closed infusion system on rates of central line-associated bloodstream infection: a meta-analysis of time-sequence cohort studies in 4 countries. *Infect Control Hosp Epidemiol.* 2011;32:50-8.
327. **Maki DG**, Ash SR, Winger RK, Lavin P. A multi-center randomized trial of a novel antimicrobial and antithrombotic lock solution for hemodialysis catheters. *Crit Care Med* 2011;39:613-20.
328. Kumar A for the Antimicrobial Therapy of Septic Shock Study Group (**Maki DG, member**). A selection bias in the study of early combination therapy in septic shock (letter). *Crit Care Med* 2011;39:1804-5.
329. Rosenthal VD, Bijie H, **Maki DG**, Mehta Y, Apisarnthanarak A, Medeiros EA, Leblebicioglu H, Fisher D, Álvarez-Moreno C, Khader IA, Del Rocío González Martínez M, Cuellar LE, Navoa-Ng JA, Abouqal R, Guanche Garcell H, Mitrev Z, Pirez García MC, Hamdi A, Dueñas L, Cancel E, Gurskis V, Rasslan O,

## PUBLICATIONS

Dennis G Maki, MD

Ahmed A, Kanj SS, Ugalde OC, Mapp T, Raka L, Yuet Meng C, Thu le TA, Ghazal S, Gikas A, Narváez LP, Mejía N, Hadjieva N, Gamar Elanbya MO, Guzmán Siritt ME, Jayatilleke K; INICC members. International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004-2009. *Am J Infect Control* 2012;40:396-407.

330. Rimmer E, Kumar A, Doucette S, Marshall J, Dial S, Gurka D, Dellinger RP, Sharma S, Penner C, Kramer A, Wood K, Ronald J, Kumar A, Turgeon AF, Houston DS, Zarychanski R; Cooperative Antimicrobial Therapy of Septic Shock Database Research Group (**Maki DG, member**). Activated protein C and septic shock: A propensity-matched cohort study. *Crit Care Med*. 2012;40::2974-2981.
331. Safdar N, **Maki DG. Intravascular device-related infections:** Catheter salvage strategies and prevention of device-related infection. In *Principles and Practice of Cancer Infectious Disease*. Second edition, Safdar A (ed). Humana Press (Springer), New York, NY, 2011:123-142.
332. Kumar A, Doucette S, Marshall J, Dial S, Gurka D, Dellinger RP, Sharma S, Penner C, Kramer A, Wood K, Ronald J, Kumar A, Turgeon AF, Houston DS, Zarychanski R, Rimmer E and the Co-operative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group (**Maki DG, member**). Activated protein C and septic shock: a propensity-matched cohort study. *Crit Care Med* 2012;40:2974-81.
333. Arabi YM, Dara SI, Memish Z, Al Abdulkareem A, Tamim HM, Al-Shirawi N, Parrillo JE, Dodek P, Lapinsky S, Feinstein D, Wood G, Dial S, Zanotti S, Kumar A and the Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group (**Maki DG, member**). Antimicrobial therapeutic determinants of outcomes from septic shock among patients with cirrhosis. *Hepatology* 2012;56:2305-15.
334. Crook DW, Walker AS, Kean Y, Weiss K, Cornely OA, Miller MA, Esposito R, Louie TJ, Stoesser NE, Young BC, Angus BJ, Gorbach SL, Peto TE; Study 003/004 Teams (**Maki DG, member**). Fidaxomicin versus vancomycin for *Clostridium difficile* infection: meta-analysis of pivotal randomized controlled trials. *Clin Infect Dis* 2012;55 Suppl 2:S93-103.
335. Chlebicki MP, Safdar N, O'Horo JC, **Maki DG**. Preoperative chlorhexidine shower or bath for prevention of surgical site infection: a meta-analysis. *Am J Infect Control*. 2013;41:167-173.
336. Kethireddy S, Light B, Miranejad y, **Maki DG**, Arabi Y, Lapinsky S, Simon D, Kumar A, Parrillo J, Kumar A. Characteristics of septic shock from *Mycobacterium tuberculosis*. *Chest* 2013;144:474-82.
337. **Maki DG**. Commentary for *ACP J Club*: Routine versus clinically indicated replacement of peripheral intravenous catheters: a randomised controlled equivalence trial. *Lancet*. 2012;380:1066-74. *Ann Intern Med* 2013;158:JC8.
338. Zelenitsky S, Rubinstein E, Ariano R, Iacovides H, Dodek P, Mirzanejad Y, Kumar A and the Cooperative Antimicrobial Therapy of Septic Shock-CATSS Database Research Group (**Maki DG, member**). Vancomycin pharmacodynamics and survival in patients with methicillin-resistant *Staphylococcus aureus*-associated septic shock. *Int J Antimicrob Agents* 2013;41:255-60.
339. Rose WE, Berti AD, Hatch JB, **Maki DG**. Relationship of in vitro synergy and treatment with daptomycin plus rifampin in patients with complex methicillin-resistant *Staphylococcus aureus* infections. *Antimicrob Ag Chemother* 2013;57: 3450-2.
340. Arabi YM, Dara SI, Tamim HM, Rishu AH, Bouchama A, Khedr MK, Feinstein D, Parrillo JE, Wood KE, Keenan SP, Zanotti S, Martinka G, Kumar A, Kumar A; Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group (**Maki DG, member**). Clinical characteristics, sepsis interventions and outcomes in the obese patients with septic shock: an international multicenter cohort study. *Crit Care*. 2013;17:R72.
341. Chopra C, O'Horo JC, Rogers MA, **Maki DG**, Safdar N. The risk of bloodstream infection with peripherally inserted central catheters compared with central venous catheters in adults. A systematic review and meta-analysis. *Infect Control Hosp Epidemiol*. 2013;34:908-18.



## PUBLICATIONS

Dennis G Maki, MD

342. **Maki DG.** Commentary for *ACP J Club*: Marschall J, Carpenter CR, Fowler S, Trautner BW; CDC Prevention Epicenters Program. Antibiotic prophylaxis for urinary tract infections after removal of urinary catheter: meta-analysis. *BMJ*. 2013;346:f3147. **Ann Intern Med** 2013 Oct 15;159:JC9.
343. Safdar N, O'Horo JC, **Maki DG.** Arterial Catheter-related bloodstream infection: Incidence, pathogenesis, risk factors and prevention. **J Hosp Infect** 2013; 85:189-95.
344. **Maki DG,** Kumar A. Prevention of donor-derived infection in solid-organ transplantation. **Management of the Potential Organ Donor Initiative.** KE Wood (Ed). United States Health and Human Services. 2013 (In press).
345. **Maki DG,** Tsigrelis C. Nosocomial infection in the intensive care unit. In: **Critical Care Medicine. Principles of Diagnosis and Management,** Fourth edition, Parrillo JE, Dellinger RP (Eds.), eds. Mosby, Philadelphia, PA. 2014: 825-869.
346. O'Horo JC, **Maki DG,** Krupp AE, Safdar N. Arterial Catheters as a Source of Bloodstream Infection: A Systematic Review and Meta-Analysis. **Crit Care Med** 2014; 42:1334-39.
347. **Maki DG.** Stethoscopes and health care-associated infection (Editorial). **Mayo Clin Proc** 2014; 89:277-80.
348. Oh CC, Ko HC, Lee HY, Safdar N, **Maki DG,** Chlebicki MP. Antibiotic prophylaxis for preventing recurrent cellulitis: A systematic review and meta-analysis. **J Infect** 2014; 69:26-34.
349. Safdar N, O'Horo JC, Ghufran A, Beardon A, Didier M, Chateau D, **Maki DG.** Chlorhexidine-impregnated dressings for prevention of catheter-related bloodstream infection: A meta-analysis. **Crit Care Med** 2014;42: 1703-13.
350. Crnich CJ, Duster M, Warrack S, **Maki DG,** Safdar N. Assessing Methicillin-Resistant Staphylococcus aureus (MRSA) Clustering in Different Healthcare Facilities: A Comparison of Pulsed-Gel Electrophoresis and a Commercial Repetitive-Element PCR Method. **J Clin Microbiol** 2014; 52:2027-32.
351. Leligdowicz A, Dodek PM, Norena M, Wong H, Kumar A, Kumar A; Co-operative Antimicrobial Therapy of Septic Shock Database Research Group (**Maki DG,** member). Association between source of infection and hospital mortality in patients who have septic shock. **Am J Respir Crit Care Med** 2014; 189:1204-13.
352. Beck V, Chateau D, Bryson GL, Pisipati A, Zanotti S, Parrillo JE, Kumar A; Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group (**Maki DG,** member). Timing of vasopressor initiation and mortality in septic shock: a cohort study. **Crit Care.** 2014; 18:R97.
353. Waechter J, Kumar A, Lapinski SE, Marshall J, Dodek P, Arabi Y, Parillo JE, Dellinger RP, Garland A; Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group (**Maki DG,** member). Interaction between fluids and vasoactive agents on mortality in septic shock: a multicenter observational study. **Crit Care Med** 2014; 42:2158-68.
354. Funk D, Doucette S, Pisipati A, Dodek P, Marshall JC, Kumar A; Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group (**Maki DG,** member). Low-dose corticosteroid treatment in septic shock: a propensity-matching study. **Crit Care Med** 2014; 42:2333-41.
355. **Maki DG,** Chlorhexidine's role in skin antisepsis: questioning the evidence. **Lancet** 2014; 384:1345-6.
356. Rosenthal VD, **Maki DG,** Mehta Y, Leblebicioglu H, Memish ZA, et al. International Nosocomial Infection Control Consortiu (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module. **Am J Infect Control.** 2014; 42:942-56.
357. Rose WE, Hatch JB, **Maki DG.** Combination therapy with daptomycin and rifampin is highly effective for the treatment of complex bone and joint infections. (Submitted for publication).

## PUBLICATIONS

Dennis G Maki, MD

358. Boriosi J, **Maki DG**, Yngsdal-Krenz RA, Wald ER, Porter WP, Cook ME, Bütz DE. Breath carbon isotope delta value may be a biomarker of catabolic inflammatory acute phase response in mechanically ventilated pediatric patients. (Submitted for publication).

1. **Maki DG.** Approximately 500 commercially-recorded and distributed audiotapes of presentations at national scientific or CME conferences since 1976.
2. University of Wisconsin Hospital and Clinics Pharmacy and Therapeutics Committee (**DG Maki**, Reviewer and Contributing Co-author). **Antimicrobial Use Guideline, University of Wisconsin Hospital and Clinics**, updated annually, Editions 1-22, Center for Drug Policy and Clinical Economics, Department of Pharmacy, University of Wisconsin Hospital and Clinics University of Wisconsin Hospital and Clinics, Board of Regents, UW-Madison, 1988-2013.
3. **Maki DG**, (Editor). **Improving Catheter Site Care**, Royal Society of Medicine Services Ltd., London-New York, 1992, pp. 1-76.
4. **Maki DG**, Boyce J, Weinstein R. Prevention and control of nosocomial infections caused by vancomycin-resistant enterococci. **Educational Video** produced by H.T. Shaw (ed).CoMed Communications, Philadelphia, PA, 1996.
5. **Maki DG**, Weinstein R, Kelly J, Lois M. The end of the antibiotic era? Controlling vancomycin resistance in the healthcare organization. **Educational Video** produced by VHA Inc., Irving, TX, 1996.
6. **Maki DG.** Infectious Diseases: Introduction to microbiology and clinical infectious diseases (1 hour); Infectious diseases in our daily lives (1 hour); Prevention of infectious diseases (1 hour); Treatment of infection; antibiotic resistance (1 hour); Emerging infectious diseases in the late Twentieth Century (1 hour). **Educational Audio Series, University of the Air**, Board of Regents, University of Wisconsin-Madison, July 1996.
7. **Maki DG** (Editor). Update on Infectious Diseases. **Educational Video** of Biennial 20-hour CME Course by Infectious Diseases Section of the University of Wisconsin Medical School, Produced by Department of Continuing Medical Education, University of Wisconsin Medical School, Board of Regents, UW-Madison, Madison, WI. 1997, 1999, 2001.
8. **Maki DG**, Budrick L, Garcia R. Reducing hospital-acquired urinary tract infections. **Educational Video** produced by VHA Inc, Irving, Tx, 1999.
9. Buchman JG, Bertino JS, Breiman RF, Cassell GH, Charach T, Doern GD, File TM, Fine MJ, Greenberg RM, Greenberg SB, Hammerschlag MR, **Maki DG**, Massoud N, Masur H, Murphy TF, Plouffe JF, Talan DA, Tomasz E, Teanor J, Weiser JN, Whitney CG, Yoshikawa TT. Community-Acquired Pneumonia in Adult and Elderly Populations. Consensus Conference sponsored by the National Institute of Allergy and Infectious Diseases. **Educational Video and CD ROM, Community-acquired Pneumonia in Adult and Elderly Population**, Produced by Gardiner-Caldwell, SynerMed, Califon, NJ, 1998, 2000.
10. **Maki DG.** The coming plague: Bioterrorism. **Educational Internet Video** produced by the Department of Continuing Medical Education, University of Wisconsin Medical School, UW-Madison, Madison, WI, 2001.
11. **Maki DG.** The Abbott Outbreak. In the **Educational DVD, The Most Important Outbreaks Investigated by the CDC During the Past 50 Years**. U.S. Centers for Disease Control and Prevention, Department of Health and Social Services, Atlanta, GA, 2001.
12. **Maki DG**, Mann H. New technologies in sepsis treatment, **Educational Video** produced by VHA, Inc., Irving, TX, 2001.
13. **Maki DG.** The CDC/HICPAC IV catheter guideline, **Educational Video** produced by VHA, Inc., Irving, TX, 2003.
14. **Maki DG**, McCormick RD, Banton J. IV Catheter-related Infection: The CDC Guideline for Prevention. **Educational Video** produced by APIC/3M, Invision Inc., Nashville, TN, 2003.
15. Cohen J, Powderly WG, Berkely SF, Calandra T, Clumeck N, Finch RG, Hammer SM, Holland SM, Kiehn TE, McAdam KP, **Maki DG**, Norrby SR, Opal SM, Ronald AR, Solberg CO, Verhoef J (eds), **Infectious Diseases, 2nd edition**. Elsevier Science, USA, Philadelphia, PA, pp. 2487, 2003.

16. **Maki DG.** Need for a new paradigm for control of nosocomial infection in the 21st Century. **Educational Web-cast** produced by 3M Corporation, Internet videocast to South America, Asia, Australia and New Zealand, 2004.
17. **Maki, DG.** Evaluation and management of septic shock, **Educational Audiotape** produced by *Practical reviews in Internal Medicine Audio Journal Club* and the *DocPod Hospitalist Audio Program* of the Society of Hospital Medicine, Oakstone Publishing, LLC, Birmingham, AL, 2005.
18. **Maki DG.** Technology may be the key to food safety—infectious diseases. **Dateline NBC**, March 25, 2007.
19. **Maki DG.** Catheter-associated bloodstream infection. Pathogenesis and prevention. **National APIC Webinar** produced by APIC/BD, Invision Inc., Nashville, TN, April 14 and November 16, 2006.
20. **Maki DG.** Prevention, diagnosis and management of intravascular catheter-related infections. **Indian Society of Critical Care Medicine Tele-symposium.** Live videoconference with approximately 3000 participants in Dehli, Mumbai, Calcutta, Bangalore and Madras. May 20, 2007.
21. **Maki DG** and Others. *Reducing Isolation in Cystic Fibrosis.* Do Pico g (Ed). **Educational DVD** produced by the Adult Cystic Fibrosis Center, Department of Continuing Medical Education, University of Wisconsin Hospital and Clinics, Board of Regents, UW-Madison, Madison, WI, 2007.
22. **Maki DG.** Infections of implanted medical devices; Line sepsis; Septic shock; Emerging infections *The Chicago Infectious Disease Board and Recertification Course.* Trenholme G, Weinstein R (Eds). **Educational DVD** produced by Rush University Medical Center and the Metro Foundation. September 2006, September 2007.
23. **Maki DG.** Infection Control Guidelines and Universal Precautions Review. **National Webinar.** Innovations in Medical Education. Office of Continuing Professional Development, University of Wisconsin School of Medicine and Public Health, Board of Regents, UW-Madison, Madison, WI, July 5, 2007..
24. **Maki DG.** Infection Control in the 21<sup>st</sup> Century—Part I. **National Webinar.** Innovations in Medical Education. Office of Continuing Professional Development, University of Wisconsin School of Medicine and Public Health, Board of Regents, UW-Madison, Madison, WI, September 7, 2007.
25. **Maki DG.** Infection Control in the 21<sup>st</sup> Century—Part II. **National Webinar.** Innovations in Medical Education. Office of Continuing Professional Development, University of Wisconsin School of Medicine and Public Health, Board of Regents, UW-Madison, Madison, WI, September 21, 2007.
26. **Maki DG.** Infections of implanted medical devices; Line sepsis; Septic shock; Emerging infections *The Chicago Infectious Disease Board and Recertification Course.* Trenholme G, Weinstein R (Eds). **Educational DVD** produced by Rush University Medical Center and the Metro Foundation. September 2006, September 2008.
27. **Maki DG.** Catheter-associated bloodstream infection. Pathogenesis and prevention. **National APIC Webinar** produced by APIC/BD, Invision Inc., Nashville, TN, April 14 and November 16, 2006.
28. **Maki DG.** Catheter-associated urinary tract infection. Pathogenesis and prevention. **Educational Video** produced by VHA, Inc., Irving, TX, November 14, 2008.
29. **Maki DG.** Can MRSA be Controlled? **National Webinar.** Innovations in Medical Education. Office of Continuing Professional Development, University of Wisconsin School of Medicine and Public Health, Board of Regents, UW-Madison, Madison, WI, March 17, 2009.
30. **Maki DG, McCormick RD.** Prevention of Catheter-related Bloodstream Infection. **Educational Video** produced by APIC/3M, Envision Inc., Nashville, TN, April 2009.

31. **Maki DG**, Olsen CW, Mejicano G. Swine Flu: What You Need to Know. **National Webinar**. Innovations in Medical Education. Office of Continuing Professional Development, University of Wisconsin School of Medicine and Public Health, Board of Regents, UW-Madison, Madison, WI, April 29, 2009.
32. **Maki DG**, Crnich CJ, Safdar N, McCormick RD, Andes DR. Influenza H1N1 Update. **National Webinar**. Innovations in Medical Education. Office of Continuing Professional Development, University of Wisconsin School of Medicine and Public Health, Board of Regents, UW-Madison, Madison, WI, April 29, 2009.
33. **Maki DG**. Infections of implanted medical devices; Line sepsis; Septic shock; Emerging infections *The Chicago Infectious Disease Board and Recertification Course*. Trenholme G, Weinstein R (Eds). **Educational DVD** produced by Rush University Medical Center and the Metro Foundation. September 2010.
34. Walsh F, **Maki DG**, Provonost P, Goldman M, Duerden B, Beggs C,. A debate: *Reducing HCAs - Creating a Culture of Patient Safety*. **Educational DVD** produced by the NHS. London, UK, December 2010.
35. **Maki DG**. Lines, tubes and prostheses: how are they going to affect vaccine development? *In the Pasteur Institute-Merieux Foundation Symposium: Vaccination and Antibody: Prevention and Therapy of Nosocomial Infections*. Annecy, France, **Educational DVD** produced by the Merieux Foundation, September 2011.
36. **Maki DG** and Others. *Reducing Isolation in Cystic Fibrosis*. Do Pico g (Ed). **Educational DVD** produced by the Adult Cystic Fibrosis Center, Department of Continuing Medical Education, University of Wisconsin Hospital and Clinics, Board of Regents, UW-Madison, Madison, WI, 2012.
37. **Maki DG**. Infections of implanted medical devices; Line sepsis; Septic shock; Emerging infections *The Chicago Infectious Disease Board and Recertification Course*. Trenholme G, Weinstein R (Eds). **Educational DVD** produced by Rush University Medical Center and the Metro Foundation. October 2012.
38. **Maki DG**. The 1970s. *Four Decades of Difference*. **40<sup>th</sup> Annual Conference of the Association for Professionals in Infection Control**. DVD produced by the Association for Professionals in Infection Control, June 2013.
39. **Maki DG**. Infections of implanted medical devices; Line sepsis; Septic shock; Emerging infections *The Chicago Infectious Disease Board and Recertification Course*. Trenholme G, Weinstein R (Eds). **Educational DVD** produced by Rush University Medical Center and the Metro Foundation. September 2014.

1. **Maki DG**, Hennekens CH, Shaw WV, Bennett JV. Nosocomial *Serratia marcescens* urinary tract infection: An epidemiologic study. **Proceedings and Abstracts of the 10th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Chicago, October 1970.
2. **Maki DG**, Bennett JV, Scheckler WE, Brachman PS. A national nosocomial infection surveillance system. **Proceedings of the Annual Meeting of the American Public Health Association**, Houston, October 1970.
3. **Maki DG**, Rhame FS, Mackel DC, Bennett JV. Septicemias consequent to contaminated infusion fluid. **Proceedings of the Annual Meeting of the American Society for Microbiology**, Minneapolis, May 1971.
4. **Maki DG**, Rhame RS, Mackel DC, Bennett JV. Mechanism of contamination of a screw-cap closure for infusion products. **Proceedings and Abstracts of the 11th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Atlantic City, October 1971.
5. Fisher EJ, **Maki DG**, Eisses J, Neblett TR, Quinn EL. Epidemic septicemias due to intrinsically contaminated infusion products. **Proceedings and Abstracts of the 11th Interscience Conference of Antimicrobial Agents and Chemotherapy**, Atlantic City, October 1971.
6. **Maki DG**, Goldmann DA, Rhame FS, Bennett JV. Infection control in intravenous therapy. **Proceedings and Abstracts of the 54th Annual Session of the American College of Physicians**, Chicago, April 1973.
7. Tenney J, **Maki D**, Rhame F, Goldmann D, Dixon R, Bennett JV. Intrinsic contamination of intravenous fluid products. **Proceedings and Abstracts of the 101st Annual Meeting of the American Public Health Association**, San Francisco, November 1973.
8. **Maki D**, Barriga P, Hussey JL. Ultrasonographic detection of intra-abdominal abscesses in renal transplant patients. *Clin Res* 23:497A (75).
9. **Maki DG**, Weiss CE, Sarafin HW. Semiquantitative method for distinguishing IV catheter-related infection. **Proceedings of the Annual Meeting of the Southern Section, American Federation for Clinical Research**, New Orleans, January 1976. *Clin Res* 24:25A (76).
10. Kimball J, Helstad A, **Maki D**. Recovery of anaerobes from clinical specimens in three transport systems. **Proceedings and Abstracts of the Annual Meeting of the American Society of Microbiology**, Atlantic City, May 1976.
11. **Maki DG**. Growth properties of microorganisms in infusion fluid and methods of detection. **Proceedings of the International Symposium, "Microbiological Hazards of Infusion Therapy,"** Brighton, England, March 1976.
12. **Maki DG**. Sepsis arising from extrinsic contamination of the infusion and measures for control. **Proceedings of the International Symposium, "Microbiological Hazards of Infusion Therapy,"** Brighton, England, March 1976.
13. **Maki DG**. The role of surveillance in prevention of hospital-acquired infection. **Symposium "The Role of Surveillance in Prevention of Infection," Proceedings of the Annual Meeting of the Society for Epidemiologic Research**, Toronto, Canada, June 1976. *Am J Epidemiol* 104:358 (76).
14. **Maki DG**, Jarrett F: A semiquantitative culture method for identification of catheter-related infection in the burn patient. **Proceedings and Abstracts of the Annual Meeting of the Association for Academic Surgery**, Key Biscayne, November 1976.
15. **Maki DG**, Craig W, Agger W. Sisomicin - clinical studies of a new aminoglycoside, comparison with gentamicin. **Proceedings of the International Sisomicin Symposium**, Geneva, Switzerland, May 1977.

16. **Maki DG.** The role of microbiologic surveillance of infusion products and devices in infection control. **Proceedings of the Symposium "The Role of Microbiologic Surveillance in Infection Control," Proceedings and Abstracts of the Annual Meeting of the American Society of Microbiology,** New Orleans, May 1977.
17. Karchmer A, Moellering R, **Maki DG,** Swartz M. Single antibiotic therapy of streptococcal endocarditis. **Proceedings and Abstracts of the 17th Interscience Conference on Antimicrobial Agents and Chemotherapy,** New York, October 1977.
18. **Maki DG,** McCormick R, Wirtenan GW. Septic endarteritis from intra-arterial catheters for chemotherapy. **Proceedings and Abstracts of the 17th Interscience Conference on Antimicrobial Agents and Chemotherapy,** New York, October 1977.
19. **Maki DG,** Kurzynski TA, Agger WA. Carbenicillin for *Bacteroides fragilis* infections - Why not penicillin G? **Presented at the Program on Infectious Diseases and Related Topics to Honor Dr. Edward Kass on the Occasion of His Sixtieth Birthday,** Boston, MA, December 1977.
20. Band JD, **Maki DG.** Morbidity associated with steel needles in patients with hematologic malignancy. **Proceedings of the Annual Meeting of the Western Section, American Federation for Clinical Research,** Carmel, California, February 1978. *Clin Res* 26:125A (78).
21. **Maki DG,** Schuna AA. Antimicrobial misuse in a university hospital. *Clin Res* 26:116A (78).
22. **Maki DG,** Agger WA, Craig WA. Comparative study of sisomicin and gentamicin. *Clin Res* 26:156A (78).
23. **Maki DG.** Control of colonization and transmission of pathogenic bacteria in the hospital. **Proceedings of the Symposium, "The Impact of Infections on Medical Care in the United States: Problems and Priorities for Future Research,"** National Institutes of Health, Bethesda, May 1978.
24. Band J, **Maki DG.** A study of the safety of changing intravenous delivery systems at intervals greater than 24 hours. **Proceedings and Abstracts of the National Meeting of the Association of Practitioners in Infection Control,** Boston, MA, June 1978. *Am J Infect Control* 6:28 (78).
25. **Maki DG,** Agger WA. Enterococcal bacteremia - clinical features and risk of endocarditis. **Proceedings and Abstracts of the 18th Interscience Conference on Antimicrobial Agents and Chemotherapy,** Atlanta, October 1978.
26. Drow D, **Maki DG,** Manning D. Enzyme-linked-immunosorbent assay (ELISA) in detection of *H. influenzae* antigen. **Proceedings and Abstracts of the 18th Interscience Conference on Antimicrobial Agents and Chemotherapy,** Atlanta, October 1978.
27. **Maki DG,** Helstad AG, Kimball JL. Screening for penicillin-resistant pneumococci. **Proceedings and Abstracts of the 18th Interscience Conference on Antimicrobial Agents and Chemotherapy,** Atlanta, October 1978.
28. Band JD, **Maki DG.** Infections caused by indwelling arterial catheters for hemodynamic monitoring. **Proceedings and Abstracts of the 18th Interscience Conference on Antimicrobial Agents and Chemotherapy,** Atlanta, October 1978.
29. Band JD, **Maki DG.** A study of the safety of changing intravenous delivery systems at intervals greater than 24 hours. **Proceedings and Abstracts of the 18th Interscience Conference on Antimicrobial Agents and Chemotherapy,** Atlanta, October 1978.
30. **Maki DG.** The consequences of antibiotic overuse; ammunition for a hospital program of self-improvement. **Antibiotic Audit-1979, Proceedings of the First National Conference on Antibiotic Review,** Atlanta, GA, March 1979.

31. **Maki DG.** Effects of a multifaceted program for improving use of antibiotics in a university hospital. **Antibiotic Audit-1979, Proceedings of the First National Conference on Antibiotic Review**, Atlanta, GA, March 1979.
32. **Maki DG.** Sepsis arising from contamination and control measures. **Proceedings of the Symposium, "Safety in Intravenous Therapy,"** Pretoria, South Africa, March 1979.
33. **Maki DG.** Physical and microbial contamination. **Proceedings of the Symposium, "Safety in Intravenous Therapy,"** Pretoria, South Africa, March 1979.
34. **Maki DG.** Pinpointing problems in use of antibiotics "Antibiotic Audit--1979 (II)," **Proceedings of the First National Conference on Antibiotic Review**, Los Angeles, September 1979.
35. **Maki DG.** A multifaceted program for improving use of antibiotics in the hospital "Antibiotic Audit--1979 (II)," **Proceedings of the First National Conference on Antibiotic Review**, Los Angeles, September 1979.
36. **Maki DG.** Sepsis from vascular access devices in intensive care units. **Proceedings of an International Symposium, Controversies in Surgical Asepsis**, Southampton, England, September 1979.
37. Reich R, **Maki DG.** Anaerobic meningitis. **Proceedings and Abstracts of the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Boston, October 1979.
38. **Maki DG, Nauseef WN.** Evaluation of protective isolation in patients with granulocytopenia. **Proceedings and Abstracts of the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Boston, October 1979.
39. **Maki DG, Zilz MA, Alvarado CJ.** Evaluation of the antibacterial efficacy of four agents for handwashing. **Proceedings and Abstracts of the 19th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Boston, October 1979.
40. Band JD, **Maki DG.** Clinical relevance of *Staph. aureus* bacteriuria, **Clin Res** 27:747A (80).
41. **Maki DG, Band JD.** Comparative study of topical antimicrobial agents in prevention of intravenous catheter-related infections. **Clin Res** 27:752A (80).
42. **Maki DG.** Updated control measures for preventing infection in infusion therapy. **Proceedings of the 7th National Meeting of the Association of Practitioners in Infection Control**, San Francisco, June 1980. **Am J Infect Control** 8:88-9 (80).
43. **Maki DG.** Nosocomial urinary tract infection. **Proceedings of a Symposium on Advances in Urology.** Pretoria, South Africa, August 1980.
44. **Maki DG.** Nosocomial bacteremia: an epidemiologic overview. **Proceedings of the 2nd International Conference on Nosocomial Infection**, Atlanta, August 1980.
45. **Maki DG, Band JD.** Study of polyantibiotic and iodophor ointments in prevention of vascular catheter-related infection. **Proceedings of the 2nd International Conference on Nosocomial Infection**, Atlanta, August 1980.
46. **Maki DG, Hassemer CA.** Endemic rate of fluid contamination and septicemia in arterial pressure monitoring. **Proceedings of the 2nd International Conference on Nosocomial Infection**, Atlanta, August 1980.
47. McCormick R, **Maki DG.** Epidemiology of needle puncture wounds in hospital employees. **Proceedings of the 2nd International Conference on Nosocomial Infection**, Atlanta, August 1980.



48. **Maki DG**, Alvarado CJ, Hassemer CA. A simple culture method for quantifying hand carriage of microbial pathogens in the hospital. **Proceedings of the 2nd International Conference on Nosocomial Infection**, Atlanta, August 1980.
49. **Maki DG**, Zilz MA, Alvarado CJ. Evaluation of the efficacy of four agents for handwashing. **Proceedings of the 2nd International Conference on Nosocomial Infection**, Atlanta, August 1980.
50. **Maki DG**, MacCormick KN. Acetone defatting in skin antisepsis. **Proceedings of the 2nd International Conference on Nosocomial Infection**, Atlanta, August 1980.
51. Nauseef WA, **Maki DG**. A study of simple protective isolation in patients with granulocytopenia. **Proceedings of the 2nd International Conference on Nosocomial Infection**, Atlanta, August 1980.
52. **Maki DG**. Growth properties of microorganisms in lipid for infusion and implications for infection control. **Proceedings and Abstracts of the 20th Interscience Conference on Antimicrobial Agents and Chemotherapy**, New Orleans, September 1980.
53. **Maki DG**, MacCormick KN. Acetone defatting in cutaneous antisepsis. **Proceedings and Abstracts of the 20th Interscience Conference on Antimicrobial Agents and Chemotherapy**, New Orleans, September 1980.
54. **Maki DG**, Alvarado CJ, Hassemer CA, Zilz MA. Prospective study of the role of the inanimate environment in endemic nosocomial infections. **Proceedings and Abstracts of the 20th Interscience Conference on Antimicrobial Agents and Chemotherapy**, New Orleans, September 1980.
55. **Maki DG**, Hassemer CA. Endemic rate of fluid contamination and septicemia in arterial pressure monitoring. **Third World Congress on Intensive and Critical Care Medicine/Tenth Annual Meeting of the Society for Critical Care Medicine**, Washington, D.C., May 1981. *Crit Care Med* 9:144 (81).
56. **Maki DG**, MacCormick KN. Acetone defatting in cutaneous antisepsis. **Third World Congress on Intensive and Critical Care Medicine/ Tenth Annual Meeting of the Society for Critical Care Medicine**, Washington, D.C., May 1981. *Crit Care Med* 9:202 (81).
57. **Maki DG**, Band JD. Study of polyantibiotic and iodophor ointments in prevention of vascular catheter-related infection. **Third World Congress on Intensive and Critical Care Medicine/Tenth Annual Meeting of the Society for Critical Care Medicine**, Washington, D.C., May 1981. *Crit Care Med* 9:201 (81).
58. **Maki DG**. A prospective study of sisomicin and gentamicin in serious gram-negative infections. **Proceedings of Symposia on Sisomicin**, Osaka, Fukuoka, Tokyo and Sapporo, June 1981.
59. **Maki DG**. Summary of Symposium: Guidelines for infection control in enteral alimentation. **Proceedings of the Symposium "Infection Control in Enteral Alimentation,"** Atlanta, October 1981.
60. Reich R, **Maki DG**: Transmission of *Neisseria meningitidis* in a critical care unit. **Proceedings and Abstracts of the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy**, Chicago, November 1981.
61. **Maki DG**, Boh L, Christopherson R. A multi-faceted program for improving use of antimicrobics in the hospital. **Proceedings and Abstracts of the 21st Interscience Conference on Antimicrobial Agents and Chemotherapy**, Chicago, November 1981.
62. **Maki DG**. Nosocomial bacteremia in the critical care unit. **Proceedings and Abstracts of the Symposium, "Infections in Surgical Patients," 21st Interscience Conference on Antimicrobial Agents and Chemotherapy**, Chicago, November 1981.
63. Bavisotto L, **Maki DG**. Does trimethoprim-sulfamethoxazole prophylaxis in acute nonlymphocytic leukemia predispose to *Candida* infection? **Proceedings of the Midwestern Section of the American Federation for Clinical Research**, Chicago, November 1981. *Clin Res* 29:726A (81).

64. **Maki DG**, Aughey D. Comparative study of cefazolin, cefoxitin, and ceftizoxime for prophylaxis in colorectal surgery. **Proceedings of the Symposium, "The Role of Ceftizoxime,"** Bermuda, November 1981.
65. **Maki DG**. Integrating the infection control and employee health programs to prevent spread of infection in the hospital. **First National Conference on Hospital Employee Health**, Atlanta, January 1982.
66. **Maki DG**. An effective protocol for managing needle-stick injuries in the hospital and update on nosocomial hepatitis. **First National Conference on Hospital Employee Health**, Atlanta, January 1982.
67. **Maki DG**. Solutions to common infectious disease problems in employee health. **First National Conference on Hospital Employee Health**, Atlanta, January 1982.
68. **Maki DG**. Nosocomial bacteremia and pseudobacteremia. **Proceedings of Symposium, *Advances in Diagnosis of Bacteremia*, Annual Meeting of the American Society for Micro-biology**, Atlanta, March 1982.
69. **Maki DG**, Intravenous therapy related infections: Their sources and the new CDC guidelines for their prevention. **Proceedings of an Association for the Advancement of Medical Instrumentation Technology Assessment Conference, Infusion Technology and Therapy, Association for the Advancement of Medical Instrumentation**, Arlington, VA, September 1982.
70. **Maki DG**, Hassemer C, Alvarado C. Faulty spore strips used for monitoring ethylene oxide sterilization. **Proceedings of the 9th National Meeting of the Association of Practitioners in Infection Control**, New Orleans, May 1982. *Am J Infect Control* 10:112 (82).
71. Baum K, **Maki DG**. Serum-inhibitory activity of seven oral antistaphylococcal antibiotics. **Proceedings and Abstracts of the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy**, Miami Beach, October 1982.
72. **Maki DG**, Zilz MA, Alvarado C, Robbins J, Parisi J. Multiply-resistant *Staph. epidermidis* surgical wound infections linked to a chronic carrier. **Proceedings and Abstracts of the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy**, Miami Beach, October 1982.
73. **Maki DG**, Hecht J. Antiseptic-containing handwashing agents reduce nosocomial infections--a prospective study. **Proceedings and Abstracts of the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy**, Miami Beach, October, 1982.
74. **Maki DG**, Aughey D, Jacob L. Comparative study of multiple-dose cefoxitin and single-dose cefonicid for surgical prophylaxis in hysterectomy. **Proceedings and Abstracts of the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy**, Miami Beach, October 1982.
75. Aughey D, **Maki DG**, Jacob L. Comparative study of multiple-dose cefoxitin and single-dose cefonicid for surgical prophylaxis in biliary tract operations. **Proceedings and Abstracts of the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy**, Miami Beach, October 1981.
76. **Maki DG**, Croy S. Prolonged parenteral antimicrobial therapy greatly improves therapeutic outcome in chronic osteomyelitis. **Proceedings and Abstracts of the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy**, Miami Beach, October 1982.
77. **Maki DG**, Zilz MA. Minimal transmissibility of gentamicin-resistant *Pseudomonas aeruginosa* from cystic fibrosis patients. **Proceedings and Abstracts of the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy**, Miami Beach, October 1982.
78. **Maki DG**. Prevention of bacteremic infections due to intravascular medical devices. **Proceedings of the Second Annual Middle East Symposium, Nosocomial Infection and Its Control**, Kuwait, October 1982.

79. **Maki DG**, Lammers JL, Aughey DR. Comparative studies of multiple-dose vs. cefoxitin vs. single-dose cefonicid for surgical prophylaxis in biliary tract operations and hysterectomy. **Proceedings of the International Symposium, "The Expanded Role of Pharmacokinetics in Antimicrobial Research -- Clinical and Economic Impact of Cefonicid,"** San Francisco, November 1982.
80. **Maki DG**. A critical overview of surgical antimicrobial prophylaxis. **Proceedings of the Symposium, "The Expanded Role of Pharmacokinetics in Antimicrobial Research -- Clinical and Economic Impact of Cefonicid,"** San Francisco, November 1982.
81. **Maki DG**. Intravascular monitoring devices and intravascular access lines. **Proceedings of the First International Symposium on Infection Control,** Vienna, Austria, April 1983.
82. **Maki DG**. Improving prescriber use of antibiotics in the hospital. **Proceedings of the First International Symposium on Infection Control,** Vienna, Austria, April 1983.
83. Nichols L, **Maki DG**, Gudmundsson S. Experience with cefsulodin for therapy of *Pseudomonas aeruginosa* lower respiratory tract infections in adults without granulocytopenia or cystic fibrosis. **In Proceedings of the Symposium, "Biology, Immunology, and Treatment of Pseudomonas aeruginosa Infection,"** Monterey, CA, May 1983.
84. **Maki DG**. Microbiologic hazards of reuse. **Proceedings of the Association for the Advancement of Medical Instrumentation Technology Assessment Conference, "Reuse of Disposables,"** Philadelphia, May 1983.
85. **Maki DG**. Debated against the motion, "Surveillance of nosocomial infections causes more problems than it solves." **Combined Meeting of the British Infection Control Society and the Society of Hospital Epidemiologists of America,** Kings College, Cambridge University, Cambridge, England, June 1983.
86. **Maki DG**. Epidemiology and control of endemic nosocomial infection. **Proceedings of the Symposium, "Current Status and Control of Nosocomial Infection." Twelfth World Congress of Anatomic and Clinical Pathology,** Tokyo, Japan, October 1983.
87. Nichols L, **Maki DG**, Gudmundsson S. Cefsulodin for therapy of major *P. aeruginosa* infections. **Proceedings and Abstracts of the 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy,** Las Vegas, October 1983.
88. **Maki DG**. Potential infectious hazards associated with embalming. A case-control study of morticians and insurance personnel. **Annual Meeting of the Central Society for Clinical Research,** Chicago, November 1983. *Clin Res* 31:504 (83).
89. Stark RB, **Maki DG**. Bacteriuria in the catheterized patient. What quantitative level of bacteriuria is significant? **Annual Meeting of the Midwest Section of American Federation for Clinical Research,** Chicago, November 1983. *Clin Res* 31:515 (83).
90. **Maki DG**, Will L. Colonization and infection associated with transparent dressings for central venous catheters: a comparative trial. **Proceedings and Abstracts of the Annual Meeting of the Surgical Infection Society,** Montreal, May 1984.
91. **Maki DG**. Protective isolation. **Proceedings of the Symposium, "Isolation of the Critically Ill Surgical Patient." Proceedings and Abstracts of the Annual Meeting of the Surgical Infection Society,** Montreal, May 1984.
92. **Maki DG**, Alvarado C, Hassemer C. Do neutralizers enhance recovery of microorganisms in epidemiological studies of hand carriage of nosocomial pathogens? **Proceedings and Abstracts of the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy,** Washington, D.C., October 1984.
93. **Maki DG**, Stevens JA. Nosocomial colonization of cardiac surgery and cardiology patients by methicillin-resistant coagulase-negative staphylococci. **Proceedings and Abstracts of the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy,** Washington, D.C., October 1984.

94. Erdmann M, **Maki DG**, Hassemer C, Alvarado C. Are hospital pharmacists who compound and administer antibiotics colonized by resistant microorganisms? A prospective study. **Proceedings and Abstracts of the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Washington, D.C., October 1984.
95. **Maki DG**, Alvarado C, Hassemer C. Comparison of organisms carried on the hands of hospital personnel and nonmedical control personnel: Methicillin-resistant coagulase-negative *Staphylococcus* is a hospital organism. **Proceedings and Abstracts of the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Washington, D.C., October 1984.
96. **Maki DG**, McCormick R, Alvarado C, Hassemer C. Clinical evaluation of the degerming efficacy of seven agents for handwashing in hospitals. **Proceedings and Abstracts of the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Washington, D.C., October 1984.
97. **Maki DG**, Will L. Colonization and infection associated with transparent dressings for central venous, arterial, and Hickman catheters: a comparative trial. **Proceedings and Abstracts of the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Washington, D.C., October 1984.
98. **Maki DG**, Aughey D, Lammers J. Study of cefazolin, cefoxitin, and ceftizoxime for prophylaxis in colorectal surgery. **Proceedings and Abstracts of the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Washington, D.C., October 1984.
99. Strinden W, Helgersen R, **Maki DG**. *Candida* septic thrombosis of the great central veins caused by central catheters: clinical features and management. **Proceedings and Abstracts of the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Washington, D.C., October 1984.
100. **Maki DG**. Biology of infections caused by coagulase-negative staphylococci. **Symposium on Nosocomial Infection Control**, Frankfurt, Germany, May 1985.
101. **Maki DG**. Epidemiology of coagulase-negative staphylococcal infections in the hospital. **Symposium on Nosocomial Infections**. Hospital Deau, Paris, France, June 1985.
102. **Maki DG**. Skin as a source of nosocomial infection. Directions for future research. **Second U.K.-U.S. Workshop on Nosocomial Infection Control**, Phoenix, September 1985.
103. **Maki DG**. Approaching the ICU patient with nosocomial blood stream infection. **Symposium, "Infections in Patients in Critical Care Units."** **Proceedings of the 25th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Minneapolis, October 1985.
104. Pirsch J, **Maki DG**. Infectious complications of bone marrow transplantation using an anti-T-cell antibody. **Proceedings and Abstracts of the 25th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Minneapolis, October 1985.
105. Fox B, **Maki DG**, Karreman E, Gould J, Belzer F. Controlled double-blind trial of trimethoprim-sulfamethoxazole in renal transplantation. I. Efficacy and effects on microflora. **Proceedings and Abstracts of the 25th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Minneapolis, October 1985.
106. **Maki DG**, Fox B, Karreman E, Sollinger H, Glass N, Bushby M. Controlled double-blind trial of trimethoprim-sulfamethoxazole in renal transplantation. II. TMP/SMZ toxicity and interaction with cyclosporine A. **Proceedings and Abstracts of the 25th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Minneapolis, October 1985.
107. **Maki DG**, Hassemer C, Alvarado C. Prospective study of the value of monitoring hospital sterilizers with biologic indicators. **Proceedings and Abstracts of the 25th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Minneapolis, October 1985.

108. **Maki DG**, Alvarado C, Hassemer C. Double-bagging of items from isolation rooms is unnecessary: A comparative study of surface contamination with single versus double bagging. **Proceedings and Abstracts of the 25th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Minneapolis, October 1985.
109. **Maki DG**, Hassemer C, McCormick R, Alvarado C, Klein B, Gould J, Liegel A. *Pseudomonas pickettii* bacteremia traced to contaminated fentanyl. **Proceedings and Abstracts of the 25th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Minneapolis, October 1985.
110. **Maki DG**, Goll M, Hassemer C, Alvarado C. Safety and cost-effectiveness of 4 dressing regimens for peripheral IV catheters, including indefinite gauze and a povidone-iodine impregnated transparent dressing. **Proceedings of the Midwestern Section of the American Federation for Clinical Research**, Chicago, November 1985. *Clin Res* 33:845A (85).
111. **Maki DG**, McCormick R, Zilz MA, Hassemer C, Alvarado C. Prospective study of the risk of transmission of *N. meningitidis* to hospital personnel. **Proceedings of the Central Society for Clinical Research**, Chicago, November 1985. *Clin Res* 33:887A (85).
112. Nichols L, **Maki DG**. The emergency of resistance to beta-lactam antibiotics during treatment of *Pseudomonas aeruginosa* lower respiratory tract infections: Is combination chemotherapy the solution? **Symposium on Resistance to Beta-Lactam Antibiotics**, Florence, Italy, December 1985.
113. **Maki DG**. Cutaneous antisepsis for prevention of nosocomial infection. **Symposium, "Skin and Infection," Proceedings of the Annual Meeting of the American Society for Microbiology**, Washington, D.C., March 1986.
114. **Maki DG**. Nosocomial infection in cardiac transplanted patients caused by coagulase-negative staphylococci. **Symposium, "Infections in Cardiac Transplantation," Proceedings of the Annual Meeting of the International Society for Cardiac Transplantation**, New York City, April 1986.
115. **Maki DG**, Stoltz S, Baker R. Susceptibility of 211 isolates of coagulase-negative *Staphylococcus* to 14 agents. **Proceedings and Abstracts of the Annual Meeting of the American Society for Microbiology**, Washington, D.C., March 1986.
116. **Maki DG**. Management of infections due to intravascular devices. **Symposium, "Infections with Prosthetic Devices," Proceedings of the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy**, New Orleans, October 1986.
117. **Maki DG**, Mackey I. Cefazolin, cefoxitin and cefamandole for prophylaxis in colorectal surgery. **Proceedings and Abstracts of the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy**, New Orleans, October 1986.
118. Bohn M, Stoltz S, **Maki DG**. Cefazolin, cefamandole, and vancomycin for prophylaxis in cardiac and vascular surgery. **Proceedings and Abstracts of the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy**, New Orleans, October 1986.
119. **Maki DG**, Botticelli J, LeRoy M. Prospective study of replacing IV administration sets at 48-hr vs. 72-hr intervals. **Proceedings and Abstracts of the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy**, New Orleans, October 1986.
120. Maki DG, Fox B, Sollinger H, Belzer F. Is TMP/SMZ safe to use with cyclosporine A in organ transplantation? **Proceedings and Abstracts of the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy**, New Orleans, October 1986.
121. **Maki DG**, Will L. Study of polyantibiotic and povidone-iodine ointments on central venous and arterial catheters dressed with gauze or polyurethane dressings. **Proceedings and Abstracts of the 26th Interscience Conference on Antimicrobial Agents and Chemotherapy**, New Orleans, October 1986.

122. **Maki DG.** Coagulase-negative *Staphylococcus* -- Biology and epidemiology of a ubiquitous and increasingly problematic nosocomial pathogen. **The Edward J.L. Lowbury Lecture. Annual Meeting of the British Infection Control Society**, London, November 1986.
123. **Maki DG.** Epidemiology of infections due to intravascular devices. **Symposium, "Infections Due to Intravascular Devices," Proceedings of the Annual Meeting of the American Society for Microbiology**, Atlanta, GA, March 1987.
124. **Maki DG.** Epidemiology and risks. **Symposium, "The Problem of Pneumonia in the Intubated Patients. Proceedings of the Annual Meeting of the American Thoracic Society**, New Orleans, May 1987.
125. Oh C, Stratta RJ, Sollinger HW, Belzer FO, **Maki DG.** Infections associated with OKT3 for treatment of rejection in renal transplantation. **Annual Meeting of the American Society of Transplant Physicians**, Chicago, May 1987.
126. **Maki DG.** Prevention of sepsis from intravascular devices. **Symposium, "Infections in Intensive Care Patients," Proceedings of the First International Conference of the Hospital Infection Society**, London, September 1987.
127. **Maki DG,** Cobb L, Garman JK, Shapiro J, Ringer M. Multicenter trial of an attachable silver-impregnated subcutaneous cuff for prevention of infection with central venous catheters. **Proceedings and Abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy**, New York, October 1987.
128. **Maki DG,** Alvarado C, Hassemer C, Ringer M. Comparison of 70% alcohol, 10% povidone-iodine, and 2% chlorhexidine for cutaneous disinfection in IV therapy. **Proceedings and Abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy**, New York, October 1987.
129. Golenbock DT, Guerra J, Golubjatnikov R, Tejado A, Abugattas J, Kemper R, **Maki DG.** Prevalence of HIV infection in Peruvian prostitutes. **Proceedings and Abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy**, New York, October 1987.
130. **Maki DG,** Agger WA. Enterococcal endocarditis: Natural history, the risk of endocarditis and management. **Proceedings and Abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy**, New York, October 1987.
131. **Maki DG,** Oh C, Stratta RJ, Sollinger HW, Belzer FO. Increased infections associated with the use of OKT3 for treatment of resistant rejection in renal transplantation. **Proceedings and Abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy**, New York, October 1987.
132. Klein BS, Perloff W, **Maki DG.** Protective isolation prevents nosocomial infections in pediatric ICU--A comparative trial. **Proceedings and Abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy**, New York, October 1987.
133. Backonja M, Stolz S, **Maki DG.** Occult *Borrelia burgdorferi* infection as a cause of neurologic disease. A case-control serologic study. **Proceedings of the Annual Meeting of the American Association of Neurology**, March 1988, *Ann Neurol* 38(Suppl 1):104 (88).
134. Meyer KC, McManus EJ, **Maki DG.** Overwhelming pulmonary blastomycosis associated with ARDS: Successful outcome with prompt diagnosis and aggressive therapy. **Proceedings of the Annual Meeting of the American Thoracic Society**, May 1988, *Am Rev Resp Dis* 137:360 (88).
135. **Maki DG.** Risk factors for IV catheter-related phlebitis. A prospective study. **Proceedings of the National Meeting of the American Federation for Clinical Research**, May 1988, *Clin Res* 36:345A (88).
136. **Maki DG.** Pecunia obediunt omnia. Cost-containment in nosocomial infection control. The National Foundation for Infectious Disease Lecture. **Proceedings of the Annual Meeting of the Association for Professionals in Infection Control**, Dallas, May 1988.

137. **Maki DG.** Use of antiseptics for hospital staff. **Symposium, "Hospital Infection and Its Control," Proceedings of the 6th Mediterranean Congress on Chemotherapy**, Jaorini - Giardini Naxos, Sicily, May 1988.
138. **Maki DG.** Infection control in the United States. **Symposium, "Hospital Infection and Its Control," Proceedings of the 6th Mediterranean Congress on Chemotherapy**, Jaorini - Giardini Naxos, Sicily, May 1988.
139. **Maki DG.** Complications related to intravenous administration of antibiotics, **Symposium, "Update on Imipenem-cilastatin and Clinical Experiences with an Intramuscular Long-Acting Formulation."** Monterey, June 1988.
140. **Maki DG.** Infusion therapy. Do the risks exceed the benefit? **Second International Conference on Infection Control**, Harrogate, England, September 1988.
141. Hirsch JD, Amherst MJ, Strata RJ, D'Alessander AM, Sollinger HW, Belzer FO, Kalayoglu M, **Maki DG.** Perioperative infections in liver transplant recipients under a quadruple immunosuppression protocol. **Proceedings of the Third International Symposium on Perioperative Care in Liver Transplantation**, Pittsburgh, September 1988.
142. **Maki DG.** Risk of infection with peripheral IV catheters. **Proceedings and Abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Los Angeles, October, 1988.
143. **Maki DG,** Backonja M, Stolz S. Occult *Borrelia burgdorferi* infection as a cause of neurologic disease. A case-control serologic study. **Proceedings and Abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Los Angeles, October, 1988.
144. **Maki DG.** Sources of infection with central venous catheters in an ICU: a prospective study. **Proceedings and Abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Los Angeles, October, 1988.
145. **Maki DG,** Fox B, Storer B. Risk factors for infection following renal transplantation: a prospective study. **Proceedings and Abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Los Angeles, October, 1988.
146. **Maki DG,** Meyer KC, McManus EJ. Overwhelming pulmonary blastomycosis associated with ARDS: Successful outcome with prompt diagnosis and aggressive therapy. **Proceedings and Abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Los Angeles, October, 1988.
147. **Maki DG,** Rischen CG, Dueland RT, Dibbell DG, Wilson J, Collins M. Comparison of medical therapy, surgical debridement, and vascular pedicle grafting in an animal model of chronic osteomyelitis. **Proceedings and Abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Los Angeles, October, 1988.
148. **Maki DG.** Risk factors for infection. Symposium, "Prevention and Management of Infections in Solid Organ Transplantation." **Proceedings and Abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Los Angeles, October, 1988.
149. **Maki DG.** Testing deserves to be tested, Symposium, "Preoperative HIV Testing: The Surgeon's Right to Know," **Annual Meeting of the Infectious Disease Society of America**, Los Angeles, October 1988.
150. **Maki DG.** The pathogenesis and prevention of infection with percutaneous intravascular catheters, Symposium, "Thromboembolism and Infectious Complications of Cardiovascular Devices," **NIH Devices and Technology Branch Workshop**, Bethesda, December 1988.
151. **Maki DG.** The case for wider use of HIV testing. **In the Symposium, Proceedings and Abstracts of the First Annual Meeting of the Society of Hospital Epidemiologists of America**, Baltimore, February 1989.

152. **Maki DG.** Nosocomial infection control in the United States. Invited address to **Annual Meeting of the Japanese Infectious Disease Society**, Tokyo, April 1989. *Jap J Infect Dis* 63 (Vol 3):33 (89).
153. **Maki DG.** Role of antibiotics and immunotherapy in the treatment of sepsis. In the symposium, "Sepsis: New Insights into Pathogenesis and Treatment," **Proceedings of the Annual Meeting of the American Thoracic Society**, Cincinnati, May 1989.
154. **Maki DG.** Epidemiology of coagulase-negative staphylococcal infection in nosocomial infections in surgical patients. In the symposium, "Surgical Wound Infection Update: Epidemiology, Pathogenesis and Treatment." **Proceedings of the Annual Meeting of the American Society for Microbiology**, Atlanta, May 1989.
155. Stolz S, **Maki DG.** In vitro susceptibility testing of *Borrelia burgdorferi*. **Proceedings of the Annual Meeting of the American Society for Microbiology**, Atlanta, May 1989.
156. **Maki DG.** Epidemiology of nosocomial staphylococcal infection, In the **Gordon Conference, "Staphylococcal Pathogenesis"**, Newport, RI, August 1989.
157. **Maki DG.** Environmental control and the use of isolation for the prevention of nosocomial infection. In the symposium, "Novel Approaches to Prevention of Nosocomial Infection", **Proceedings of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Houston, September 1989.
158. **Maki DG,** Haynes B, Nichols L. Comparison of a beta-lactam vs. an aminoglycoside for treatment of gram-negative rod lower respiratory tract infection. **Proceedings of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Houston, September 1989.
159. Alvarado C, **Maki DG.** Prospective study of a novel physico-chemical integrator for monitoring hospital sterilizers. **Proceedings of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Houston, September 1989.
160. Mermel L, Stolz S, **Maki DG.** Epidemiology of infection with PA/Swan-Ganz catheters: A prospective study with plasmid profile subtyping. **Proceedings of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Houston, September 1989.
161. Klein BS, Hirsch JD, **Maki DG.** Risk factors for nosocomial infection in children requiring prolonged mechanical ventilatory support in a pediatric ICU: A prospective study. **Proceedings of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Houston, September 1989.
162. Alvarado C, **Maki DG.** Nosocomial infection from contaminated endoscopes: A flawed commercial endoscope washer. **Proceedings of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Houston, September 1989.
163. **Maki DG,** Ringer M. Prospective study of arterial catheter-related infection: Incidence, sources of infection and risk factors. **Proceedings of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Houston, September 1989.
164. McCormick R, **Maki DG.** The importance of maximal sterile barriers during insertion of central venous catheters: A prospective study. **Proceedings of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Houston, September 1989.
165. Stolz S, Alvarado C, **Maki DG.** Pseudomonas bacteremia from contaminated LAK cells used in cancer chemotherapy: A new nosocomial problem. **Proceedings of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Houston, September 1989.
166. Stolz S, Spiegel C, **Maki DG.** Vancomycin-resistant gram-positive cocci causative of nosocomial infection. **Proceedings of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy**, Houston, September 1989.



167. **Maki DG.** Infections in the ICU. An invited colloquium. **Proceedings of the VI World Congress of the American College of Chest Physicians**, Boston, October 1989.
168. **Maki DG.** Intravascular catheter-related infection. **Proceedings of the Infectious Diseases Society of the Netherlands and Flanders and the Netherlands Society for Critical Care Medicine Workshop and Symposium, "Infections and Intensive Care"**, Rotterdam, The Netherlands, November 1989.
169. **Maki DG.** Concerns of the user. In the symposium, "New Technology for the Diagnosis of Hepatitis B and HIV Infection." **Proceedings of the Symposium and Workshop, Hepatitis B and HIV Infection**, The National Foundation for Infectious Diseases and the Society of Hospital Epidemiologists of America, Washington, D.C., November 1989.
170. **Maki DG.** Optimal care of intravenous catheters. **Proceedings of the Symposium, "Problemes medicaux les aux catheters veineux centraux,"** Geneva, Switzerland, March 23, 1990.
171. **Maki DG.** Catheters as risk factors for nosocomial infections. **Proceedings of the Symposium, "Problemes medicaux les aux catheters veineux centraux,"** Geneva, Switzerland, March 23, 1990.
172. Alvarado CJ, Stolz SM, **Maki DG.** Nosocomial *P. aeruginosa* infections from contaminated endoscopes. **Program and Abstracts of the ASM International Symposium on Chemical Germicides**, Atlanta, 27-29 July, 1990.
173. **Maki DG,** Hecht J. Antiseptic-containing handwashing agents reduce nosocomial infections--a prospective clinical trial. **Program and Abstracts of the ASM International Symposium on Chemical Germicides**, Atlanta, 27-29 July, 1990.
174. **Maki DG,** Alvarado C, Hassemer C, Ringer M. Comparison of 70% alcohol, 10% povidone-iodine and 2% chlorhexidine for cutaneous disinfection in IV therapy. **Program and Abstracts of the ASM International Symposium on Chemical Germicides**, Atlanta, 27-29 July, 1990.
175. **Maki DG,** Hassemer C, Alvarado C. Value of monitoring hospital sterilizers with biologic indicators. **Program and Abstracts of the ASM International Symposium on Chemical Germicides**, Atlanta, 27-29 July, 1990.
176. Alvarado C, **Maki DG.** Prospective study of a physico-chemical integrator for monitoring hospital sterilizers. **Program and Abstracts of the ASM International Symposium on Chemical Germicides**, Atlanta, 27-29 July, 1990.
177. **Maki DG.** The epidemiology and prevention of nosocomial bloodstream infections. **Program and Abstracts of the Third International Conference on Nosocomial Infections**, Centers for Disease Control, The National Foundation for Infectious Diseases and the American Society for Microbiology, Atlanta, July 31-August 3, 1990.
178. **Maki DG,** McCormick RD, Zilz MA, Stolz SM, Alvarado CJ. An MRSA outbreak in a SICU during universal precautions: New Epidemiology for Nosocomial MRSA: downside for universal precautions. **Program and Abstracts of the Third International Conference on Nosocomial Infections**, Centers for Disease Control, The National Foundation for Infectious Diseases and the American Society for Microbiology, Atlanta, July 31-August 3, 1990.
179. **Maki DG,** Will L. Risk factors for central venous catheter-related infection within the ICU. A prospective study of 345 catheters. **Program and Abstracts of the Third International Conference on Nosocomial Infections**, Centers for Disease Control, The National Foundation for Infectious Diseases and the American Society for Microbiology, Atlanta, July 31-August 3, 1990.
180. Alvarado CJ, Stolz SM, **Maki DG.** Nosocomial *P. aeruginosa* infections from contaminated endoscopes. **Program and Abstracts of the Third International Conference on Nosocomial Infections**, Centers for Disease Control, The National Foundation for Infectious Diseases and the American Society for Microbiology, Atlanta, July 31-August 3, 1990.

181. **Maki DG.** Marked differences in skin colonization of insertion sites for central venous, arterial and peripheral IV catheters. The major reason for differing risks of catheter-related infection? **Program and Abstracts of the Third International Conference on Nosocomial Infections**, Centers for Disease Control, The National Foundation for Infectious Diseases and the American Society for Microbiology, Atlanta, July 31-August 3, 1990.
182. Mermel L, Stolz S, **Maki DG.** Epidemiology of infection with PA/Swan-Ganz catheters: a prospective study. **Program and Abstracts of the Third International Conference on Nosocomial Infections**, Centers for Disease Control, The National Foundation for Infectious Diseases and the American Society for Microbiology, Atlanta, July 31-August 3, 1990.
183. McCormick RD, Meisch M, Ircink F, **Maki DG.** Epidemiology of hospital sharps injuries: a 14-year perspective in the pre-AIDS and AIDS eras. **Program and Abstracts of the Third International Conference on Nosocomial Infections**, Centers for Disease Control, The National Foundation for Infectious Diseases and the American Society for Microbiology, Atlanta, July 31-August 3, 1990.
184. **Maki DG.** Risk factors for IV catheter-related phlebitis: statistical models derived from a large prospective study. **Program and Abstracts of the Third International Conference on Nosocomial Infections**, Centers for Disease Control, The National Foundation for Infectious Diseases and the American Society for Microbiology, Atlanta, July 31-August 3, 1990.
185. Stolz SM, **Maki DG.** Western blotting and chromosomal restriction enzyme analysis with pulsed field electrophoresis to subtype nosocomial *P.aeruginosa*. **Program and Abstracts of the Third International Conference on Nosocomial Infections**, Centers for Disease Control, The National Foundation for Infectious Diseases and the American Society for Microbiology, Atlanta, July 31-August 3, 1990.
186. Stolz SM, **Maki DG.** The use of Western blotting to subtype nosocomial isolate s of methicillin-resistant *Staphylococcus aureus*. **Program and Abstracts of the Third International Conference on Nosocomial Infections**, Centers for Disease Control, The National Foundation for Infectious Diseases and the American Society for Microbiology, Atlanta, July 31-August 3, 1990.
187. Stolz SM, **Alvarado C, Maki DG.** Pseudomonas bacteremia from contaminated LAK cells used in cancer chemotherapy: a new nosocomial problem. **Program and Abstracts of the Third International Conference on Nosocomial Infections**, Centers for Disease Control, The National Foundation for Infectious Diseases and the American Society for Microbiology, Atlanta, July 31-August 3, 1990.
188. **Maki DG,** McCormick R, Klein B, Hassemer C, Alvarado C, Gould J, Zilz MA, Liegel A. *Pseudomonas pickettii* bacteremias traced to narcotic tampering. A case for selected drug screening of health care workers. **Program and Abstracts of the Third International Conference on Nosocomial Infections**, Centers for Disease Control, The National Foundation for Infectious Diseases and the American Society for Microbiology, Atlanta, July 31-August 3, 1990.
189. Zilz MA, **Maki DG.** Trends in the incidence and profile of nosocomial bacteremia: a thirteen year study in a university hospital. **Program and Abstracts of the Third International Conference on Nosocomial Infections**, Centers for Disease Control, The National Foundation for Infectious Diseases and the American Society for Microbiology, Atlanta, July 31-August 3, 1990.
190. Fox B, Belzer F, **Maki DG.** Safe use of Hickman catheters for access in solid-organ transplantation. **Program and Abstracts of the Third International Conference on Nosocomial Infections**, Centers for Disease Control, The National Foundation for Infectious Diseases and the American Society for Microbiology, Atlanta, July 31-August 3, 1990.
191. **Maki DG,** Ringer M. Prospective study of arterial catheter-related infection: incidence, sources of infection and risk factors. **Program and Abstracts of the Third International Conference on Nosocomial Infections**, Centers for Disease Control, The National Foundation for Infectious Diseases and the American Society for Microbiology, Atlanta, July 31-August 3, 1990.

192. Alvarado C, **Maki DG**. Prospective study of a physico-chemical integrator for monitoring hospital sterilizers. **Program and Abstracts of the Third International Conference on Nosocomial Infections**, Centers for Disease Control, The National Foundation for Infectious Diseases and the American Society for Microbiology, Atlanta, July 31-August 3, 1990.
193. **Maki DG**, Seitz J, Newman J, Alvarado CJ. Physiologic correlates of heavy bacterial carriage on hands of health care professionals. **Program and Abstracts of the Third International Conference on Nosocomial Infections**, Centers for Disease Control, The National Foundation for Infectious Diseases and the American Society for Microbiology, Atlanta, July 31-August 3, 1990.
194. **Maki DG**. Risk factors for nosocomial infections in ICUs: Devices vs nature, goals for the next decade. In the symposium, "Predictors and Risk Determinants for Hospital Infection". **Program and Abstracts of the Second International Conference of the Hospital Infection Society**, London, September 1990.
195. **Maki DG**. Infections due to intravascular lines. In the symposium, "Implants and Invasive Procedures--A Recipe for Infection". **Program and Abstracts of the Second International Conference of the Hospital Infection Society**, London, September 1990.
196. **Maki DG**. Summary comments. In the symposium, "Hand Antiseptics - Efficacy or Acceptability". **Program and Abstracts of the Second International Conference of the Hospital Infection Society**, London, September 1990.
197. **Maki DG**, McCormick RD, Zilz MA, Stolz SM, Alvarado CJ. An MRSA outbreak in a SICU during universal precautions: New Epidemiology for Nosocomial MRSA: downside for universal precautions. **Program and Abstracts of the Second International Conference of the Hospital Infection Society**, London, September 1990.
198. Alvarado CJ, Stolz SM, Maki DG. Nosocomial *P. aeruginosa* infections from contaminated endoscopes. **Program and Abstracts of the Second International Conference of the Hospital Infection Society**, London, September 1990.
199. Stolz SM, Alvarado C, **Maki DG**. Pseudomonas bacteremia from contaminated LAK cells used in cancer chemotherapy: a new nosocomial problem. **Program and Abstracts of the Second International Conference of the Hospital Infection Society**, London, September 1990.
200. **Maki DG**, Fox B, Storer B. Risk factors for infection following renal transplantation: a prospective study. **Program and Abstracts of the Second International Conference of the Hospital Infection Society**, London, September 1990.
201. McCormick RD, Meisch M, Ircink F, **Maki DG**. Epidemiology of hospital sharps injuries: a 14-year perspective in the pre-AIDS and AIDS eras. **Program and Abstracts of the Second International Conference of the Hospital Infection Society**, London, September 1990.
202. **Maki DG**. Risk factors for IV catheter-related phlebitis. A prospective study. **Program and Abstracts of the Second International Conference of the Hospital Infection Society**, London, September 1990.
203. **Maki DG**, Wheeler S, Stolz S. Prospective study of a novel, transparent, highly-permeable dressing for intravascular catheters. **Program and Abstracts of the Second International Conference of the Hospital Infection Society**, London, September 1990.
204. **Maki DG**. Role of the environment in nosocomial infection control. In the symposium, "Environmental Aspects of Nosocomial Infection Control". **Program and Abstracts of the Thirtieth Interscience Conference on Antimicrobial Agents and Chemotherapy**, Atlanta, October 1990.
205. **Maki DG**. Institutional Methicillin-resistant Staph. aureus. What can be done? In the symposium, "New and Emerging Gram-Positive Pathogens". **Program and Abstracts of the Thirtieth Interscience Conference on Antimicrobial Agents and Chemotherapy**, Atlanta, October 1990.

206. **Maki DG**, Seitz J, Newman J, Alvarado CJ. Physiologic correlates of heavy bacterial carriage on hands of health care professionals. **Program and Abstracts of the Thirtieth Interscience Conference on Antimicrobial Agents and Chemotherapy**, Atlanta, October 1990.
207. McCormick RD, Meisch M, Ircink F, **Maki DG**. Epidemiology of hospital sharps injuries: a 14-year perspective in the pre-AIDS and AIDS eras. **Program and Abstracts of the Thirtieth Interscience Conference on Antimicrobial Agents and Chemotherapy**, Atlanta, October 1990.
208. **Maki DG**, McCormick RD, Zilz MA, Stolz SM, Alvarado CJ. An MRSA outbreak in a SICU during universal precautions: New Epidemiology for Nosocomial MRSA: downside for universal precautions. **Program and Abstracts of the Thirtieth Interscience Conference on Antimicrobial Agents and Chemotherapy**, Atlanta, October 1990.
209. **Maki DG**. Marked differences in skin colonization of insertion sites for central venous, arterial and peripheral IV catheters. The major reason for differing risks of catheter-related infection? **Program and Abstracts of the Thirtieth Interscience Conference on Antimicrobial Agents and Chemotherapy**, Atlanta, October 1990.
210. **Maki DG**, Will L. Risk factors for central venous catheter-related infection within the ICU. A prospective study of 345 catheters. **Program and Abstracts of the Thirtieth Interscience Conference on Antimicrobial Agents and Chemotherapy**, Atlanta, October 1990.
211. **Maki DG**. Western blotting and chromosomal restriction enzyme analysis with pulsed field electrophoresis to subtype nosocomial *Pseudomonas aeruginosa*. **Program and Abstracts of the Thirtieth Interscience Conference on Antimicrobial Agents and Chemotherapy**, Atlanta, October 1990.
212. **Maki DG**. Infection caused by intravascular devices: Pathogenesis, strategies for prevention. **Program and Abstracts of the Symposium, "Improving Catheter Site Care."** Royal College of Medicine, London, March 9, 1991.
213. **Maki DG**, Stolz S, Wheeler S. A prospective randomized three-way clinical comparison of a novel, highly-permeable, polyurethane dressing with 206 Swan-Ganz pulmonary artery catheters. I. Cutaneous colonization under the dressing, catheter-related infection. **Program and Abstracts of the Symposium, "Improving Catheter Site Care."** Royal College of Medicine, London, March 9, 1991.
214. Wheeler S, Stolz S, **Maki DG**. A prospective randomized three-way clinical comparison of a novel, highly-permeable, polyurethane dressing with 206 Swan-Ganz pulmonary artery catheters. II. Effectiveness and tolerance as catheter dressings. **Program and Abstracts of the Symposium, "Improving Catheter Site Care."** Royal College of Medicine, London, March 9, 1991.
215. **Maki DG**. Epidemiology of intravascular catheter-related infections. In the symposium, "Intravascular Catheter-Related Infections". **Program and Abstracts of the Annual Meeting of the American Society for Microbiology**, Dallas, May 1991.
216. **Maki DG**, Wheeler SJ, Stolz SM. Study of a novel antiseptic-coated central venous catheter. **Twentieth Annual Scientific Symposium of the Society of Critical Care Medicine**, Washington, D.C., May 1991. *Crit Care Med* 19:S99 (91).
217. **Maki DG**. Nosocomial infections associated with intravascular devices used for infusion therapy: incidence, risk factors, and sources of infection. In, **International Symposium on Nosocomial Infection Due to Intravascular Devices**, Freiburg, Germany, June 1991.
218. **Maki DG**. Prevention of infections due to intravascular devices used for infusion therapy. In, **International Symposium on Nosocomial Infection Due to Intravascular Devices**, Freiburg, Germany, June 1991.

219. **Maki DG.** Unnecessary architectural design for hospital infection control. In the symposium, "Current Aspects of Nosocomial Infections". **Program and Abstracts of the 17th International Congress of Chemotherapy**, Berlin, Germany, June 1991.
220. **Maki DG.** Goals and reasons for using severity of illness scoring systems in ICU patients with emphasis on continuum of response. **ACP-SCCM Consensus Conference on Standardizing Terminology in Sepsis and Multi-Organ Failure**, American College of Chest Physicians, Chicago, August 16-18, 1991.
221. **Maki DG.** Universal precautions: strategies for protection against blood-borne pathogens. In the symposium, "Blood-Borne Infections: Risks to Health Care Workers vs. Risks Posed by the Infected Healthcare Worker". **Program and Abstracts of the 31st Interscience Conference in Antimicrobial Agents and Chemotherapy**, Chicago, September 30 - October 2, 1991.
222. Stolz SM, Alvarado J, **Maki DG.** Endemic nosocomial legionellosis occurring despite very low-level contamination of hospital water, identified by molecular subtyping of legionella with restriction enzyme digestion and pulsed-field electrophoresis. **Program and Abstracts of the 31st Interscience Conference in Antimicrobial Agents and Chemotherapy**, Chicago, September 30 - October 2, 1991.
223. Fox B, Belzer F, **Maki DG.** Safe use of Hickman catheters for access in solid-organ transplantation. **Program and Abstracts of the 31st Interscience Conference in Antimicrobial Agents and Chemotherapy**, Chicago, September 30 - October 2, 1991.
224. Stolz SM, **Maki DG.** The use of western blotting to subtype nosocomial isolates of methicillin-resistant *Staphylococcus aureus*. **Program and Abstracts of the 31st Interscience Conference in Antimicrobial Agents and Chemotherapy**, Chicago, September 30 - October 2, 1991.
225. Mermel LA, Velez LA, Zilz MA, **Maki DG.** Epidemiologic and microbiologic features of nosocomial bloodstream infection (NBSI) implicating a vascular catheter source: A case-control study of 85 vascular catheter-related and 101 secondary NBSIs. **Program and Abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy**, Chicago, September 30 - October 2, 1991.
226. **Maki DG,** Kuntz J. A prospective trial of Foley catheter replacement for treatment of early catheter-associated bacteriuria or candiduria. **Program and Abstracts of the 31st Interscience Conference in Antimicrobial Agents and Chemotherapy**, Chicago, September 30 - October 2, 1991.
227. **Maki DG,** Wheeler SJ, Stolz SM, Mermel LA. Clinical trial of a novel antiseptic central venous catheter. **Program and Abstracts of the 31st Interscience Conference in Antimicrobial Agents and Chemotherapy**, Chicago, September 30 - October 2, 1991.
228. **Maki DG.** AIDS in the critical care unit. **All-India Symposium on Critical Care Medicine**, New Delhi and Madras, India, December 18-22, 1991.
229. **Maki DG.** Nosocomial infections and their prevention. **All-India Symposium on Critical Care Medicine**, New Delhi and Madras, India, December 18-22, 1991.
230. **Maki DG.** Initial management of life-threatening infections. **All-India Symposium on Critical Care Medicine**, New Delhi and Madras, India, December 18-22, 1991.
231. **Maki DG.** Strategies for prevention of nosocomial infection with antibiotic resistant bacteria and fungi. In the symposium, "Infections caused by antibiotic-resistant bacteria and fungi," **Program and Abstracts of the Annual Meeting of the Surgical Infection Society**, Los Angeles, April 4, 1992.
232. **Maki DG,** Bohn MJ, Stolz SM. Comparative study of cefazolin, cefamandole, and vancomycin for prophylaxis in cardiovascular surgery. **Proceedings and Abstracts of the Second Annual Meeting of the Society of Hospital Epidemiologists of America**, Baltimore, April 12-14, 1992.
233. **Maki DG,** Stolz SM, Bohn MJ. Effect of systemic antimicrobial prophylaxis in cardiac and vascular surgery on nosocomial colonization by methicillin-resistant coagulase-negative staphylococci.

- Proceedings and Abstracts of the Second Annual Meeting of the Society of Hospital Epidemiologists of America**, Baltimore, April 12-14, 1992.
234. **Maki DG**, Kuntz JG. A prospective trial of Foley catheter replacement for treatment of early catheter-associated bacteriuria or candiduria. **Proceedings and Abstracts of the Second Annual Meeting of the Society of Hospital Epidemiologists of America**, Baltimore, April 12-14, 1992.
235. Stolz SM, **Maki DG**. Endemic nosocomial Legimellosis despite very low-level contamination of hospital water, identified by molecular subtyping by restriction enzyme digestion and pulsed-field electrophoresis. **Proceedings and Abstracts of the Second Annual Meeting of the Society of Hospital Epidemiologists of America**, Baltimore, April 12-14, 1992.
236. Kulak K, **Maki DG**. Risk factors for vascular catheter-related septic thrombosis of the great central veins caused by *Candida*. **Proceedings and Abstracts of the Second Annual Meeting of the Society of Hospital Epidemiologists of America**, Baltimore, April 12-14, 1992.
237. Velez LA, Mermel LA, Zilz MA, **Maki DG**. Epidemiologic and microbiologic features of nosocomial bloodstream infection (NBSI) implicating a vascular source: A case-control study of 85 vascular catheter-related and 101 secondary NBSIs. **Proceedings and Abstracts of the Second Annual Meeting of the Society of Hospital Epidemiologists of America**, Baltimore, April 12-14, 1992.
238. Kulak K, **Maki DG**. Comparison of nosocomial bloodstream infections with *Candida albicans* and non-albicans *Candida*. **Proceedings and Abstracts of the Second Annual Meeting of the Society of Hospital Epidemiologists of America**, Baltimore, April 12-14, 1992.
239. **Maki DG**, Stolz SM, Wheeler SJ, Mermel LA. A prospective, randomized, three-way comparison of a novel, highly-permeable, polyurethane dressing with 449 Swan-Ganz catheters. **Proceedings and Abstracts of the Second Annual Meeting of the Society of Hospital Epidemiologists of America**, Baltimore, April 12-14, 1992.
240. **Maki DG**, Stolz Sm, Wheeler SJ. Marked differences in cutaneous colonization of infection sites for central venous (internal jugular, subclavian, femoral), arterial and peripheral venous catheters. A prospective study. **Proceedings and Abstracts of the Second Annual Meeting of the Society of Hospital Epidemiologists of America**, Baltimore, April 12-14, 1992.
241. **Maki DG**. New medical devices with decreased infection risks. In the symposium, "Progress in Achieving the Year 2000 Objectives; Preventing Infection in Surgical and ICU Patients." **Proceedings and Abstracts of the Second Annual Meeting of the Society of Hospital Epidemiologists of America**, Baltimore, April 12-14, 1992.
242. **Maki DG**. Role of glycopeptides in antimicrobial prophylaxis. In the symposium, "Antibioprophylaxis in Surgery: New Protocols." **Proceedings and Abstracts of the 2nd International Congress for the Prevention of Infection (CIPI-2)**. Nice, France, May 5, 1992.
243. **Maki DG**. Epidemiology and prevention of intravascular device-related infection. **Proceedings and Abstracts of the Infection Control Symposium: "Influence of Medical Device Design."** Food and Drug Administration, Bethesda, June 29-July 3, 1992.
244. **Maki DG**. Use of barrier products for prevention of nosocomial infection. **Proceedings of the Annual Research Meeting of Kimberly-Clark Scientists**. Madison, WI, August 1992.
245. Mermel LA, Stolz SM, **Maki DG**. Antimicrobial activity of intravascular catheters. **Proceedings and Abstracts of the Annual Meeting of the American Federation for Clinical Research**, Baltimore, May 7, 1992. *Clin Res* 40:384A (92).
246. Mermel LA, **Maki DG**. Inferior yield of small-volume blood cultures in adult patients. **Proceedings and Abstracts of the 92nd Meeting of American Society of Microbiology**, New Orleans, May 27, 1992.

247. Hanson P, McCormick R, **Maki DG**. Successful reduction of biophazardous injuries in OR personnel by a comprehensive injury-preventive program. **Proceedings and Abstracts of the National Conference on Prevention of Device-Mediated Bloodborne Infections**. USDHH/CDC/FDA/OSHA, Washington, DC, August 18, 1992.
248. Kulak K, **Maki DG**. Successful treatment of Hickman catheter-related candidemia without removing the catheter. **Proceedings and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy**, Anaheim, October 12-14, 1992.
249. **Maki DG**, Stolz SM, Wheeler SJ, Mermel LA. A prospective, randomized, three-way comparison of a novel, highly-permeable, polyurethane dressing with 449 Swan-Ganz catheters. **Proceedings and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy**, Anaheim, October 12-14, 1992.
250. **Maki DG**, Stolz SM, Wheeler SJ. Marked differences in cutaneous colonization of infection sites for central venous (internal jugular, subclavian, femoral), arterial and peripheral venous catheters. A prospective study. **Proceedings and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy**, Anaheim, October 12-14, 1992.
251. Velez LA, Zilz MA, **Maki DG**. Risk factors for mortality in nosocomial bloodstream infection. A case-control study. **Proceedings and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy**, Anaheim, October 12-14, 1992.
252. Kulak K, **Maki DG**. Comparison of nosocomial bloodstream infections with *Candida albicans* and non-albicans *Candida*. **Proceedings and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy**, Anaheim, October 12-14, 1992.
253. Meyer K, **Maki DG**. The syndrome of overwhelming blastomycosis with ARDS. **Proceedings and Abstracts of the Annual Meeting of the American College of Chest Physicians**, Chicago, October 1992, *Chest* 102:99S(92).
254. **Maki DG**. Nosocomial infection control in the 1990s. **Proceedings and Abstracts of the Annual Meeting of the New Zealand Infectious Disease Society**. Lake Taupo, New Zealand, November 6-7, 1992.
255. **Maki DG**. Management of herpes simplex virus and varicella-zoster virus infections in clinical practice. **Annual Meeting of the New Zealand Infectious Disease Society**. Lake Taupo, New Zealand, November 6-7, 1992.
256. **Maki DG**. Management of HIV infection. **Annual Meeting of the Australian-New Zealand Royal College of Physicians**, Nelson, New Zealand, November 12-13, 1992.
257. **Maki DG**. Management of meningitis in clinical practice. **Annual Meeting of the Australian-New Zealand Royal College of Physicians**, Nelson, New Zealand, November 12-13, 1992.
258. **Maki DG**. Infections due to medical devices. In the symposium, "Emerging Problems with Management of Gram-Positive Infections," **Mid-year Meeting of the American Society of Hospital Pharmacists**, Orlando, December 1992.
259. **Maki DG**. Prevention and management of infections of intravascular prosthetic devices. **Proceedings and Abstracts of the Symposium on Advances in Infectious Disease**, Jeddah, Saudi Arabia, January 17-18, 1993.
260. **Maki DG**. Nosocomial infection control in the ICU: An overview. **Proceedings and Abstracts of the Symposium on Advances in Infectious Disease**, Jeddah, Saudi Arabia, January 17-18, 1993.
261. **Maki DG**. Prophylactic antimicrobial therapy in surgery. **Proceedings and Abstracts of the Symposium on Advances in Infectious Disease**, Jeddah, Saudi Arabia, January 17-18, 1993.

262. **Maki DG.** Management of burn wound infection. **Current Challenges in Infectious Disease**, First China National Medical Program, Beijing, China, March 12-14, 1993.
263. **Maki DG.** Infections in the intensive care unit. **Current Challenges in Infectious Diseases**, First China National Medical Program, Beijing, China, March 12-14, 1993.
264. **Maki DG.** Prevention of infections due to intravascular devices. **Proceedings and Abstracts of the Annual Meeting of the Canadian Infection Control Association**, Edmonton, Alberta, April 21, 1993.
265. **Maki DG.** Technology to prevent infections with devices used for vascular access. In the Symposium, "Infections of Implants," **Proceedings and Abstracts of the Annual Meeting of the American Society for Artificial Internal Organs**, New Orleans, LA, April 30, 1993.
266. **Maki DG.** Diagnosis of infection. In the Symposium, "Infections Due to Intravascular Devices," **Proceedings and Abstracts of the Annual Meeting of the American Society for Microbiology**, Atlanta, GA, May 20, 1993.
267. **Maki DG.** New technologies for prevention of nosocomial infection. **Proceedings and Abstracts of the Annual Meeting of the Association for Professionals in Infection Control**, Orlando, FL, May 27, 1993.
268. **Maki DG.** Intravascular catheter-related infections: diagnosis and treatment. In: **International Symposium on Foreign Body Infections**, Helsinki, June 1993.
269. **Maki DG.** Gram-positive infections of associated medical devices. In the Symposium: The Challenge of Gram-positive Bacteria. **Annual Meeting of the American Society for Hospital Pharmacists**, Orlando, FL, June 1993.
270. **Maki DG.** Incidence, epidemiology and strategies for prevention. In the Symposium, "Prosthetic Material Infections", **Proceedings and Abstracts of the 14th International Chemotherapy Congress**, Stockholm, Sweden, June 29, 1993.
271. **Maki DG.** Prophylactic use of glycopeptides. In the Symposium, "Update on the Use of Glycopeptides in the Management of Gram-Positive Infections", **Proceedings and Abstracts of the 14th International Chemotherapy Congress**, Stockholm, Sweden, June 29, 1993.
272. **Maki DG.** Pathogenesis, prevention and management of infections due to intravascular devices. In the Symposium. "Foreign Body Infections", **Annual Meeting of the Infectious Disease Society of Finland**, Helsinki, September 2, 1993.
273. **Maki DG.** Advances in the prevention of infections due to vascular access. **Annual Meeting of the National Association of Vascular Access Networks**, Washington, DC, September 16, 1993.
274. **Maki DG.** Intravascular devices as sources of sepsis. In: **The 18th Australian and New Zealand Scientific Meeting on Intensive Care**, Perth, Australia, October 1993.
275. **Maki DG.** Infection control in the ICU environment: an overview. In: **The 18th Australian and New Zealand Scientific Meeting on Intensive Care**. Perth, Australia, October 1993.
276. **Maki DG.** Technology for prevention of nosocomial infection. In the Symposium, "Nosocomial Infection", **Annual Meeting of the Infectious Disease Society of America**, New Orleans, LA, October 16-18, 1993.
277. **Maki DG.** Infections of vascular access devices. Prevention and management. In the Symposium, "Prosthetic Intravascular Device Infections", **Annual Meeting of the Infectious Disease Society of America**, New Orleans, LA, October 16-18, 1993,
278. **Maki DG.** Pathogenesis and strategies for prevention. In the Symposium, "Prevention and management of infections due to intravascular devices", **Proceedings and Abstracts of the Thirty-Third**



- Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, October 18-20, 1993.
279. **Maki DG.** Methicillin-resistant *Staph. aureus*. **Proceedings and Abstracts of the Second National Symposium on Control of Hospital Infection**, Riyadh, Saudi Arabia, November 29-December 1, 1993.
280. **Maki DG.** Prevention of infections due to intravascular devices. **Proceedings and Abstracts of the Second National Symposium on Control of Hospital Infection**, Riyadh, Saudi Arabia, November 29-December 1, 1993.
281. **Maki DG.** Intravenous devices: can we reduce the risk further? In the Symposium, Intravenous Devices. **Proceedings and Abstracts of the Fourth Annual Meeting of the Society for Hospital Epidemiology of America**. New Orleans, March 1994.
282. **Maki DG.** Antimicrobial therapy of septic shock. In the Symposium, Conference and Clinical Trials for the Treatment of Sepsis, **Proceedings and Abstracts of the Fourth Annual Meeting of the Society for Hospital Epidemiology of America**. New Orleans, March 1994.
283. **Maki DG.** Antimicrobial therapy of septic shock. In the Symposium, Conference and Clinical Trials for the Treatment of Sepsis, in the **Fourteenth International Symposium, Intensive Care Medicine and Emergency Medicine, Brussels**, March 1994.
284. Unger JM, **Maki DG.** Nosocomial pneumonia in the 1990s. **Proceedings and Abstracts of the Annual Meeting of the Society of Thoracic Radiology**, Scottsdale, AZ, March 1994 (abstract).
285. **Maki DG.** The use of antiseptics for prevention of infection with intravascular access. In: **International Symposium on Germicides in Health Care, The Twenty-first Annual Educational Conference of the Association for Professionals in Infection Control**, Cincinnati, OH, May 1994.
286. **Maki DG.** In the Symposium, Nosocomial Bloodstream Infections, **Annual Meeting of the Australian Society for Microbiology**, Melbourne, May 1994.
287. **Maki DG,** Off D, STOL S, Zilz MA. Impact of extending the interval for ventilator circuit changes from 2 to 7 days on the incidence of nosocomial ventilator-associated pneumonia. **Annual Meeting of the Australian Society for Microbiology**, Melbourne, May 1994.
288. **Maki DG,** Zilz MA, Ircink F, HIA M. Frequent nosocomial exposure to pertussis from a large ongoing community outbreak -- efficacy of control resources with emphasis on chemoprophylaxis. In: **Annual Meeting of the Australian Society for Microbiology**, Melbourne, May 1994.
289. **Maki DG,** Stolz S, McCormick R. Pathogenesis of Hickman catheter-related bacteremia. **Annual Meeting of the Australian Society for Microbiology**, Melbourne, May 1994.
290. **Maki DG,** Stolz S. Epidemiology of central venous catheter-related bloodstream infection (BSI). **Annual Meeting of the Australian Society for Microbiology**, Melbourne, May 1994.
291. **Maki DG.** The increasingly complex problem of nosocomial *infection in the 1990s*. **Symposium: Infection Control and IV Therapy 1994: Taking Up the Gauntlet**, Brisbane, Australia, May 1994.
292. **Maki DG.** New frontiers in medical microbiology, Keynote address, **Annual Meeting of the Australian Society for Microbiology**, Melbourne, May 1995.
293. **Maki DG.** Central venous access infection -- where have we been and where are we going? In the Symposium, **Venous Access Complications**, Brisbane, Australia, May 1994.
294. **Maki DG.** Complications of peripheral intravenous therapy. In: **The IV World Congress of Nurse Anesthetists**, Paris, May 1994.

295. **Maki DG**, Stolz S, McCormick R, Spiegel C. Possible association of commercial needleless system with central venous catheter-related bacteremia. In: **Proceedings and Abstracts of the Thirty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy**, Orlando, FL, October 1994 (Abstract J201).
296. **Maki DG**, Stolz S. The epidemiology of central venous catheter-related bloodstream infection (BSI). In: **Proceedings and Abstracts of the Thirty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy**, Orlando, FL, October 1994 (Abstract).
297. **Maki DG**, Stolz S, McCormick R. Pathogenesis of Hickman catheter-related bacteremia. In: **Proceedings and Abstracts of the Thirty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy**, Orlando, FL, October 1994 (Abstract).
298. **Maki DG**, Off D, Stolz S, Zilz MA. Impact of extending the interval for ventilator change from 2 to 7 days on the incidence of nosocomial ventilator-associated pneumonia. **Third International Conference of the Hospital Infection Society**, London, September 1994,
299. **Maki DG**, Zilz MA, Ircink F, Hla M. Frequent nosocomial exposure to pertussis from a large ongoing community outbreak -- efficacy of control resources with emphasis on chemoprophylaxis. **Third International Conference of the Hospital Infection Society**, London, September 1994.
300. **Maki DG**, Stolz S. Epidemiology of central venous catheter-related bloodstream infection (BSI). **Third International Conference of the Hospital Infection Society**, London, September 1994.
301. **Maki DG**. Infections of CFS shunts. In: the Symposium, *Advances in preventing implant infections*. **Third International Conference of the Hospital Infection Society**, London, September 1994.
302. **Maki DG**. Vancomycin- and ampicillin-resistant enterococci. In the Symposium, *Infection in the seriously ill patient*. **Third International Conference of the Hospital Infection Society**, London, September 1994.
303. **Maki DG**. Intravenous devices: can we reduce the risk further? In the Symposium, *Advances in the Control of Nosocomial Infection*. **Proceedings and Abstracts of the Fourth Annual Meeting of the Society for Hospital Epidemiology of America**, New Orleans, March 1994.
304. **Maki DG**. Prevention of infections in the ICU. In the Symposium, *Prevention of Infection in Operating Rooms and ICU Wards*” **Third International Conference on the Prevention of Infection (CIPI)**, Nice, France, April 1994.
305. **Maki DG**. Prevention of infection of intravascular catheters. In the Symposium, *Prevention of Infection of Foreign Devices: New Strategies* **Third International Conference on the Prevention of Infection (CIPI)**, Nice, France, April 1994.
306. **Maki DG**. New strategies in antimicrobial prophylaxis and new trends in chemo-prophylaxis of post-operative infections. **Third International Conference on the Prevention of Infection (CIPI)**, Nice, France, April 1994.
307. **Maki DG**, Off D, STOL S, Zilz MA. Impact of extending the interval for ventilator circuit changes from 2 to 7 days on the incidence of nosocomial ventilator-associated pneumonia. **Proceedings and Abstracts of the Thirty-second Annual Meeting of the Infectious Disease Society of America**, Orlando, FL, October 1994 (Abstract 136).
308. **Maki DG**, Stoll S. Epidemiology of Swan-Ganz catheter-related bacteremia. **Proceedings and Abstracts of the Thirty-second Annual Meeting of the Infectious Disease Society of America**, Orlando, FL, October 1994 (Abstract 135).
309. **Maki DG**. Epidemiology and prevention of intravascular device-related infections. In: **Proceedings of the Conference: Infection Control Symposium: Influence of medical device design**.

- USDHHS:Public Health Service, HSS, Food and Drug Administration, Center for Devices and Radiologic Health. Washington, D.C., January 1995.
310. Panacek E, MacArthur R, Johnson S, Albertson T, **Maki DG**, Tobias J, Benjamin E, Zaloga G, Matuschak G, Silverstein J, Haentfling K and the T88 Sepsis Study Group. Results of a phase 3 clinical trial of the human monoclonal antibody MAB-T88 vs placebo in gram-negative sepsis. In: **Program and Abstracts of the 1995 Annual Meeting of the Society for Critical Care Medicine**, San Francisco, CA, January 1995.
  311. **Maki DG**. Prevention of infections due to vascular access. **The 42nd Annual Meeting of the Japanese Society of Anesthesiology**, Hamamatsu, Japan, April 1995.
  312. **Maki DG**, Farr BM. Point-counterpoint: Resolved: routine intravascular catheter changes reduce the risk of nosocomial infection. A debate. In: the Symposium, *Controversies in the prevention of device-related infection in patients*. **Proceedings and Abstracts of the Fifth Annual Scientific Meeting of the Society for Healthcare Epidemiology of America**, San Diego, April 1995.
  313. **Maki DG**. New therapies for septic shock. In: the Symposium, *Sepsis*. **Seventh Pan-American Congress on Infectious Diseases**, Cartagena, Colombia, May 1995.
  314. **Maki DG**. Catheter-related infections. In the Symposium, *Other Infections in the Critical Outpatient*. **Seventh Pan-American Congress on Infectious Diseases**, Cartagena, Colombia, May 1995.
  315. **Maki DG**. The crisis in antibiotic resistance: causes and solutions. **First Annual Becton-Dickinson Worldwide Clinical Symposium**. Park City, UT, September 1995.
  316. **Maki DG**. The prevention and management of infections in IV therapy. In the **Proceedings and Abstracts of the International Symposium, Safe Infusion Therapy**. Mexico City, September 1995.
  317. Methicillin-resistant *Staphylococcus aureus*. In the Symposium, *Antibiotic Resistance*. **Nineteenth International Chemotherapy Congress**, Toronto, 1995.
  318. **Maki DG**. Germicides for prevention of infection of percutaneous devices used for vascular access. **Proceedings of the Third International Symposium on Cutaneous Fungal, Bacterial and Viral Infection and Therapy**. San Francisco, CA, September 14-17, 1995.
  319. **Maki DG**. Bacteriological safety studies. In the International Symposium, **Kogenate (Recombinant Factor VIII)**. Keystone, Colorado, March 1996.
  320. **Maki DG**, Mermel L, Martin M, Berry D. A prospective comparison of semiquantitative (SQ) and sonication cultures of catheter segments for diagnosis of CV-related BSI. **Proceedings and Abstracts of the Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy**, American Society for Microbiology, New Orleans, September 1996 (Abstract J53)
  321. **Maki DG**, Mermel L, Martin M, Knasinski V, Berry D. A highly-semipermeable polyurethane dressing does not increase the risk of CVCs-related BSI: a prospective, multi-center, investigator-blinded trial. **Proceedings and Abstracts of the Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy**, American Society for Microbiology, New Orleans, September 1996 (Abst. J64).
  322. Urban A, Havighurst T, Rowley J, Cheung L, Meyer K, **Maki DG**. Risk factors for overwhelming pulmonary blastomycosis: a case-control study. **Proceedings and Abstracts of the Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy**, American Society for Microbiology, New Orleans, September 1996: (Abstract K54).
  323. **Maki DG**, Halvorson K, Fischer S. The stethoscope: a medical device with potential for amplifying cross-infection of resistant nosocomial organisms in the hospital. **Proceedings and Abstracts of the Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy**, American Society for Microbiology, New Orleans, September 1996 (Abstract J154).

324. Halvorson K, Urban A, **Maki DG**. Refrigeration at 4° C for 24-72 hours does not compromise the accuracy of quantitative urine cultures. **Proceedings and Abstracts of the Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemo-therapy**, American Society for Microbiology, New Orleans, September 1996 (Abstract D98).
325. **Maki DG**, Zilz MA, McCormick R. The effectiveness of using preemptive barrier precautions routinely (protective isolation) in all high-risk patients to prevent nosocomial infection with resistant organisms, especially MRSA, VRE and *C. difficile*. **Proceedings and Abstracts of the Thirty-fourth Annual Meeting of the Infectious Disease Society of America**, New Orleans, LA, September 1996. *Clin Infect Dis* 23:43(1996).
326. Didier, ME, Havighurst T, **Maki DG**. Epidemiology of nosocomial infection caused by multi-resistant ESBL-producing Klebsiella. **Proceedings and Abstracts of the Thirty-fourth Annual Meeting of the Infectious Disease Society of America**, New Orleans, September 1996. *Clin Infect Dis* 23:50(1996).
327. **Maki DG**. New infectious disease syndromes of the late Twentieth Century. **Second Annual Becton-Dickinson Worldwide Clinical Symposium**. Park City, UT, September 1996.
328. **Maki DG**. Vancomycin-resistant enterococci. In the Symposium, *The Challenge of Emerging Pathogens*, **Proceedings and Abstracts of the Sixth Annual Meeting of the Society for Healthcare Epidemiology of America**, Washington D.C., April 1996.
329. Johnson SB, Albertson TE, MacArthur R, Panacek E, Cowens W, **Maki DG**, Black G. Impact of surgical source control on outcome from gram-negative sepsis. **Proceedings and Abstracts of the Sixteenth Annual Meeting of the Surgical Infection Society**, Milwaukee, 1996.
330. **Maki DG**. New infectious disease syndromes of the late 20th Century. **Annual Meeting of the National Association of Vascular Access Networks**, Anaheim, CA, September 1996.
331. **Maki DG**. Needleless IV systems. The risks of infection. **Annual Meeting of the National Association of Vascular Access Networks**, Anaheim, CA, September 1996.
332. **Maki DG**. Overview of nosocomial infection control in the late 1990s. **Proceedings of the 25th Annual Meeting of the Norwegian Forum for Hospital Infection Control**, Sandefjord, Norway, September 1996.
333. **Maki DG**. Pathogenesis, prevention and management of infections due to intravenous devices. **Proceedings of the 25th Annual Meeting of the Norwegian Forum for Hospital Infection Control**, Sandefjord, Norway, September 1996.
334. **Maki DG**. Control of an emerging pathogen: vancomycin-resistant enterococcus. **Proceedings of the 25th Annual Meeting of the Norwegian Forum for Hospital Infection Control**, Sandefjord, Norway, September 1996.
335. **Maki DG**. The magnitude of the problem, epidemiology and pathogenesis. **Proceedings of a Conference of the American College of Chest Physicians, Central Venous Catheter Infections: Consensus Development and Recommendations Based on Current Evidence**. Chicago, IL, October 25-26, 1996.
336. **Maki DG**. New and novel technologic approaches. **Proceedings of a Conference of the American College of Chest Physicians Central Venous Catheter Infections: Consensus Development and Recommendations Based on Current Evidence**. Chicago, IL, October 25-26, 1996.
337. **Maki DG**. The evolving crisis in antibiotic resistance: causes and solutions. **Proceedings and Abstracts of the 62nd Annual Meeting of the American College of Chest Physicians -- CHEST 1996**, San Francisco, October 28-31, 1996.
338. **Maki DG**. Implications of penicillin-resistant pneumococci for the management of community-acquired pneumonia. In the Symposium, *Pulmonary Infections: New Horizons in Diagnosis, Therapy and*

- Prevention. Proceedings and Abstracts of the 62nd Annual Meeting of the American College of Chest Physicians -- CHEST 1996*, San Francisco, October 28-31, 1996.
339. **Maki DG.** Vascular catheter-related sepsis. **Proceedings of the Symposium, Intensive Care Medicine Facing the Fourth Decade.** Leuven, Belgium, January 11, 1997.
340. **Maki DG.** Controlling antibiotic resistance in the ICU. In the Symposium, *Key Issues Related to Serious Infections. Proceedings and Abstracts of the Annual Meeting of the Society for Critical Care Medicine*, San Diego, CA, February 1997.
341. **Maki DG.** An overview and historical trends of the HICPAC Guidelines. The impact of novel technology designed for prevention. **Clinical Staff Conference, Vascular catheter-related infections. National Institutes of Health**, Bethesda, MD, February 26, 1997.
342. Didier ME, Fisher S, **Maki DG.** 3-in-1 total nutrient admixture solutions appear safer than lipid emulsions used for TPN as regards microbial contamination: growth properties in microbial pathogens at 25 C. **Proceedings and Abstracts of the Seventh Annual Meeting of the Society for Health-care Epidemiology of America**, St. Louis, MO, April 27-29, 1997. *Infect Control Hosp Epidemiol* 1997;18(Suppl):M57.
343. Didier ME, Fisher S, **Maki DG.** Reconstituted recombinant factor VIII can be safely infused continuously for at least 3 days: it is a poor microbial growth medium. **Proceedings and Abstracts of the Seventh Annual Meeting of the Society for Health-care Epidemiology of America**, St. Louis, MO, April 27-29, 1997. *Infect Control Hosp Epidemiol* 1997;18(Suppl):M59.
344. Didier ME, **Maki DG.** Epidemiology of nosocomial infection caused by multi-resistant ESBL-producing *Klebsiella*. **Proceedings and Abstracts of the Seventh Annual Meeting of the Society for Health-care Epidemiology of America**, St. Louis, MO, April 27-29, 1997. *Infect Control Hosp Epidemiol* 1997;18(Suppl):S22.
345. **Maki DG,** Knasinski V, Tambyah PA. An prospective investigator-blinded trial of a novel nitrofurazone-impregnated indwelling urinary catheter. **Proceedings and Abstracts of the Seventh Annual Meeting of the Society for Health-care Epidemiology of America**, St. Louis, MO, April 27-29, 1997. *Infect Control Hosp Epidemiol* 1997;18(Suppl):M49.
346. **Maki DG,** Mermel LA. Transparent polyurethane dressings do not increase risk of CVCS-associated BSI. A meta-analysis of prospective randomized trials. **Proceedings and Abstracts of the Seventh Annual Meeting of the Society for Health-care Epidemiology of America**, St. Louis, MO, April 27-29, 1997. *Infect Control Hosp Epidemiol* 1997;18(Suppl):M54.
347. **Maki DG,** Urban A, Zilz MA, Marks J, McCormick R. Containment of an outbreak of vancomycin- and ampicillin-resistant *E. pecium* in a university hospital by pre-emptive use of barrier precautions (protective isolation) in all patients on the involved units. **Proceedings and Abstracts of the Seventh Annual Meeting of the Society for Health-care Epidemiology of America**, St. Louis, MO, April 27-29, 1997. *Infect Control Hosp Epidemiol* 1997;18(Suppl):S57.
348. **Maki DG.** Topical antiseptics to prevent infection caused by devices for vascular access. In the Symposium, *Sterilization, Disinfection and Antisepsis. Current Topics and Future Challenges. Proceedings and Abstracts of the 24th Annual Conference of the Association for Practitioners in Infection Control.* New Orleans, LA, June 12-13, 1997.
349. **Maki DG.** Diagnosis and treatment of infections caused by devices used for vascular access. **Proceedings and Abstracts of the National Association of Vascular Access Networks (NAVAN).** Philadelphia, PA, September 20, 1997.
350. **Maki DG.** Evolving innovative technologies for the prevention of infection due to vascular access. **Third Annual Becton-Dickinson Worldwide Clinical Symposium.** Park City, Utah, September 1997.

351. **Maki DG.** Blood cultures and intravenous catheters. In the Symposium, *Evaluation of Infection in the Intensive Care Unit. Proceedings and Abstracts of the Interscience Conference on Antimicrobials Agents and Chemotherapy*, Toronto, Canada, September 28-October 1, 1997.
352. McCormick RA, Buchman T, **Maki DG.** A randomized trial of a novel barrier cream and an oil-containing hand lotion for protecting hands of healthcare workers. **Proceedings and Abstracts of the 35th Annual Meeting of the Infectious Diseases Society of America**, San Francisco, CA, September 13-16, 1997.
353. Tambyah PA, Knasinski V, **Maki DG.** Catheter-associated urinary tract infection (CAUTI) is rarely symptomatic and an infrequent cause of nosocomial bloodstream infection (NBSI). A prospective study of 1035 catheterized patients. **Proceedings and Abstracts of the 35th Annual Meeting of the Infectious Diseases Society of America**, San Francisco, CA, September 13-16, 1997.
354. Tambyah PA, Knasinski V, **Maki DG.** The direct economic cost of catheter-associated urinary tract infection (CAUTI) in 1996. **Proceedings and Abstracts of the 35th Annual Meeting of the Infectious Diseases Society of America**, San Francisco, CA, September 13-16, 1997.
355. **Maki DG.** Blood and catheter infections. In the Symposium, *Evaluation of Fever in the ICU. Proceedings and Abstracts of the 35th Annual Meeting of the Infectious Disease Society of America*, San Francisco, CA, September 13-16, 1997.
356. **Maki DG, Zilz MA.** What is the cause of primary bloodstream infections not linked to an intravascular catheter? Most are IV-catheter-related. **Proceedings and Abstracts of the 35th Annual Meeting of the Infectious Disease Society of America**, San Francisco, CA, September 13-16, 1997.
357. Wenzel RP, **Maki DG.** Nosocomial infections, outcomes and healthcare reform. **Proceedings and Abstracts of the 35th Annual Meeting of the Infectious Disease Society of America**, San Francisco, CA, September 13-16, 1997.
358. **Maki DG.** The problem of infection. In *Thrombosis and Infection with Implanted Circulatory Support Systems: Selection and Clinical Relevance of Diagnostic Tests. Proceedings of a Consensus Conference sponsored by the National Heart, Lung and Blood Institute and the Food and Drug Administration*, Washington, DC, October 15-16, 1997.
359. **Maki DG.** New threats in infectious disease: VRE, MRSA, multi-drug-resistant TB. **Proceedings and Abstracts of the 63rd International Scientific Assembly of the American College of Chest Physicians -- CHEST 1997.** New Orleans, LA, October 26-30, 1997.
360. **Maki DG.** Pathogenesis, epidemiology and management of infections caused by medical devices. In the **European Workshop, Medical Needs in Device-associated Infection.** Manchester, England, December 2, 1997.
361. **Maki DG.** Hospital infection control in the next millennium. **Proceedings and Abstracts of the 37th St. Andrews Day Symposium of the Royal College of Physicians**, Edinburgh, Scotland, December 4-5, 1997.
362. **Maki DG.** Epidemiology of emerging resistant organisms in the ICU. In the Symposium, *Crisis in Antibiotic Resistance. Proceedings and Abstracts of the 27th Scientific Symposium of the Society for Critical Care Medicine*, San Antonio, TX, February 4-8, 1998.
363. **Maki DG.** Antibiotic resistance in the ICU. In the Symposium, *Optimizing Antibiotic Use in the Critically-Ill Patient. Proceedings and Abstracts of the 27th Scientific Symposium of the Society for Critical Care Medicine*, San Antonio, TX, February 4-8, 1998.
364. **Maki DG.** Antibiotic resistance: how should we prevent it and how should therapy of ventilator-associated pneumonia be designed to avoid it? In the Symposium, *Controversies in the Management of Nosocomial Pneumonia. Proceedings and Abstracts of the 27th Scientific Symposium of the Society for Critical Care Medicine*, San Antonio, TX, February 4-8, 1998.

365. **Maki DG.** Cultures of blood and intravascular catheters. In the Symposium, *Fever in the ICU. Proceedings and Abstracts of the 27th Scientific Symposium of the Society for Critical Care Medicine*, San Antonio, TX, February 4-8, 1998.
366. Eastman M, Khorsan B, **Maki DG**, Williams E, Kim K, Sondell P, Schiller J, Albertini MR. Catheter-related bacteremia and thrombosis in patients treated with moderate-dose continuous-infusion interleukin 2. **Proceedings and Abstracts of the Annual Meeting of the American Society for Clinical Oncology**, May 1998.
367. **Maki DG.** Pathogenesis, prevention and management of infection due to intravascular devices. **Proceedings and Abstracts of the Fourth National Critical Care Conference, Indian Society for Critical Care Medicine**, Pune, India, January 3-6, 1998.
368. **Maki DG.** Work-up of fever in an ICU. **Proceedings and Abstracts of the Fourth National Critical Care Conference, Indian Society for Critical Care Medicine**, Pune, India, January 3-6, 1998.
369. **Maki DG.** Antifungal therapy in the ICU. **Proceedings and Abstracts of the Fourth National Critical Care Conference, Indian Society for Critical Care Medicine**, Pune, India, January 3-6, 1998.
370. **Maki DG.** The crisis in antibiotic resistance: causes and solutions. **Proceedings and Abstracts of the Fourth National Critical Care Conference, Indian Society for Critical Care Medicine**, Pune, India, January 3-6, 1998.
371. **Maki DG**, Off D, Zilz MA. Impact of extending the interval for ventilator circuit change from seven to fourteen days on the incidence of nosocomial ventilator-associated pneumonia. **Proceedings and Abstracts of the Eighth International Meeting of the Society for Healthcare Epidemiology of America**, Orlando, FL, April 5-7, 1998.
372. **Maki DG**, Knasinski V, Halvorson K, Tambyah PA. A novel silver-hydrogel-impregnated indwelling urinary catheter reduces CAUTI. A prospective double-blind trial. **Proceedings and Abstracts of the Eighth International Meeting of the Society for Healthcare Epidemiology of America**, Orlando, FL, April 5-7, 1998.
373. Tambyah PA, Halvorson K, **Maki DG.** Catheter-associated urinary tract infection (CAUTI) is rarely symptomatic: results from a prospective study of 1035 patients. **Proceedings and Abstracts of the Eighth International Meeting of the Society for Healthcare Epidemiology of America**, Orlando, FL, April 5-7, 1998.
374. Tambyah PA, Knasinski V, **Maki DG.** Risk factors for mortality in hospitalized patients with indwelling urinary catheters: catheter-associated urinary tract infection alone is not a risk factor for mortality. **Eighth International Congress on Infectious Diseases**, Boston, MA, May 15-18, 1998.
375. **Maki DG**, Knasinski V, Halvorson, K, Tambyah PA, Holcomb R. A prospective randomized investigator-blinded trial of a novel nitrofurazone-impregnated urinary catheter. **Eighth International Congress on Infectious Diseases**, Boston, MA, May 15-18, 1998.
376. Tambyah PA, Zilz MA, **Maki DG.** A comparison of amphotericin B lipid complex (ABLC) with conventional amphotericin B for the treatment of invasive aspergillosis. **Eighth International Congress on Infectious Diseases**, Boston, MA, May 15-18, 1998.
377. **Maki DG.** The hospitalized patient with community-acquired pneumonia. In the **Consensus Conference, Community-acquired Pneumonia in Elderly Populations. National Institutes of Allergy and Infectious Diseases**, Washington DC, June 3-4, 1998.
378. **Maki DG.** Primary bloodstream infections derive predominantly from intravascular devices. Invited presentation, **Meeting of the Committee on Anti-infectives, Food and Drug Administration**, Washington, DC, March, 1998.

379. Maki DG. Patient preoperative skin preparations. Invited presentation, **Meeting of the OTC Non-Prescription Drugs Advisory Committee, Food and Drug Administration**, July 28, 1998.
380. **Maki DG**, Narans LL, Banton J. A prospective study of the pathogenesis of PICC-related bloodstream infection. **Proceedings and Abstracts of the Thirty-eighth Annual Meeting of the Interscience Conference on Antimicrobials and Chemotherapy**, San Diego, September 24-27, 1998.
381. **Maki DG**, Halvorson KT. A prospective study of the surface antimicrobial activity of commercially-available medicated central venous catheters. **Proceedings and Abstracts of the Thirty-eighth Annual Meeting of the Interscience Conference on Antimicrobials and Chemotherapy**, San Diego, September 24-27, 1998.
382. **Maki DG**, Narans LL. A new method for quantifying carriage of hand organisms in clinical trials of handwashing agents used for degerming hands. **Proceedings and Abstracts of the Thirty-eighth Annual Meeting of the Interscience Conference on Antimicrobials and Chemotherapy**, San Diego, September 24-27, 1998.
383. Tambyah PA, Marx JA, **Maki DG**. The epidemiology of nosocomial infection with vancomycin-dependent enterococci. **Proceedings and Abstracts of the Thirty-eighth Annual Meeting of the Interscience Conference on Antimicrobials and Chemotherapy**, San Diego, September 24-27, 1998.
384. Maki DG, Knazinski V, Halvorson KT, Tambyah PA. A novel silver-hydrogel urinary catheter reduces catheter-associated urinary tract infections: a prospective randomized double-blind trial. **Proceedings and Abstracts of the Thirty-eighth Annual Meeting of the Interscience Conference on Antimicrobials and Chemotherapy**, San Diego, September 24-27, 1998.
385. **Maki DG**. Nosocomial infections. **Fourth Annual Becton-Dickinson Worldwide Clinical Symposium**. Park City, UT, November 1998.
386. **Maki DG**. Nosocomial infections in the ICU. In the symposium: "Emerging and Practical Infectious Disease Issues for the Critical Care Practitioner." "What the practitioner needs to know - prevention of nosocomial infections. **Proceedings and Abstracts of the Twenty-eighth Scientific Symposium of the Society for Critical Care Medicine**, San Francisco, CA, January 23-27, 1999.
387. **Maki DG**. Resistance of bacterial pathogens: what the intensivist needs to know." In the symposium, "Emerging and Practical Infectious Disease Issues for the Critical Care Practitioner." "Resistant pathogens/infection control - how did we get into this situation?" **Proceedings and Abstracts of the Twenty-eighth Scientific Symposium of the Society for Critical Care Medicine**, San Francisco, CA, January 23-27, 1999.
388. **Maki DG**. Infections acquired during CPR: risk and prevention. In the symposium, "Environmental illness." In the symposium, "What the practitioners needs to know - prevention of nosocomial infections." **Proceedings and Abstracts of the Twenty-eighth Scientific Symposium of the Society for Critical Care Medicine**, San Francisco, CA, January 23-27, 1999.
389. **Maki DG**. Apocalypse now? New paradigms needed for nosocomial infection control. The 1999 SHEA Lecture. **Proceedings and Abstracts of the Ninth Annual Meeting of the Society for Healthcare Epidemiology of America**, San Francisco, CA, April 18-20, 1999.
390. **Maki DG**, Raad II. Should we use therapeutic antimicrobial agents incorporated into or onto biomaterial to prevent infections?: Point/Counterpoint. **Proceedings and Abstracts of the Ninth Annual Meeting of the Society for Healthcare Epidemiology of America**, San Francisco, CA, April 18-20, 1999.
391. **Maki DG**, Narans LL. A new method for quantifying carriage of hand organisms in clinical trials of handwashing agents used for degerming hands. **Proceedings and Abstracts of the Ninth Annual Meeting of the Society for Healthcare Epidemiology of America**, San Francisco, CA, April 18-20, 1999.



392. **Maki DG**, Halvorson KT. A prospective study of the surface antimicrobial activity of commercially-available medicated central venous catheters. **Proceedings and Abstracts of the Ninth Annual Meeting of the Society for Healthcare Epidemiology of America**, San Francisco, CA, April 18-20, 1999.
393. Tambyah PA, Marx JA, **Maki DG**. The epidemiology of nosocomial infection with vancomycin-dependent enterococci. **Proceedings and Abstracts of the Annual Meeting of the Society for Healthcare Epidemiology of America**, San Francisco, April 20, 1999.
394. **Maki DG**. Nosocomial infection control in the 21<sup>st</sup> Century. Keynote address. **Proceedings and Abstracts of the Annual Meeting of the Canadian Hospital Infection Control Association**, Moncton, New Brunswick, Canada, May 30, 1999.
395. **Maki DG**. Line sepsis: pathogenesis, prevention and management. *Critical Issues in Respiratory and Critical Care Medicine: Science and Technology*. **Proceedings of an International Symposium**, St. Jean Cap Ferrat, France, June 709, 1999.
396. **Maki DG**. The crisis in antibiotic resistance: causes and solutions. *Critical Issues in Respiratory and Critical Care Medicine: Science and Technology*. **Proceedings of an International Symposium**, St. Jean Cap Ferrat, France, June 709, 1999.
397. **Maki DG**. New Strategies in Critical Care. **Second Annual Meeting of the Tuscany Critical Care Group**. Florence, Italy, June 10-12, 1999.
398. **Maki DG**. Infection control strategies in the ICU. **Second Annual Meeting of the Tuscany Critical Care Group**. Florence, Italy, June 10-12, 1999.
399. **Maki DG**. Keynote Address: Pathogenesis, prevention and management of line sepsis. **Annual Meeting of the British Infection Control Nurses' Association**, Torquay, England, September 22, 1999.
400. **Maki DG**. State-of-the-Art Mini-lecture: Intravascular catheter-related infections. Lessons learned over the last 25 years. **Proceedings and Abstracts of the Thirty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy**, San Francisco, September 27-29, 1999.
401. Kluger DM, **Maki DG**. A meta-analysis of the risk of intravascular device-related bloodstream infection (BSI) based on 223 published prospective studies. **Proceedings and Abstracts of the Thirty-Ninth Interscience Conference on Antimicrobial Agents and Chemotherapy**, San Francisco, September 27-29, 1999.
402. **Maki DG**, Knasinski V, Tambyah PA. Risk factors for catheter-associated urinary tract infection (CAUTI). A prospective study showing the minimal impact of catheter care violations on the risk of CAUTI. **Proceedings and Abstracts of the Thirty-Ninth Interscience Conference on Anti-microbial Agents and Chemotherapy**, San Francisco, September 27-29, 1999.
403. **Maki DG**. Antimicrobial-resistance in the ICU. In the symposium, *Emerging Pathogens*. **Proceedings and Abstracts of the Twenty-Ninth Scientific Symposium of the Society for Critical Care Medicine**, Orlando, FL, January 11-13, 2000.
404. **Maki DG**. The problem of resistance. In the symposium, *Fluoroquinolone use in the ICU*. **Proceedings and Abstracts of the Twenty-Ninth Scientific Symposium of the Society for Critical Care Medicine**, Orlando, FL, January 11-13, 2000.
405. **Maki DG**. Prevention of infection. In the symposium, *Prevention and Management of Infections Caused by Intravascular Devices. The New SCCM-SHEA-IDSA-CDC Guideline*. **Proceedings and Abstracts of the Twenty-Ninth Scientific Symposium of the Society for Critical Care Medicine**, Orlando, FL, January 11-13, 2000.

406. **Maki DG.** Invited State-of-the-Art Presentation: The role of cutaneous antisepsis for prevention of infections caused by intravascular devices. **Program and Abstracts of the Fourth Decennial International Conference on Nosocomial and Healthcare-Associated Infections**, Atlanta, GA, March 5-8, 2000.
407. **Maki DG.** Invited State-of-the-Art Presentation: Urinary tract infection: Engineering out urinary catheter risk. In the symposium, *State-of-the-Art: Preventing healthcare-associated infections using new technologies*. **Program and Abstracts of the Fourth Decennial International Conference on Nosocomial and Healthcare-Associated Infections**, Atlanta, GA, March 5-8, 2000.
408. Kluger DM, **Maki DG.** A meta-analysis of risk factors for catheter-related BSI with percutaneously-inserted central venous catheters. **Program and Abstracts of the Fourth Decennial International Conference on Nosocomial and Healthcare-Associated Infections**, Atlanta, GA, March 5-8, 2000.
409. McCormick RD, Ircink FG, **Maki DG.** The epidemiology of sharps injuries in a University Hospital. Part III. The impact of 20 years of a multi-faceted control program. **Program and Abstracts of the Fourth Decennial International Conference on Nosocomial and Healthcare-Associated Infections**, Atlanta, GA, March 5-8, 2000.
410. **Maki DG,** Hla KM, Ircink FG. A mid-west university hospital's experience with biohazardous exposure of HCWs to HIV: the continued occurrence of sharps injuries from patients with known HIV infection. **Program and Abstracts of the Fourth Decennial International Conference on Nosocomial and Healthcare-Associated Infections**, Atlanta, GA, March 5-8, 2000.
411. Kluger DM, **Maki DG.** A meta-analysis of risk of intravascular device-related blood stream infection based on 223 prospective studies. **Program and Abstracts of the Fourth Decennial International Conference on Nosocomial and Healthcare-Associated Infections**, Atlanta, GA, March 5-8, 2000.
412. Safdar N, **Maki DG.** A meta-analysis of risk factors for nosocomial infection with antimicrobial-resistant pathogens, MRSA, VRE, *C. difficile*, EFBL-positive GMB and candida. **Program and Abstracts of the Fourth Decennial International Conference on Nosocomial and Healthcare-Associated Infections**, Atlanta, GA, March 5-8, 2000.
413. **Maki DG,** Knasinski V, Tambyah PA. Risk factors for catheter-associated urinary tract infection: A prospective study showing the minimal effects of catheter care violations on the risk of CAUTI. **Program and Abstracts of the Fourth Decennial International Conference on Nosocomial and Healthcare-Associated Infections**, Atlanta, GA, March 5-8, 2000.
414. **Maki DG,** Hla KM, Ircink FG. Comparative clinical trial in 3,031 health care workers of the two commercial tuberculin antigens available in the U.S.; Applisol® and Tubersol®. **Program and Abstracts of the Fourth Decennial International Conference on Nosocomial and Healthcare-Associated Infections**, Atlanta, GA, March 5-8, 2000.
415. **Maki DG,** Narans LL, Knasinski V, Kluger D. Prospective randomized investigator-masked trial of a novel chlorhexidine-impregnated disk (Biopatch®) on central venous and arterial catheters. **Program and Abstracts of the Fourth Decennial International Conference on Nosocomial and Healthcare-Associated Infections**, Atlanta, GA, March 5-8, 2000.
416. **Maki DG.** Participant in the debate: *Should we use vancomycin for prophylaxis of catheter-associated infections?* **Program and Abstracts of the Fourth Decennial International Conference on Nosocomial and Healthcare-Associated Infections**, Atlanta, GA, March 5-8, 2000.
417. **Maki DG.** Antimicrobials incorporated into prosthetic materials to prevent infection. *International Symposium on Sterilization, Disinfection and Antisepsis*. **proceedings and Abstracts of the 27th Annual Educational and International Conference of the Association of Association for Professionals in Infection Control Epidemiology**, Minneapolis, MN, June 20-23, 2000.
418. **Maki DG.** Management of infections caused by antibiotic-resistant organisms. In the Symposium, *Gram-positive Resistance in the ICU: Prevention and Management*. **Proceedings and Abstracts of the 27th**

- Annual Educational and International Conference of the Association of Association for Professionals in Infection Control Epidemiology**, Minneapolis, MN, June 20-23, 2000.
419. **Maki DG.** Invited State-of-the-Art presentation: *Strategies for prevention of infection of implanted medical devices.* **Program and Abstracts of Surfaces in Biomaterials Annual Symposium**, Scottsdale, AZ, August 31-September 2, 2000.
420. **Maki DG.** How to diminish the impact of invasive devices on the development of resistance. In the International symposium, *Global Resistance Day.* **Proceedings and Abstracts of the 40th Interscience Conference on Antimicrobial Agent Chemotherapy**, Toronto, September 16-20, 2000.
421. **Maki DG,** Mermel LA, Kluger D, Narans L, Knasinski V, Parenteau S, Covington P. The efficacy of a chlorhexidine-impregnated sponge (Biopatch®) for the prevention of intravascular catheter-related infection. A prospective, randomized, multicenter study. **Proceedings and Abstracts of the 40th Interscience Conference on Antimicrobial Agent Chemotherapy**, Toronto, September 16-20, 2000.
422. **Maki DG.** Guidelines for prevention. In the symposium, *Intravascular-Catheter-Related Infections: Guidelines for Treatment and Prevention.* **Proceedings and Abstracts of the 40th Interscience Conference on Antimicrobial Agent Chemotherapy**, Toronto, September 16-20, 2000
423. **Maki DG.** Antibiotic prophylaxis in surgery. In the symposium, *Controversies in Surgical Site Infections.* **Program and Abstracts of the Third Pan-American Congress on Control of Infections and Hospital Epidemiology**, Belo Horizonte, Brazil, November 10-14, 2000.
424. **Maki DG.** New technologies applied to intravascular devices. Their critical analysis. In the symposium, *New Technologies for Prevention of Nosocomial Infection.* **Program and Abstracts of the Third Pan-American Congress on Control of Infections and Hospital Epidemiology**, Belo Horizonte, Brazil, November 10-14, 2000.
425. **Maki DG.** Infections, antibiotics and resistance in the ICU. In the symposium, *Advances in Critical Care.* **Program and Abstracts of the 30th International Educational Scientific Symposium of the Society for Critical Care Medicine**, San Francisco, CA, February 10-14, 2001.
426. **Maki DG.** Managing resistant infections in the ICU. In the symposium, *Managing Resistant Infections in the ICU.* **Program and Abstracts of the 30th International Educational Scientific Symposium of the Society for Critical Care Medicine**, San Francisco, CA, February 10-14, 2001.
427. McCormick RD, Ircink FG, **Maki DG.** The epidemiology of sharps injury on a University Hospital-Part III—The impact of 25 years of a multi-faceted control program. **Program and Abstracts of the 30th International Educational Scientific Symposium of the Society for Critical Care Medicine**, San Francisco, CA, February 10-14, 2001.
428. **Maki DG,** Hla KM, Ircink FG. A mid-western University Hospital's experience with biohazardous exposures of healthcare workers to HIV: The continued occurrence of sharps injuries from patients with known HIV infection. **Program and Abstracts of the 30th International Educational Scientific Symposium of the Society for Critical Care Medicine**, San Francisco, CA, February 10-14, 2001.
429. Safdar N, **Maki DG.** An analysis of risk factors from nosocomial infection with antimicrobial-resistant pathogens: MRSA, VRE, *C. difficile*, ESBL-positive GNB and *Candida*. **Program and Abstracts of the 30th International Educational Scientific Symposium of the Society for Critical Care Medicine**, San Francisco, CA, February 10-14, 2001.
430. Kluger DM, **Maki DG.** A review of risk factors for catheter-related bloodstream infection caused by percutaneously-inserted, non-cuffed central venous catheters. **Program and Abstracts of the 30th International Educational Scientific Symposium of the Society for Critical Care Medicine**, San Francisco, CA, February 10-14, 2001.
431. **Maki DG,** Knasinski KV, Tambyah PA. Risk factors for catheter-associated UTI (CAUTI): a prospective study showing the minimal impact of catheter care violations on the risk of CAUTI. **Program and**

- Abstracts of the 30th International Educational Scientific Symposium of the Society for Critical Care Medicine**, San Francisco, CA, February 10-14, 2001.
432. **Maki DG**, Knasinski KV, Mermel L. A prospective randomized trial of 1% chlorhexidine-75% alcohol tincture versus 10% povidone-iodine for cutaneous disinfection and followup site care with central venous and arterial catheters. **Program and Abstracts of the 30th International Educational Scientific Symposium of the Society for Critical Care Medicine**, San Francisco, CA, February 10-14, 2001.
433. **Maki DG**, Knasinski KV, Mermel L. A prospective randomized investigator-masked trial of a novel chlorhexidine-impregnated dressing (Biopatch®) for central venous and arterial catheters. **Program and Abstracts of the 30th International Educational Scientific Symposium of the Society for Critical Care Medicine**, San Francisco, CA, February 10-14, 2001.
434. Kluger D, **Maki DG**. A meta-analysis of risk factors for catheter-related BSI with percutaneously-inserted central venous catheters. **Program and Abstracts of the 30th International Educational Scientific Symposium of the Society for Critical Care Medicine**, San Francisco, CA, February 10-14, 2001.
435. **Maki DG**. Line sepsis. In the, **Annual State of the Art Review CME Course of the American Thoracic Society**, San Juan, Puerto Rico, March 1-4, 2001.
436. **Maki DG**. Evaluation of fever in the ICU. In the Symposium, Plenary 2: *What's New in the ICU?* **Program and Abstracts of the Eleventh Annual Scientific Meeting of the Society for Health Care Epidemiology of America**, Toronto, Canada, April 1-3, 2001.
437. **Maki DG**, Knasinski B, Narans LL, Gordon BJ. A randomized trial of the novel 1% chlorhexidine-75% alcohol tincture versus 10% povidone-iodine for percutaneous disinfection of vascular catheters. **Program and Abstracts of the Eleventh Annual Scientific Meeting of the Society for Health Care Epidemiology of America**, Toronto, Canada, April 1-3, 2001.
438. **Maki DG**. Recent advances in the control of device-associated infections. In the symposium, *Current Issues in Infection Control, Disinfection and Sterilization*. **Programs and Abstracts of the Eleventh Annual Scientific Meeting of the Society for Health Care Epidemiology of America**, Toronto, Canada, April 1-3, 2001.
439. **Maki DG**. The Abbott epidemic. **Proceedings of the Fiftieth Anniversary Celebration of the CDC Epidemic Intelligence Service**, Atlanta, GA, April 21-22, 2001.
440. **Maki DG**. Antimicrobial-coated devices: effectiveness and potential impact on resistance. In the symposium, *Prevention and management of antimicrobial resistance in the ICU*. **Program and Abstracts of the Ninety-seventh International Conference of the American Thoracic Society**, San Francisco, May 18-23, 2001.
441. **Maki DG**. The promise of novel technology for prevention of nosocomial infection. **Program and Abstracts of the Annual Meeting of the Association of Professionals in Infection Control**, Seattle, WA, June 11-15, 2001.
442. Lotto ML, Strother C, **Maki DG**. Antimicrobial prophylaxis is not necessary for implantation of cerebral and endovascular platinum coils. A study of 94 patients with newly placed coils heavily exposed to infection in the early post-implantation period. **Program and Abstracts of the Society of Neurological Anesthesia and Critical Care**, New Orleans, LA, October 12, 2001.
443. **Maki DG**, Raad S. Point-counter-point: Antibiotic-coated catheters should be used to prevent central venous catheter-related BSI. **Program and Abstracts of the 39th Annual Meeting of the Infectious Diseases Society of America**, San Francisco, CA, October 25-28, 2001.
444. **Maki DG**, Levy H, for the PROWESS Clinical Evaluation Committee. Mortality reduction associated with recombinant human activated protein seen in patients with severe sepsis as assessed by site of

- infection. **Program and Abstracts of the 39th Annual Meeting of the Infectious Diseases Society of America**, San Francisco, CA, October 25-28, 2001.
445. **Maki DG**, Dhainault JF, for the PROWESS Clinical Evaluation Committee. Recombinant human activated protein C (drotrecogin alfa [activated]) improves markers of coagulation and inflammation in patients with severe sepsis and community-acquired pneumonia. **Annual Meeting of the American College of Chest Physicians**, Philadelphia, PA, November 1-5, 2001.
446. **Maki DG**, Mann H. New technologies in sepsis treatment. National Satellite Broadcast, VHA, Dallas, TX, November 14, 2001.
447. **Maki DG**. The need for a new paradigm for control of institutionally-acquired infections: the promise of novel technology. **Combined Meeting of the Finnish Societies of Infection Control and of Hematology**, Helsinki, Finland, November 19, 2001.
448. **Maki DG**. The need for a new paradigm for control of infection in the ICU: the promise of novel technology. **Annual Meeting of the Finnish Society for Intensive Care Medicine**, Helsinki, Finland, November 20, 2001.
449. **Maki DG**. Prevention of line sepsis in the ICU. **Annual Meeting of the Finnish Society for Intensive Care Medicine**, Helsinki, Finland, November 20, 2001.
450. **Maki DG**. Clinical evaluation of medicated intravascular devices and urinary catheters. In the symposium, **Antimicrobial Device Testing**, Center for Devices and Radiologic Health, Food and Drug Administration, Rockville, MD, December 3-4, 2001.
451. **Maki DG**, Crnich CJ. Line sepsis in the neutropenic patient: prevention, diagnosis and management. In *Infections in the Neutropenic Patient*, **Proceedings and Abstracts of the 43rd meeting of the American Society of Hematology**. Orlando, FL, December 7-9, 2001.
452. Safdar N, **Maki DG**. Inflammation at the insertion site is not predictive of catheter-related infection with CVCs. **Program and Abstracts of the 41st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy**, Chicago, IL, December 16-18, 2001.
453. Safdar N, **Maki DG**. Risk of catheter-related bloodstream infection with peripherally inserted central venous catheters (PICCs). **Program and Abstracts of the 41st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy**, Chicago, IL, December 16-18, 2001.
454. **Maki DG**. Advances in cutaneous antisepsis. In the symposium, *Emerging therapies*. **Program and Abstracts of the 41st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy**, Chicago, IL, December 16-18, 2001.
455. **Maki DG**. Clinical management of septic shock. In the symposium, *Advances in the Treatment of Septic Shock*. **Program and Abstracts of the 41st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy**, Chicago, IL, December 16-18, 2001.
456. **Maki DG**. Strategies to reduce nosocomial infection. **6th Critical Care Refresher Course at the 31st Annual Meeting of the Society of Critical Care Medicine**. San Diego, CA, January 25-26, 2002.
457. **Maki DG**. Prevention of infection from intravascular devices. Invited plenary presentation. **29th Congress of the Japanese Society of Intensive Care Medicine**, Yokohama, Japan, March 1, 2002.
458. **Maki DG**. Prevention of infection from intravascular devices. **Yokohama Municipal University Hospital Symposium**, Yokohama, Japan, March 2, 2002.
459. **Maki DG**. The coming plague: bioterrorism. **National Conference on Undergraduate Research**, Whitewater, WI, April 19, 2002.
460. Andes DR, **Maki DG**. Central vascular catheter candidiasis. **International Forum on Severe Fungal Infections**. Paris, France, May 2002.

461. Aiyanger A, Crone WC, Crnich CJ, **Maki DG**. Effect of ethanol in the mechanical properties of silicone and polyurethane vascular catheters. **Proceedings and Abstracts of the SEM Annual Conference on Experimental Mechanics**, Milwaukee, WI, 2002.
462. Garland JS, Alex CP, Hendrickson KJ, **Maki DG**. A randomized trial of a vancomycin-heparin lock solution (VHLS) for prevention of catheter-related bloodstream infection (CRBSI) in a NNICU. **Annual Meeting of the American Society for Pediatric Research**, Baltimore, MD, May 2002
463. **Maki DG**. New and emerging infections in the ICU. In the symposium, *Critical Care Medicine: 2002 Scientific Program of the Annual Session of the American College of Physicians-American Society of Internal Medicine*, Philadelphia, PA, April 11-14, 2002.
464. **Maki DG**. Germs and biologic warfare. Time to panic? In the symposium, *Critical Care Medicine: 2002 Scientific Program of the Annual Session of the American College of Physicians-American Society of Internal Medicine*, Philadelphia, PA, April 11-14, 2002.
465. **Maki DG**, Kalil AC, Basson BR, Johnson III G, CEC. Drotrecogin alfa (activated) mortality benefit in patients with severe sepsis is unaffected by adequacy of antibiotic therapy: the PROWESS experience. **Program and Abstracts of the 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy**, San Diego, CA, September 27-30, 2002.
466. **Maki DG**, Lotto ML, Strother C. Antimicrobial prophylaxis is not necessary for implantation of cerebral endovascular platinum coils: a study of 107 patients with newly-placed coils heavily exposed to infection in the early post-implantation period. **Program and Abstracts of the 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy**, San Diego, CA, September 27-30, 2002.
467. **Maki DG**, Garland JS, Hendrickson K. A randomized trial of a vancomycin-heparin lock solution (VHLS) for prevention of PICC-related bloodstream infection in a NNICU. **Program and Abstracts of the 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy**, San Diego, CA, September 27-30, 2002.
468. Crnich CJ, Safdar N, **Maki DG**. Successful use of a 25% alcohol lock solution for prevention of recurrent CVC-related bloodstream infection with a patient on home TNA. **Program and Abstracts of the 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy**, San Diego, CA, September 27-30, 2002.
469. Safdar N, **Maki DG**. The incidence and pathogenesis of catheter-related bloodstream infection with arterial catheters. **Program and Abstracts of the 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy**, San Diego, CA, September 27-30, 2002.
470. Safdar N, **Maki DG**. Pathogenesis of catheter-related bloodstream infection with percutaneously-placed short-term, non-cuffed CVCs. **Program and Abstracts of the 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy**, San Diego, CA, September 27-30, 2002.
471. Crnich CJ, Aiyanger A, Crone WC, **Maki DG**. Prolonged exposure to 70% ethanol does not alter the mechanical properties of polyurethane silicone catheters. **Program and Abstracts of the 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy**, San Diego, CA, September 27-30, 2002.
472. Safdar N, Narans LL, Gordon BG, **Maki DG**. A prospective clinical evaluation of 16 microbiologic methods for detection of MRSA in nasal carriage. **Program and Abstracts of the 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy**, San Diego, CA, September 27-30, 2002.
473. **Maki DG**. Activated protein C for sepsis. In the symposium, *Formulary 2002*. **Program and Abstracts of the 40th Annual Meeting of the Infectious Diseases Society of America**, Chicago, IL, October 26-28, 2002.

474. **Maki DG**, Kluger DM, Crnich CJ. The microbiology of intravascular device-related (IVDR) infection in adults: 1). an analysis of 159 prospective studies; 2). implications for prevention and treatment. **Program and Abstracts of the 40th Annual Meeting of the Infectious Diseases Society of America**, Chicago, IL, October 26-28, 2002.
475. Kluger DM, Safdar N, **Maki DG**. The risk of intravascular device-related (IVDR) bloodstream infection (BSI) in children and neonates: a meta-analysis of 88 published prospective studies. **Program and Abstracts of the 40th Annual Meeting of the Infectious Diseases Society of America**, Chicago, IL, October 26-28, 2002.
476. **Maki DG**, Parillo JE, Weil MH. Update on Sepsis Definitions Consensus Symposium. **Annual Meeting of the American College of Chest Physicians (CHEST: 2002)**. San Diego, CA, November 2-7, 2002.
477. Said A, Safdar N, **Maki DG**. Post-liver transplant infected fluid collections: Risk factors, management and outcome. **Proceedings and Abstracts of the American Society for Transplantation Annual Meeting**, Washington D.C., April 2003.
478. Safdar N, **Maki DG**. The risk of infection following colonization with MRSA, VRE and gram-negative bacilli resistant to third generation cephalosporins. **Proceedings and Abstracts of the Third Conference on Antimicrobial Resistance**, Bethesda, MD, May 2003.
479. Safdar N, **Maki DG**. A comparative trial of 16 different microbiologic methods for detection of MRSA in nasal specimens. **Proceedings and Abstracts of the 13th Annual Meeting of the Society for Healthcare Epidemiology of America**, Arlington, VA, May 2003.
480. Safdar N, **Maki DG**. Incidence, pathogenesis and risk factors for arterial catheter-related bloodstream infection. **Proceedings and Abstracts of the 13th Annual Meeting of the Society for Healthcare Epidemiology of America**, Arlington, VA, May 2003.
481. Hahlen HS, Dietrich CJ, Marx JA, **Maki DG**. Cloth lanyards used by healthcare workers: an unsuspected reservoir of resistant nosocomial pathogens. **Program and Abstracts of the 29th Annual Educational International Conference of the Association of Professionals in Infection Control and Epidemiology**, Nashville, TN, May 2003.
482. **Maki DG**. Strategies to reduce nosocomial infection, *Seventh Critical Care Refresher Course*. **31st Annual Meeting of the Society of Critical Care Medicine**. San Antonio, TX, January 29, 2003.
483. **Maki DG**. Prevention of highly-resistant gram-positive cocci in the ICU. In the symposium, *Battling Resistance: Implications and Management of Gram-positive Infections in the ICU*. **31st Annual Meeting of the Society of Critical Care Medicine**. San Antonio, TX, January 31, 2003.
484. **Maki DG**. New and emerging infections in the ICU. In the symposium, *Critical Care Medicine: 2003. Scientific Program at the Annual Session of the American College of Physicians-American Society of Internal Medicine*, San Diego, CA, April 3-5, 2003.
485. **Maki DG**. The CDC/HICPAC Guideline for prevention of intravascular catheter-related infection. National satellite broadcast, VHA, Dallas, TX, April 9-10, 2003.
486. **Maki DG**. Advances in the management of septic shock beyond antimicrobial therapy. *Joint Foundation of Intensive Care Medicine Lecture*, **Australian and New Zealand College of Anesthetists – Joint Faculty of Intensive Care Medicine – Faculty of Pain Medicine (ANZCA-JFICM) Annual Scientific Meeting**, Hobart, Australia, May 3-6, 2003.
487. **Maki DG**. The new plague: bioterrorism. In the symposium, *Border Protection*, **ANZCA-JFICM Annual Scientific Meeting**, Hobart, Australia, May 3-6, 2003.
488. **Maki DG**. The need for new paradigm for infection control in the ICU. In the symposium, *New Paradigms*, **ANZCA-JFICM Annual Scientific Meeting**, Hobart, Australia, May 3-6, 2003.

489. **Maki DG.** SARS – the new threat. In the symposium, *Current Microbiologic Hazards*, **ANZCA-JFICM Annual Scientific Meeting**, Hobart, Australia, May 3-6, 2003.
490. **Maki DG.** Prevention of infections of implanted medical devices, *The 2003 Division L Lecture*, **Annual Meeting of the American Society for Microbiology**, Washington, DC, May 20, 2003.
491. **Maki DG.** Infection with Long-Term Intravascular Devices: Novel Approaches to Prevention, **Third Annual Conference of the Center for Prostheses Infection (CPI) and Second Meeting of the Multidisciplinary Alliance against Device-Related Infections (MADRI)**, San Antonio, Texas, August 8, 2003.
492. **Maki DG.** Activated Protein C in Sepsis. **27th Congress of the Scandinavian Society of Anaesthesiology and Intensive Care Medicine**, Helsinki, Finland, August 17, 2003.
493. **Maki DG.** IV-Related Infections. In the symposium, *Current Thinking and Practices, Future Trends and Vision*, **European Infection Prevention Option Leader Conference**, Neuss, Germany, September 2003.
494. **Maki DG.** IV-Related Infections. In the symposium, *Current Thinking and Practices Leading to Future Trends*, **3M Germany Symposium**, Dusseldorf, Germany, September 2003.
495. **Maki DG.** The Need for a New Paradigm for Preventing Nosocomial Infections in the 21st Century. **IVD-related Infections in the Third Millenium**, Milan, Italy, September 2003.
496. **Maki DG.** Prevention of Line Sepsis: State of the Art. **IVD-related Infections in the Third Millenium**, Milan, Italy, September 2003.
497. Safdar N, Fine JP, **Maki DG.** Diagnosis of catheter-related bloodstream infection: a meta-analysis. **Proceedings and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy**, Chicago, IL, September 2003.
498. Safdar N, Handelsman J, **Maki DG.** Does combination therapy reduce mortality in gram-negative bacteremia? A meta-analysis. **Proceedings and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy**, Chicago, IL, September 2003.
499. Safdar N, **Maki DG.** The effectiveness of enhanced barrier precautions in prevention of nosocomial MRSA colonization and infection in a burn unit: A time-series analysis. **Proceedings and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy**, Chicago, IL, September 2003.
500. Safdar N, Said A, **Maki DG.** The epidemiology of biloma formation following liver transplantation: microbiology, risk factors and outcomes. **Proceedings and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy**, Chicago, IL, September 2003.
501. **Maki DG**, Brookmeyer PR. EKG telemetry harnesses as a reservoir of resistant nosocomial pathogens. **Proceedings and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy**, Chicago, IL, September 2003.
502. Safdar N, Said A, Musat A, Knechtle SJ, D'Alessandro AM, Lucey MR, Kalayoglu M, **Maki DG.** Infected Bilomas Post-liver Transplantation: Risk Factors and Microbiology. A Nested Case-control Study. **Proceedings and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy**, Chicago, IL, September 2003.
503. Rosenthal VD, **Maki DG.** Prospective study of the impact of open and closed infusion systems and rates of central venous catheter-related bacteremia. **Proceedings and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy**, Chicago, IL, September 2003.



504. **Maki DG.** The promise of new technology for prevention of intravascular device-related infection. In *Meet-the-Experts* symposium, **Proceedings and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy**, Chicago, IL, September 2003.
505. Fox BC, Palmer M, Bland S, Maphanta S, Fish J, **Maki DG.** Role of an Electronic Scannable Antimicrobial Order Form in the Analysis of Prescribing Patterns in an Intensive Care Unit. **Proceedings and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy**, Chicago, IL, September 2003.
506. Safdar N, Marx J, **Maki DG.** Effectiveness of Preemptive Barrier Precautions in Controlling Nosocomial Colonization and Infection by Methicillin-resistant *Staphylococcus aureus* in a Burn Unit: A Time-Sequence Study. **Proceedings and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy**, Chicago, IL, September 2003.
507. **Maki DG.** Antibiotic Tolerance in Biofilms and Role in Persistent Infections in: Breaking the Biofilm Barrier Satellite Symposium, **Proceedings and Abstracts of the 41st Annual Meeting of the Infectious Diseases Society of America**, San Diego, CA, October 2003.
508. **Maki DG.** Controversies in Clinical Infectious Debate: CVCs Should not be Replaced over a Guidewire (Pro). **Proceedings and Abstracts of the 41st Annual Meeting of the Infectious Diseases Society of America**, San Diego, CA, October 2003.
509. **Maki DG.** Controversies in Clinical Infectious Debate: rhAPC – Do benefits justify the cost (Pro). **Proceedings and Abstracts of the 41st Annual Meeting of the Infectious Diseases Society of America**, San Diego, CA, October 2003.
510. **Maki DG.** Management of Coagulase-negative Staphylococcal Infection. In the Symposium, *Staphylococcal Infections*. **33rd Annual Meeting of the Society of Critical Care Medicine**. Orlando, FL, February 2004.
511. **Maki DG.** Management of Infections Caused by Multi-resistant Organisms for SCCM Board Review Course at the **33rd Annual Meeting of the Society of Critical Care Medicine**. Orlando, FL, February 2004.
512. **Maki DG.** The role of rhAPC for treatment of Septic Shock in a Symposium. In the symposium, *Advances in the Management of Septic Shock*. **International Chemotherapy Congress**, Cancun, March 2004.
513. **Maki DG.** Initial management of life-threatening infections. **2004 Meeting of the Singapore ID Society**, Singapore, March 2004.
514. **Maki DG.** The Upcoming Plague: Bioterrorism – an Update. **2004 Meeting of the Singapore ID Society**, Singapore, March 2004.
515. **Maki DG.** New approaches to prevention of infections caused by intravascular devices. A satellite symposium, In: **Infection Control – Towards Quality Care: Proceedings of the Second International Congress of the Asia Pacific Society of Infection Control**, Singapore, March 2004.
516. **Maki DG.** The need for a new paradigm for control of nosocomial infection in the 21st century: the promise of new technology. Keynote, **Infection Control – Towards Quality Care: Proceedings of the Second International Congress of the Asia Pacific Society of Infection Control**, Singapore, March 2004.
517. **Maki DG.** Surveillance of the organ transplant patients: the promise of molecular diagnostics. In: **Infection Control – Towards Quality Care: Proceedings of the Second International Congress of the Asia Pacific Society of Infection Control**, Singapore, March 2004.
518. **Maki DG.** Hospital renovation: protecting the vulnerable patient. In: **Infection Control – Towards Quality Care: Proceedings of the Second International Congress of the Asia Pacific Society of Infection Control**, Singapore, March 2004.

519. **Maki DG.** Technology for prevention of intravascular device-related bloodstream infection. In: **Infection Control – Towards Quality Care: Proceedings of Second International Congress of the Asia Pacific Society of Infection Control**, Singapore, March 2004.
520. **Maki DG.** New and Emerging Infections in the ICU. In: **Critical Care 2004 – A PreSession Course for the American College of Physicians-American Society of Internal Medicine Annual Scientific Meeting**, New Orleans, April 2004.
521. **Crnich CJ, Slattery WR, Maki DG.** Risk of bloodstream infection with different types of intravascular devices in a large outpatient infusion service. **Abstracts and Proceedings from the Fourteenth annual scientific meeting of the Society for Healthcare Epidemiology of America**. Philadelphia, PA, April 2004.
522. Safdar N, Fine JP, **Maki DG.** Diagnosis of catheter-related bloodstream infection: a meta-analysis. **Abstracts and Proceedings from the Fourteenth annual scientific meeting of the Society for Healthcare Epidemiology of America**, Philadelphia, PA, April 2004.
523. Safdar N, **Maki DG.** The effectiveness of enhanced barrier precautions in prevention of nosocomial MRSA colonization and infection in a burn unit: A time-series analysis. **Abstracts and Proceedings from the Fourteenth annual scientific meeting of the Society for Healthcare Epidemiology of America**, Philadelphia, PA, April 2004.
524. Safdar N, Said A, **Maki DG.** The epidemiology of biloma formation following liver transplantation: microbiology, risk factors and outcomes. **Abstracts and Proceedings from the Fourteenth annual scientific meeting of the Society for Healthcare Epidemiology of America**, Philadelphia, PA, April 2004.
525. Safdar N, **Maki DG.** The use of vancomycin lock and flush solutions for the prevention of catheter-related bloodstream infection. **Abstracts and Proceedings from the Fourteenth annual scientific meeting of the Society for Healthcare Epidemiology of America**, Philadelphia, PA, April 2004.
526. Garland JS, Alex CP, **Maki DG.** Is the Portal of Entry for Organisms Causing PICC-Related Bloodstream Infections (CRBSI) in VLBW Neonates Extraluminal or Intraluminal? **Program and Abstracts from the 2004 Pediatric Academic Societies' Annual Meeting**, San Francisco, CA, May 2004.
527. Garland JS, Kannenberg SM, Porter DM, Mayr KB, Mishfeske MJ, Alex CP, **Maki DG.** Reducing PICC-Related Bloodstream Infections (CRBSI) and Systemic Vancomycin Use in VLBW Neonates with Routine Use of a Vancomycin/Heparin Lock Solution. **Program and Abstracts from the 2004 Pediatric Academic Societies' Annual Meeting**, San Francisco, CA, May 2004.
528. Menyhay S, **Maki DG.** A Novel Antiseptic-Microbial Barrier Cap for CVC Hubs or Injection Ports for Prevention of CVC-Related BSI. **Program and Abstracts of the 31st Annual Educational International Conference of the Association of Professionals in Infection Control and Epidemiology**, Phoenix, AZ, June 2004.
529. **Maki DG.** Prevention of nosocomial infections in the ICU. **Proceedings and Abstracts of the 2nd Asia Pacific Centre of Excellence on Critical Care Interventions**. Hyderabad, India, July 30-August 1, 2004.
530. **Maki DG.** Antiinfective therapy for life-threatening infections. **Proceedings and Abstracts of the 2nd Asia Pacific Centre of Excellence on Critical Care Interventions**. Hyderabad, India, July 30-August 1, 2004.
531. **Maki DG.** The promise of new technologies for prevention of device-related bloodstream infection. **Program and Abstracts of the IXth Brazilian Congress on Hospital Infection Control and Epidemiology**. Salvador, Brazil, September 1, 2004.

532. **Maki DG.** Prevention of intravascular device-associated infection. **Argentine National Academy of Medicine.** Buenos Aires, Argentina, September 2, 2004.
533. **Maki DG.** The need for a new paradigm for control of nosocomial infection. **Annual meeting of the American Vascular Access Association.** Vancouver, Canada, September 18, 2004.
534. **Maki DG.** Transparent dressings in clinical practice. **Annual meeting of the American Vascular Access Association.** Vancouver, Canada, September 19, 2004.
535. Garland J, Kannenberg S, Porter D, Mayr K, Mishefske M, Alex C, **Maki DG.** Reducing PICC-Related Bloodstream Infections (CRBSI) and Systemic Vancomycin Use in VLBW Neonates with Routine Use of a Vancomycin/Heparin Lock Solution. **Program and Abstracts of the 42nd Annual Meeting of the Infectious Diseases Society of America,** Boston, MA, September 30-October 3, 2004.
536. Menyhay S, **Maki DG.** Alcohol Prepping of CVC Hubs or Injection Ports for Prevention of BSI May Not Prevent Microbial Entry. The Promise of a Novel Antiseptic-Barrier Cap. **Program and Abstracts of the 42nd Annual Meeting of the Infectious Diseases Society of America,** Boston, MA, September 30-October 3, 2004.
537. Fox BC, Fish J, Zheng L, **Maki DG.** Prospective Study of De-escalation Antimicrobial Therapy in an ICU. **Program and Abstracts of the 42nd Annual Meeting of the Infectious Diseases Society of America,** Boston, MA, September 30-October 3, 2004.
538. **Maki DG.** An evidence-based approach to prevention of vascular catheter-related infection. **Annual Meeting of the Canadian Intravenous Nurses Society.** Toronto, Canada, October 21, 2004.
539. **Maki DG,** Jones AM, Narans LL. Prospective, Randomized Investigator-Blinded Trial of a Novel Antiseptic Urine-Collection Device for Prevention of Intraluminally-Acquired Catheter-Associated Urinary Tract Infection (CAUTI). **Proceedings and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy,** Washington, DC, October 2004.
540. **Maki DG,** Kluger DJ, Crnich CJ. Microbiology of intravascular device-related bloodstream infection (IVDR BSI) in adults. I. An analysis of 159 prospective studies. II. Implications for management. **Proceedings and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy,** Washington, DC, October 2004.
541. **Maki DG,** Mermel L, McCormick RD, Friedland DH, MBI 226 Study Group. Prospective, randomized, investigator-blinded multi-center trial of a novel, topical cationic antimicrobial peptide for prevention of vascular catheter-related infection. **Proceedings and Abstracts of the 44th Interscience Conference on Antimicrobial Agents and Chemotherapy,** Washington, DC, October 2004.
542. **Maki DG.** An evidence-based approach to prevention of intravascular device-associated infection. The promise of novel technology. **Annual Meeting of the Intravenous Nurses Association.** Palm Springs, California, November 5, 2004.
543. **Maki DG.** Management of infection in the ICU caused by multiresistant organisms. In the *9<sup>th</sup> Annual Critical Care Refresher Course.* **34<sup>th</sup> Annual Congress of the Society for Critical Care Medicine.** Phoenix, Arizona, January 14-18, 2005.
544. **Maki DG.** Management of severe community-acquired pneumonia. In the symposium, *Management of Severe Community-acquired Pneumonia and Sepsis.* **34<sup>th</sup> Annual Congress of the Society for Critical Care Medicine.** Phoenix, Arizona, January 14-18, 2005.
545. **Maki DG.** Antimicrobial-impregnated catheters should be routinely used in all ICU patients. In the symposium debate, *Antimicrobial-impregnated Catheters Should be Routinely Used in all ICU Patients.* **34<sup>th</sup> Annual Congress of the Society for Critical Care Medicine.** Phoenix, Arizona, January 14-18, 2005.

546. **Maki DG.** Impact of new technologies on prevention of vascular catheter-related BSI. In the symposium, *Vascular catheter-related BSI. Epidemiology and Prevention*. **34<sup>th</sup> Annual Congress of the Society for Critical Care Medicine**. Phoenix, Arizona, January 14-18, 2005.
547. **Maki DG.** An evidence-based approach to prevention of line sepsis with long-term vascular access for parenteral nutrition. The promise of novel technology. In the HPEN Workshop. **Annual Meeting of the Society for Parenteral and Enteral Nutrition**. Orlando, Florida, January 28, 2005.
548. **Maki DG.** Advances in the prevention of infection with long-term vascular access. The promise of novel technology. In the Nutritional Support Workshop, *Annual Meeting of the Oley Foundation*. **Annual Meeting of the Society for Parenteral and Enteral Nutrition**. Orlando, Florida, January 28, 2005.
549. **Maki DG.** Control of MRSA in the hospital. In the **National Japanese Workshop, Control of MRSA**. Tokyo, Japan, February 18, 2005.
550. **Maki DG.** An evidence-based approach to prevention of vascular catheter-related bloodstream infection. In the symposium, **Advances in the Prevention of Hospital Infection**. Tokyo, Japan. February 19, 2005.
551. **Maki DG.** Prevention of surgical site infection, with an emphasis on optimal surgical prophylaxis. In the symposium, **Advances in the Prevention of Hospital Infection**. Tokyo, Japan. February 19, 2005.
552. **Maki DG.** An evidence-based approach to prevention of vascular catheter-related bloodstream infection. In the symposium, **Advances in the Prevention of Hospital Infection**. Nagoya, Japan. February 20, 2005.
553. **Maki DG.** Prevention of surgical site infection, with an emphasis on optimal surgical prophylaxis. In the symposium, **Advances in the Prevention of Hospital Infection**. Nagoya, Japan. February 20, 2005.
554. **Maki DG.** An evidence-based approach to prevention of vascular catheter-related bloodstream infection. **Korean Infection Prevention Association**. Seoul, Korea. February 22, 2005.
555. **Maki DG.** Advances in the prevention of infection with long-term vascular access. The promise of novel technology. **Annual Meeting of the Korean Oncology Society**. Seoul, Korea. February 23, 2005.
556. **Maki DG.** The pathogenesis of ventilator-associated pneumonia. Its relevance to developing effective preventive strategies. In the AARC *J Resp Care* symposium, *Ventilator-associated Pneumonia*. **American Association of Respiratory Care. Cancun**. Mexico. February 25-26, 2005.
557. **Maki DG.** The role of the ICU environment in the pathogenesis and prevention of ventilator-associated pneumonia. In the AARC *J Resp Care* symposium, *Ventilator-associated Pneumonia*. **American Association of Respiratory Care**. Cancun, Mexico. February 25-26, 2005.
558. **Maki DG.** The promise of new technology for prevention of infection of intravascular devices. Keynote Address, **5th International IV Therapy Conference**. Oxford, U.K., March 9, 2005.
559. **Maki DG.** Emerging infectious diseases of the 21<sup>st</sup> Century. **Annual Meeting of the American College of Physicians**. New Orleans, LA, April 16, 2005.
560. **Maki DG.** The need for a new paradigm for control of nosocomial infection in the ICU in the 21st Century. **American Association of Critical Care Nurses 2005 National Teaching Institute and Critical Care Exposition**, New Orleans, LA, May 10, 2005.
561. **Maki DG.** Emerging infectious diseases of the 21<sup>st</sup> century. Keynote Address and Felix Pifano Memorial Lecture, **13<sup>th</sup> Annual Congress of the Venezuelan Society of Internal Medicine–American College of Physicians**. Margarita Island, Venezuela, May 25, 2005.

562. **Maki DG.** Protection of the patient from nosocomial infection. In the symposium, *In-hospital Medicine, 13<sup>th</sup> Annual Congress of the Venezuelan Society of Internal Medicine–American College of Physicians.* Margarita Island, Venezuela, May 24, 2005.
563. **Maki DG.** Advances in the management of septic shock. In the symposium, *Emergencies in Internal Medicine, 13<sup>th</sup> Annual Congress of the Venezuelan Society of Internal Medicine–American College of Physicians.* Margarita Island, Venezuela, May 24, 2005.
564. **Maki DG.** The crisis in antimicrobial resistance: causes and solutions. Plenary lecture, **13<sup>th</sup> Annual Congress of the Venezuelan Society of Internal Medicine–American College of Physicians.** Margarita Island, Venezuela, May 24, 2005.
565. **Maki DG.** Management of infections caused by multiresistant organisms. **13<sup>th</sup> Annual Congress of the Venezuelan Society of Internal Medicine–American College of Physicians.** Margarita Island, Venezuela, May 25, 2005.
566. **Maki DG.** New and old approaches to reducing line sepsis in hospitalized children. **CHCA Clinical Improvement Collaborative: Reducing Catheter-associated Bloodstream Infections in Children.** Chicago, September 13-14, 2005.
567. **Maki DG.** Prevention and management of vascular catheter-related bloodstream infections. In the symposium, *Impact of New technologies on Catheter-related Bloodstream Infections. Proceedings and Abstracts of the Annual Meeting of the American College of Chest Physicians—CHEST 2005.* Toronto, November 1, 2005.
568. **Maki DG.** Protecting the catheter as a source of bloodstream infections: Antimicrobial CVC and lock solutions. In the, **First Annual MD Anderson Cancer Center Symposium, Infections in Cancer.** Houston, November 10, 2005.
569. **Maki DG.** Coating central venous catheters with antimicrobial/antiseptic agents works! In the debate, *Intravenous Catheters: Coating or Not. Proceedings and Abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy.* Washington DC, December 16-18, 2005.
570. **Maki DG.** Evidence-based medicine recommends technology. In the symposium, *Decreasing Catheter-related Bloodstream Infections - A Practical Approach. Proceedings and Abstracts of the 35<sup>th</sup> Congress of the Society for Critical Care Medicine.* San Fransisco, January 8, 2006.
571. **Maki DG.** Advances in the prevention of intravascular device-related bloodstream infection with longterm access. **Proceedings and Abstracts of the 19<sup>th</sup> Annual Conference of the Association for Vascular Access Networks.** Savannah, GA, January 13, 2006.
572. **Maki DG.** The need for a new paradigm for prevention of nosocomial infection. Keynote Address, **6th International IV Therapy Conference.** Oxford, U.K., March 8, 2006.
573. **Maki DG.** Catheter-related infection control and product evaluation. **15<sup>th</sup> annual Conference of the National Home Infusion Association.** Houston, TX. March 11, 2006.
574. **Maki DG.** Catheter-Related BSIs: Pathogenesis and Prevention. **Association for Professionals in Infection Control and Epidemiology National Webinar.** March 16, 2006.
575. Chlebicki p, Crnich CJ, **Maki DG.** Prospective Evaluation of 6 Preoperative Cutaneous Antisepsis Regimens for Prevention of Surgical Site Infection. **Abstracts and Proceedings from the 16th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America.** Chicago, IL. March 19, 2006.
576. Safdar N, **Maki DG.** From colonization to infection with multiresistant nosocomial bacteria: preventing infection must begin with blocking colonization. **Abstracts and Proceedings from the 16th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America.** Chicago, IL. March 19, 2006.

577. **Maki DG.** Prevention of short-term catheter-related bloodstream infections: role of antimicrobial catheters. In the symposium, *Prevention and Management of Bloodstream Infections. Abstracts and Proceedings from the 16th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America*. Chicago, IL. March 19, 2006.
578. **Maki DG.** Locks and flushes: Can they prolong safe catheter use? In the symposium, *Preventing Bloodstream Infections in 2006: Seeking Zero Tolerance. Abstracts and Proceedings from the 16th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America*. Chicago, IL. March 20, 2006.
579. **Maki DG.** Catheter-related infections. Plenary lecture, **26<sup>th</sup> International Society for Intensive Care and Emergency Medicine (ISICEM)**, Brussels, March 23, 2006.
580. **Maki DG:** What are the Causes? In the symposium, *Antibiotic resistance. 26<sup>th</sup> International Society for Intensive Care and Emergency Medicine (ISICEM)*. Brussels, March 23, 2006.
581. **Maki DG** Emerging infectious diseases: the next SARS. In the symposium, *Epidemics. 26<sup>th</sup> International Society for Intensive Care and Emergency Medicine (ISICEM)*. Brussels, March 23, 2006.
582. **Maki DG** Biologic weapons. In the symposium, *Disasters. 26<sup>th</sup> International Society for Intensive Care and Emergency Medicine (ISICEM)*. Brussels, March 23, 2006.
583. **Maki DG.** The promise of new technologies but why not use what we already know?. **4<sup>th</sup> Vascular Infusion Technology Congress**. Waalwijk, Netherlands, April 10, 2006.
584. **Maki DG.** The future of infusion technology. **4<sup>th</sup> Vascular Infusion Technology Congress**. Waalwijk, Netherlands, April 10, 2006.
585. **Maki DG.** Prevention of bloodstream infections: What else can we do? In the symposium, *Prevention of Catheter-related Bloodstream Infections*. Utrecht, Netherlands, April 13, 2006.
586. Crnich CJ, Zimmerman DR, **Maki DG.** Antibiotic resistance in nursing homes: A proposal to determine the impact of infection control and staffing quality. *National Institutes of Health Multidisciplinary Clinical Research Career Development K12 Roadmap Meeting*. Silver Spring, Maryland, May 4-5, 2006.
587. Fox BC, Schenck GS, Peterson D, **Maki DG.** Choosing more effective antimicrobial combinations for empiric antimicrobial therapy of serious gram-negative rod infections using a dual-combination antibiogram. **Program and Abstracts of the 44th Annual Meeting of the Infectious Diseases Society of America**. Toronto, Canada, October 10-12, 2006.
588. Fox BC, Schenck GS, Peterson D, **Maki DG.** Differences in institutional antibiograms for gram-negative bacilli based on use of the *latest* patient isolate and unit-specific data. **Program and Abstracts of the 44th Annual Meeting of the Infectious Diseases Society of America**. Toronto, Canada, October 10-12, 2006.
589. **Maki DG.** Prevention of infections of implanted medical devices. The promise of novel technology. **Annual Medtronics Scientific Conference**. St Paul, MN, October 29, 2006.
590. **Maki DG.** State-of-the-art: Management of septic shock..Concepts and controversies. **Twenty-sixth Annual Convention and Scientific Sessions of the American College of Osteopathic Medicine**. Scottsdale, AZ, October 21, 2006.
591. **Maki DG.** The prevalence of antimicrobial resistance, In the symposium, *Antimicrobial Resistance: Waking Up to the Challenge. Annual Meeting of the American Society of Hospital Pharmacy*. St Louis, MO, October 26, 2006.

592. **Maki DG.** Protecting the ICU patient from secondary sepsis. **Society for Critical Care Medicine *Critical Care Focus Symposium on Sepsis, Glycemic Control, and Antithrombotics.*** San Diego, CA, November 3-4, 2006.
593. **Maki DG.** Point-counterpoint debate: Antimicrobial restriction is imperative to control antibiotic resistance. **Society for Critical Care Medicine *Critical Care Focus Symposium on Sepsis, Glycemic Control, and Antithrombotics.*** San Diego, CA, November 3-4, 2006.
594. **Maki DG.** Preparing for the unknown: bioterrorism vs avian influenza. **Society for Critical Care Medicine *Critical Care Focus Symposium on Sepsis, Glycemic Control, and Antithrombotics.*** San Diego, CA, November 3-4, 2006.
595. **Maki DG.** Line sepsis. Magnitude, pathogenesis, evidence-based strategies for prevention. **University College London Hospitals NHS Foundation Trust Symposium, *Prevention of Catheter-related Infections.*** London, UK, November 25, 2006.
596. **Maki DG.** Catheter-Related BSIs: Pathogenesis and Prevention. **Association for Professionals in Infection Control and Epidemiology National Webinar.** November 14, 2006.
597. **Maki DG.** Pro-Con Debate: Preemptive Barrier Infection Prophylaxis. **Proceedings and Abstracts of the 36<sup>th</sup> Congress of the Society for Critical Care Medicine.** Orlando, FLA, February 19, 2007.
598. **Maki DG.** Controversial catheter maintenance to reduce BSI. In the symposium, The Latest in Nosocomial Infections. **Proceedings and Abstracts of the 36<sup>th</sup> Congress of the Society for Critical Care Medicine.** Orlando, FLA, February 20, 2007.
599. **Maki DG.** Antimicrobial therapy and severe sepsis. In the symposium, Epidemiology and Outcomes of Sepsis: 2007 and Beyond. **Proceedings and Abstracts of the 36<sup>th</sup> Congress of the Society for Critical Care Medicine.** Orlando, FLA, February 21, 2007.
600. **Maki DG.** Line sepsis. Magnitude, pathogenesis and prevention. **The 16<sup>th</sup> Annual Conference of the National Home Infusion Association.** Savannah, GA, February 27, 2007.
601. **Maki DG.** Prevention of device-related bloodstream infection with permanent intravascular devices. **First European Conference on Bacteremia.** Geneva, Switzerland, March 4, 2007.
602. **Maki DG.** Efficacy of antimicrobial devices in reducing catheter-related BSI. In the symposium, Current Issues in the Control of Healthcare-associated Infections and Disinfection and Sterilization. **Proceedings and Abstracts of the 17<sup>th</sup> Annual Scientific Meeting of the Society for Healthcare Epidemiology of America.** Baltimore, MD, April 14, 2007.
603. **Maki DG.** Prevention, diagnosis and management of intravascular catheter related infections. **Indian Society of Critical Care Medicine Telesymposium.** May 20, 2007.
604. **Maki DG, Abad C, Safdar N.** The risks of intravascular device-related bloodstream infection in children and neonates: A systematic review. **Proceedings and Abstracts of the 47<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy.** Chicago, IL, September 17-19, 2007.
605. **Maki DG, Marx J, Stolz S.** Twelve Years of total prevention of endemic nosocomial legionellosis by continuous copper-silver ionization of hospital water. **Proceedings and Abstracts of the 47<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy.** Chicago, IL, September 17-19, 2007.
606. **Maki DG.** Novel approaches to catheter maintenance to prevent CRBSI. **International Federation of Infection Control (IFIC) Telesymposium.** Budapest, October 17, 2007.
607. **Maki DG.** Novel approaches to catheter maintenance to prevent CRBSI. **Annual Meeting of the Intravenous Nurses Society.** Anaheim, CA, November 11, 2007.

608. **Maki DG.** Infections of implanted medical devices. In the symposium, Post-operative Infections. **Finnish National Conference for Surgery and Anesthesiology: *Operatiiviset Päivät*.** Helsinki, Finland, November 23, 2007.
609. **Maki DG.** Prevention of perioperative healthcare-associated infection. **Annual Meeting of the New York State Society of Anesthesiology,** New York, NY, December 9, 2007.
610. **Maki DG.** The promise of novel technology. In the Symposium, ***Insights and Interventions for Prevention of Vascular Catheter-related Bloodstream Infection.*** 3M Corporation, St Paul, MN, January 11, 2008,
611. **Maki DG.** Vascular catheter-related bloodstream infection. In **The 11<sup>th</sup> International Symposium, *Current Topics in Infectious Disease.*** Grindelwald, Switzerland, January 28, 2008.
612. **Maki DG.** Prevention and management of antibiotic resistance in the ICU. In the ***Adult Refresher Course. Proceedings and Abstracts of the 37<sup>th</sup> Congress of the Society for Critical Care Medicine.*** Honolulu, HI, February 1, 2008.
613. **Maki DG.** Worldwide pandemics. The Scope of the problem. In the symposium, ***Disaster Planning - Is Your ICU Prepared? Proceedings and Abstracts of the 37<sup>th</sup> Congress of the Society for Critical Care Medicine.*** Honolulu, HI, February 3, 2008.
614. **Maki DG.** Challenges of the epidemic strain of *C difficile*. In the symposium, ***Clostridium difficile 2008: New Focus On Familiar Problem. Proceedings and Abstracts of the 37<sup>th</sup> Congress of the Society for Critical Care Medicine.*** Honolulu, HI, February 4, 2008.
615. **Maki DG.** Efficacy of antimicrobial devices in reducing catheter-related BSI. In the symposium, ***Current Issues in the Control of Healthcare-associated Infections and Disinfection and Sterilization. Proceedings and Abstracts of the 18<sup>th</sup> Annual Scientific Meeting of the Society for Healthcare Epidemiology of America.*** Orlando, FLA, April 5, 2008.
616. **Maki DG,** Stahl J, Jacobson C, Pyrek MS. A Novel integrated chlorhexidine transparent dressing for prevention of vascular catheter-related bloodstream infection (CRBSI); three comparative studies. **Proceedings and Abstracts of the 18<sup>th</sup> Annual Scientific Meeting of the Society for Healthcare Epidemiology of America.** Orlando, FLA, April 7, 2008.
617. Rosenthal V, **Maki DG** et al. Effectiveness of outcome and process surveillance for reducing central vascular catheter-associated BSI rates in 71 ICUs in 71 countries. Findings of the International Nosocomial Infection Control Consortium (INICC). **Proceedings and Abstracts of the 18<sup>th</sup> Annual Scientific Meeting of the Society for Healthcare Epidemiology of America.** Orlando, FLA. April 7, 2008.
618. Thompson D, **Maki DG,** Tambyah p, Safdar N. Predictors of candiduria in hospitalized patients with indwelling urinary catheters: A multivariate analysis. **Proceedings and Abstracts of the 18<sup>th</sup> Annual Scientific Meeting of the Society for Healthcare Epidemiology of America.** Orlando, FLA. April 7, 2008.
619. **Maki DG.** Bloodstream-associated infections, a state of the art review (Keynote). **Joint International Symposium on Infectious Diseases of the University of Illinois and Pan American Society of Infectious Diseases Society.** Chicago, IL, May 21-23, 2008.
620. Gordon BJ, **Maki DG.** A collaborative approach to increasing appropriate usage of surgical prophylactic antibiotics. **Program and Abstracts of the 2008 Annual Educational International Conference of the Association of Professionals in Infection Control and Epidemiology,** Denver, CO, June 15-19, 2008.
621. **Maki DG.** Need for a new paradigm for control of hospital-acquired infection. In the symposium, ***Hospital-acquired Infection.*** San Juan, Puerto Rico, June 18, 2008.



622. **Maki DG.** Evidence-based approach to prevention of line sepsis. In the symposium, *Hospital-acquired Infection*. San Juan, Puerto Rico, June 18, 2008.
623. **Maki DG.** The crisis in antimicrobial resistance: Causes and solutions. **The 2008 Annual Meeting of the Alaskan Chapter of the American College of Physicians, *The Physician as a Patient***. Anchorage, AK, June 26, 2008.
624. **Maki DG.** Insights from a physician-patient and a physician who cares for many physician-patients. **The 2008 Annual Meeting of the Alaskan Chapter of the American College of Physicians, *The Physician as a Patient***. Anchorage, AK, June 27, 2008.
625. **Maki DG.** The challenge of *Clostridium difficile*. **The 2008 Annual Meeting of the Alaskan Chapter of the American College of Physicians, *The Physician as a Patient***. Anchorage, AK, June 27, 2008.
626. **Maki DG.** New technological developments in CRBSI prevention. In the international symposium, ***Status of Healthcare Acquired Infections. Mexico City, Mexico, July 21, 2008.***
627. **Maki DG.** The need for a new paradigm for control of nosocomial infection (Keynote). In the symposium, ***Evidence in Infection Control. 25<sup>th</sup> Annual Meeting of the Scandinavian Society for Antimicrobial Chemotherapy. Copenhagen Denmark. September 19-21, 2008.***
628. **Maki DG.** Emerging infectious diseases of the 21st century. *Clostridium difficile* antibiotic-associated colitis. **Twenty-eight Annual Convention and Scientific Sessions of the American College of Osteopathic Medicine.** Marco Island, FLA, October 31, 2008.
629. **Maki DG.** The need for a new paradigm for control of nosocomial infection. **Twenty-eight Annual Convention and Scientific Sessions of the American College of Osteopathic Medicine.** Marco Island, FLA, October 31, 2008.
630. **Maki DG.** Advances in the prevention of line sepsis. **Critical Care Forum 2009.** Toronto, Canada, November 11, 2008.
631. **Maki DG.** Control of antimicrobial resistance in the ICU. Screening versus preemptive barrier isolation. **Critical Care Forum 2009.** Toronto, Canada, November 11, 2008.
632. **Maki DG.** US approaches to the prevention of line sepsis. The promise of novel technology. In the symposium, ***Fighting Infection From the Inside Out. The Lancet Conference -- Healthcare-associated Infections.*** London, UK, December 11, 2008.
633. **Maki DG.** The role of novel technology in the prevention of catheter-related bloodstream infection. In the symposium, ***Preventing Bloodstream Infections in Critically Ill Patients. Proceedings and Abstracts of the 38<sup>th</sup> Congress of the Society for Critical Care Medicine.*** Nashville, TN, February 2-4, 2009.
634. **Maki DG.** The published data do not support the routine use of combination therapy. In the debate, ***Monotherapy vs Combination Therapy of Sepsis and Septic Shock. Proceedings and Abstracts of the 38<sup>th</sup> Congress of the Society for Critical Care Medicine.*** Nashville, TN, February 2-4, 2009.
635. **Maki DG.** *In vitro* studies of a novel antimicrobial Luer-activated connector for prevention of catheter related BSI. **Proceedings and Abstracts of the 38<sup>th</sup> Congress of the Society for Critical Care Medicine.** Nashville, TN, February 2-4, 2009.
636. **Maki DG.** Prevention of ventilator-associated pneumonia and catheter-related bloodstream infection. **14th Annual State-of-the-Art.** American Thoracic Society. Chicago, IL, February 5-7, 2009.
637. **Maki DG.** The need for a new paradigm for control of hospital infection. The promise of innovative technology. **The National Health Service HCAI Innovative Technology Summit.** London, UK, February 26, 2009.

638. Crnich CJ, Drinka P, Zimmerman D, **Maki DG**. The Impact of functional status on colonization with antibiotic-resistant bacteria among nursing home residents. **Proceedings and Abstracts of the 19<sup>th</sup> Annual Scientific Meeting of the Society for Healthcare Epidemiology of America**. San Diego, March 18-20, 2009.
639. Crnich CJ, Drinka P, Zimmerman D, **Maki DG**. Multi-anatomical versus nares-only surveillance cultures for detection of MRSA colonization status among nursing home residents. **Proceedings and Abstracts of the 19<sup>th</sup> Annual Scientific Meeting of the Society for Healthcare Epidemiology of America**. San Diego, March 18-20, 2009.
640. Crnich CJ, Drinka P, Zimmerman D, **Maki DG**. Differences in risk factors for colonization with MRSA and fluoroquinolone-resistant bacteria among nursing home residents. **Proceedings and Abstracts of the 19<sup>th</sup> Annual Scientific Meeting of the Society for Healthcare Epidemiology of America**. San Diego, March 18-20, 2009.
641. **Maki DG**. Emerging infectious diseases of the 21<sup>st</sup> Century. **Annual Meeting of the American College of Physicians—Internal Medicine 2009**. Philadelphia, April 24, 2009.
642. **Maki DG**. The need for a new paradigm for control of healthcare-associated infections in the 21<sup>st</sup> Century. **Annual Meeting of the American College of Physicians—Internal Medicine 2009**. Philadelphia, April 24, 2009.
643. **Maki DG**. Evidenced-based strategies for prevention of line sepsis. **Annual Meeting of the American Critical Care Nurses Association**. New Orleans, LA, May 20, 2009.
644. **Maki DG**. The imperative for a new paradigm for control of healthcare-associated infection. Keynote, In: **Proceedings of the Fourth International Congress of the Asia Pacific Society of Infection Control**, Macau SAR, China, July 5-8, 2009.
645. **Maki DG**. Prevention of catheter-related BSI: zero is achievable but not without technology. In: **Proceedings of the Fourth International Congress of the Asia Pacific Society of Infection Control**, Macau SAR, China, July 5-8, 2009.
646. **Maki DG**. Controlling the new plague: *C. difficile*. In the symposium, *Resistant Pathogens*. **Proceedings of the Fourth International Congress of the Asia Pacific Society of Infection Control**, Macau SAR, China, July 5-8, 2009.
647. **Maki DG**. An evidence-based approach to prevention of catheter-related bloodstream infection. Zero is not achievable without technology. In the symposium: **Advances in the Prevention of Catheter-related Bloodstream Infection**. Auckland, New Zealand, July 8, 2009.
648. **Maki DG**. An evidence-based approach to prevention of catheter-related bloodstream infection. Zero is not achievable without technology. In the symposium: **Advances in the Prevention of Catheter-related Bloodstream Infection**. The Royal Prince Alfred Hospital, Sydney, Australia 10, 2009.
649. **Maki DG**. An evidence-based approach to prevention of catheter-related bloodstream infection. Zero is not achievable without technology. In the symposium: **Advances in the Prevention of Catheter-related Bloodstream Infection**. Brisbane, Australia, July 11, 2009.
650. **Maki DG**. An evidence-based approach to prevention of catheter-related bloodstream infection. Zero is not achievable without technology. In the symposium: **Advances in the Prevention of Catheter-related Bloodstream Infection**. Melbourne, Australia, July 13, 2009.
651. **Maki DG**. An evidence-based approach to the management of septic shock. **Annual Conference of the Wisconsin Chapter of the American College of Physicians**. Wisconsin Dells, WI. September 13, 2009.
652. **DG Maki**, VD Rosenthal, R Salomao, F Franzetti, MS Rangel-Frausto, F Higuera, JM Soto. Open infusion systems may be safer than closed systems as regards risk of CLABSI: a meta-analysis of 4

- time-series cohort trials. **Proceedings and Abstracts of the 49<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy**. San Francisco, CA, September 12-14, 2009.
653. **Maki DG**, Ash SR, Winger RK, Lavin P. A multi-center randomized trial of a novel antimicrobial and antithrombotic lock solution for hemodialysis catheters. **Proceedings and Abstracts of the 49<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy**. San Francisco, CA, September 12-14, 2009.
654. Rosenthal VD, **Maki DG** for INICC. The impact of education and feedback of outcome and process surveillance on rates of CLABSI in 86 ICUs of 15 developed countries. **Proceedings and Abstracts of the 49<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy**. San Francisco, CA, September 12-14, 2009.
655. Crnich CJ, Duster M, Jones A, **DG Maki**. Prospective randomized double-blind trial of an ethanol lock for prevention of CLABSI. **Proceedings and Abstracts of the 49<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy**. San Francisco, CA, September 12-14, 2009.
656. **Maki DG**, Duster M. The promise of simple and total disinfection of hospital surfaces by aerosolization of peroxyacetic acid. **Proceedings and Abstracts of the 49<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy**. San Francisco, CA, September 12-14, 2009.
657. **Maki, DG**. Simulation studies of a silver-coated leur-activated needleless connector for prevention of CRBSI. **Proceedings and Abstracts of the 49<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy**. San Francisco, CA, September 12-14, 2009.
658. Safdar, N, **Maki, DG**. Multidrug-resistant (MDR) nosocomial pathogens travel together: A prospective study. **Proceedings and Abstracts of the 49<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy**. San Francisco, CA, September 12-14, 2009.
659. **DG Maki**. Silver for prevention of healthcare-associated infection. Meet-the-Professor. **Proceedings and Abstracts of the 49<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy**. San Francisco, CA, September 12-14, 2009.
660. **Maki DG**, Ash SR, Winger RK, Lavin P. A multi-center randomized trial of a novel antimicrobial and antithrombotic lock solution for hemodialysis catheters. **Proceedings and Abstracts of the 23<sup>rd</sup> Annual Conference of the Association for Vascular Access (AVA)**. Las Vegas, NEV. September 16-18, 2009.
661. **Maki DG**. Lock solutions to prevent IV catheter infections. *In* the symposium, **Has the Time to "Lock" Arrived? Program and Abstracts of the 47th Annual Meeting of the Infectious Diseases Society of America**. Philadelphia, October 30-November 1, 2009.
662. Crnich CJ, Drinka P, Zimmerman DR, **Maki DG**. Persistence of colonization with antibiotic-resistant bacteria among nursing home residents. **Program and Abstracts of the 47th Annual Meeting of the Infectious Diseases Society of America**. Philadelphia, October 30-November 1, 2009.
663. Crnich CJ, Drinka P, Zimmerman DR, **Maki DG**. Health outcomes of nursing home residents colonized with antibiotic-resistant bacteria. **Program and Abstracts of the 47th Annual Meeting of the Infectious Diseases Society of America**. Philadelphia, October 30-November 1, 2009.
664. Rose We, Hatch JB, **Maki DG**. Clinical evaluation of deep-seated gram-positive infections treated with daptomycin in combination with rifampin. **Program and Abstracts of the 47th Annual Meeting of the Infectious Diseases Society of America**. Philadelphia, October 30-November 1, 2009.
665. **Maki DG**. Prevention of ventilator-associated pneumonia and catheter-related bloodstream infection. **15th Annual State-of-the-Art**. American Thoracic Society. Miami, IL, February 25-28, 2010.
666. **Maki DG**. The New Plague: *Clostridium difficile*. **Annual Meeting of the Select Hospitals CEOs and Medical Directors**. Washington, DC, April 16, 2010.

667. **Maki DG.** Keynote. Getting CRBSI rates to zero. **First World Congress on Vascular Access.** Amsterdam, Netherlands, June 16-18, 2010.
668. **Maki DG.** The promise of novel technologies. In the symposium, *Consensus on Prevention of Catheter-related Infection; Towards Worldwide Guidelines.* **First World Congress on Vascular Access.** Amsterdam, Netherlands, June 16-18, 2010.
669. **Maki DG.** Strategies of CHG use to prevent CRBSI. In the symposium, *New Approaches to prevent CRBSI* **First World Congress on Vascular Access.** Amsterdam, Netherlands, June 16-18, 2010.
670. **Maki DG.** An international perspective: the need for a new paradigm for control of hospital infection. The promise of innovative technology. **The UK National Health Service HCAI Annual Conference. Reducing HCAIs – A Transformation Process: Embedding the Culture of Patient Safety.** London, UK, September 9, 2010.
671. **DG Maki.** The Maki semiquantitative catheter culture technique. In the Symposium, *Classic Papers..Proceedings and Abstracts of the 50<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy.* Boston, MA, September 12-14, 2010.
672. **DG Maki.** Prevention of catheter-associated urinary tract infection. *Meet-the-Professor..Proceedings and Abstracts of the 50<sup>th</sup> Interscience Conference on Antimicrobial Agents and Chemotherapy.* Boston, MA, September 12-14, 2010.
673. **Maki DG.** The promise of novel technology. In the symposium, *New Strategies for Prevention of Vascular Catheter-related Infection.* **Proceedings and Abstracts of the 23rd Annual Conference of the Association for Vascular Access Networks.** Washington, DC, September 24, 2010.
674. **Maki DG.** The imperative for a new paradigm for control of healthcare-associated infection. **Proceedings of the Annual Meeting of the Australian Infection Control Association,** Perth, AUS, October 4-6, 2010).
675. **Maki DG.** Intravascular device-related infections: How do we get to zero? In the symposium, *Intravascular Infections.***Proceedings of the Annual Meeting of the Australian Infection Control Association,** Perth, AUS, October 4-6, 2010).
676. **Maki DG.** Ventilator-associated pneumonia. In the symposium, *Infections in Specialized Areas.* **Proceedings of the Annual Meeting of the Australian Infection Control Association,** Perth, AUS, October 4-6, 2010).
677. Crnich CJ, Duster M, Warrack S, Safdar N, **Maki DG.** Strain typing of MRSA by repetitive element PCR and pulsed-field gel electrophoresis: a comparison. **Program and Abstracts of the 48th Annual Meeting of the Infectious Diseases Society of America.** Vancouver, BC, Canada, October 20-22, 2010.
678. **Maki DG.** Vancomycin prophylaxis or decolonization for control of MRSA SSI? In the symposium, *MRSA.* **Proceedings and Abstracts of the 12th Western Pacific Congress on Chemotherapy and Infectious Disease.** Singapore, December 3, 2010.
679. **Maki DG.** Is isolation necessary for control? In the symposium, *Multi-drug-resistant Acinetobacter.* **Proceedings and Abstracts of the 12th Western Pacific Congress on Chemotherapy and Infectious Disease.** Singapore, December 4, 2010.
680. **Maki DG,** Provonost P, Goldman M, Duerden B, Beggs C, Walsh F. A debate: *Reducing HCAIs - Creating a Culture of Patient Safety.* **NHS Government Today.** London, UK, December 8, 2010.
681. **Maki DG.** Multi-drug resistant gram-negative bacilli. In the symposium, *Rallying the Troops to Escape Drug Resistance.* **Proceedings and Abstracts of the 40<sup>th</sup> Congress of the Society for Critical Care Medicine.** San Diego, CA, January 16-19, 2011.

682. **Maki DG.** Hospital-based epidemics. *In the symposium, Infection Control and Prevention. Proceedings and Abstracts of the 40<sup>th</sup> Congress of the Society for Critical Care Medicine.* San Diego, CA, January 16-19, 2011.
683. **Maki DG.** Selective digestive decontamination. *In the symposium, Airway and Infections. Proceedings and Abstracts of the 40<sup>th</sup> Congress of the Society for Critical Care Medicine.* San Diego, CA, January 16-19, 2011.
684. **Maki DG.** The imperative for a new paradigm for control of healthcare-associated infections in the 21<sup>st</sup> Century. **Annual Meeting of the Select Hospitals CEOs and Medical Directors.** Washington, DC, April 1, 2011.
685. **Maki DG.** Preventing development of biofilms: can we make invasive devices safer? *In the symposium, New Technologies for Detecting and Preventing Healthcare-Associated Infections. Proceedings and Abstracts of the 21st Annual Scientific Meeting of the Society for Healthcare Epidemiology of America.* Dallas, April 2, 2011.
686. **Maki DG.** The imperative for a new paradigm for control of healthcare-associated infections in the 21<sup>st</sup> Century. *The American Society of Infectious Diseases Lecture: 85<sup>th</sup> Annual Meeting of the Japanese Association for Infectious Diseases.* Tokyo, April 22, 2011. *Jap J Infect Dis* 2011;xx:xx.
687. **Maki DG.** The imperative for a new paradigm for control of healthcare-associated infections in the 21<sup>st</sup> Century. *In the AATS/STS Critical Care Symposium. Proceedings and Abstracts of the 91st Annual Meeting of the American Association for Thoracic Surgery.* Philadelphia, May 8, 2011.
688. **Maki DG.** The new nosocomial plague: *Clostridium difficile.* *In the AATS/STS Critical Care Symposium..Proceedings and Abstracts of the 91st Annual Meeting of the American Association for Thoracic Surgery.* Philadelphia, May 8, 2011.
689. **Maki DG.** Management of lifethreatening infection. *In the 2011 Fellows Track Critical Care Symposium, Proceedings and Abstracts of the Annual Meeting of the American Thoracic Society,* Denver, May 14, 2011.
690. **Maki DG.** Prevention of catheter-related BSI: Zero will not be achievable without technology. *The International Lecture of the Annual Meeting of the Chilean Society for Hospital Infection Control -- VI Curso IASS.* Santiago, Chile, June 21, 2011.
691. **Maki DG.** Prevention of catheter-related BSI: Zero will not be achievable without technology. *In the symposium, Intravascular Catheter-related BSI: Getting to Zero. Proceedings and Abstracts of II Congreso Latino-Americano de Resistencia Micobiana. IX Sul Encontro de Controle de Infeccao.* Gramado, Brazil. June 22-25, 2011.
692. **Maki DG.** The imperative for a new paradigm for control of healthcare-associated infections in the 21<sup>st</sup> Century. *In Proceedings and Abstracts of the 3rd International Conference on Fibrous Products in Medical and Health Care – Fiber Med 11.* Tampere, Finland. June 28-30, 2011.
693. **Maki DG.** The need for a new paradigm for control of healthcare-associated infections. **Annual Conference of the Wisconsin Chapter of the American College of Physicians.** Wisconsin Dells, WI. September 11 , 2011.
694. **Maki DG.** Yes, of course. *A debate: Should we be routinely using antimicrobial lock solutions to prevent catheter-associated bloodstream infections?* **Proceedings and Abstracts of the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy.** Chicago, IL, September 17-20, 2011.
695. Rose WE, Berti, AD, Hatch JB, **Maki DG.** Relationship of *in vitro* synergy and outcome with daptomycin (DAP) plus rifampin (RIF) treatment of patients with gram-positive pathogens. **Proceedings and Abstracts of the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy.** Chicago, IL, September 17-20, 2011.

696. **Maki DG.** Lines, tubes and prostheses: how are they going to affect vaccine development? *In the Pasteur Institute-Merieux Foundation Symposium: Vaccination and Antibody: Prevention and Therapy of Nosocomial Infections.* Annecy, France, Septmber 26-28, 2011.
697. **Maki DG.** Candidemic patient with a CVC - remove the catheter: *In Great Debates in Mycology. 49th Annual Meeting of the Infectious Diseases Society of America.* Boston, MA, October 19-23, 2011.
698. **Maki DG.** Management of lifethreatening infection. *In the 2012 Fellows Track Critical Care Symposium, Proceedings and Abstracts of the Annual Meeting of the American Thoracic Society,* San Francisco, May 24, 2012.
699. **Maki DG.** Evidence-based management of septic shock. **Annual Meeting of the American Longtern Care Association.** Dallas, TX, May 17, 2012.
700. **Maki DG.** Evidence-based prevention of catheter-related BSI: zero will not be achievable without technology. **Program and Abstracts of the Annual Conference of the Association for Professionals in Infection control..** San Antonio, TX, June 5, 2012.
701. **Maki DG.** Prevention of infections of implanted medical devices. **Program and Abstracts of the Annual Conference of the Association for Professionals in Infection control..** San Antonio, TX, June 5, 2012.
702. **Maki DG.** Zero will not be achievable without technology. *In the Symposium: Preventing line-associated BSI. Which measures are essential? Proceedings and Abstracts of the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy.* San Francisco, CA, September 9-12, 2012.
703. **Maki DG.** Central line-associated BSI. Can it be eliminated? *In Proceedings and Abstracts of the 2<sup>nd</sup> Saudi Symposium on Sefety in Healthcare.* Ryadh, Saudi Arabia, April 10-12, 2013.
704. **Maki DG.** Prevention of line sepsis. **Annual Meeting of the Select Hospitals CEOs and Medical Directors.** Washington, DC, April 12, 2013.
705. **Maki DG.** The new plague, *Clostridium difficile.* Prevention and management. **Annual Meeting of the Select Hospitals CEOs and Medical Directors.** Washington, DC, April 12, 2013.
706. **Maki DG.** Update on prevention of line sepsis. *In the Workshop on Healthcare-associated Infections and Pathogens in ICUs.* Hong Kong, April 15-17, 2013.
707. **Maki DG.** Update on prevention of ventilator-associated pneumonia. *In the Workshop on Healthcare-associated Infections and Pathogens in ICUs.* Hong Kong, April 15-17, 2013.
708. **Maki DG.** Antimicrobial therapy for MDR pathogens. *In the Workshop on Healthcare-associated Infections and Pathogens in ICUs.* Hong Kong, April 15-17, 2013.
709. **Maki DG.** The imperative for a new paradigm for control of healthcare-associated infections. *Keynote address in the symposium, Legacy of Life: Healthcare Epidemiology as a Paradigm for Patient Safety.* University of Utah School of Medicine. Salt Lake City, Utah, April 19, 2013.
710. **Maki DG.** Management of refractory pneumonia in the ICU. *In the Annual AATS/STS Critical Care Symposium..Proceedings and Abstracts of the 93rd Annual Meeting of the American Association for Thoracic Surgery.* Mineapolis, May 5, 2013.
711. **Maki DG.** The 1970s. In the opening plenary symposium, *Four Decades of Difference.* **Program and Abstracts of the Annual Conference of the Association for Professionals in Infection Control..** Fort Lauderdale, FLA, June 5, 2013.

712. **Maki DG.** Prevention of healthcare-associated pneumonia in the ICU. *In* the Annual AATS/STS Critical Care Symposium..**Proceedings and Abstracts of the 94rd Annual Meeting of the American Association for Thoracic Surgery.** Toronto, May 25, 2014.
713. **Maki DG.** Utility of antimicrobial solutions for prevention and treatment of infections. *In* the Symposium: Device-associated infections. **Proceedings and Abstracts of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy.** Washington, DC, September 9-12, 2014.
714. **Maki DG.** Chlorhexidine in the ICU: chlorhexidine everywhere?. *In* the Symposium: *Improved infection control in the ICU.* **Proceedings and Abstracts of the 3<sup>rd</sup> International Conference on Prevention and Infection Control.** Geneva, Switzerland, June 15-19, 2015.
715. **Maki DG.** *Keynote Lecture:* CLABSI prevention: my view from the past to the future. **Proceedings and Abstracts of the 3<sup>rd</sup> International Conference on Prevention and Infection Control.** Geneva, Switzerland, June 15-19, 2015.